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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) comprises 85% of all pancreatic cancers and 
is characterized by an extremely poor prognosis. It is becoming increasingly obvious 
that attention has to be focused on early tumour development, when the disease is still 
manageable. Thus, in this study, I aimed to assess the contribution of adult acinar and 
duct cells to PDAC development and to identify PDAC tumour-initiating cells (TICs). 
Our laboratory had previously identified Fbw7 as a potent tumour suppressor in PDAC 
(unpublished data). Fbw7F/F; KRasLSL-G12D/wt; Pdx1-Cre mice exhibited accelerated 
PDAC onset compared with KRasLSL-G12D/wt; Pdx1-Cre mice. I confirmed this 
observation and demonstrated that Fbw7 loss in the pancreatic epithelium had a greater 
proliferative effect in ductal cells, in the presence and absence of KRasG12D, leading to 
increased numbers of duct cells positive for phosphorylated histone 3. The selective loss 
of Fbw7 in adult ductal cells with concomitant KRasG12D expression (Fbw7F/F; KRasLSL-
G12D/wt; Ck19-CreER mice) led to PDAC development, which was not preceded by 
mucinous lesions. These results were confirmed with the loss of p53 with simultaneous 
KRasG12D expression in adults duct cells (p53F/F; KRasLSL-G12D/wt; Ck19-CreER mice). 
The absence of mucinous PDAC precursors was not dependent on the genotype, as loss 
of Fbw7 in KRasG12D-expressing acinar cells allowed the development of mucinous 
murine pancreatic intraepithelial neoplasia (PanIN). Additionally, I induced bystander 
PanINs using orthotopic transplantation of PDAC cells. These results provide evidence 
that ductal cells can originate PDAC and that different pancreatic cells types might 
adopt different routes to PDAC development. Additionally, the observation of bystander 
PanINs questioned the sole pre-neoplastic nature of these lesions highlighting the need 
for a deeper understanding of PDAC biology.  
 In the present work, I have also described CD9 as a marker of TICs within PDAC 
derived from pancreatic progenitors and adult ductal cells. CD9High PDAC cells 
exhibited higher in vitro organoid-forming capacity, compared with CD9Low cells, 
isolated from the primary tumour and after long-term cultures. Contrasting with CD9Low 
tumour cells, CD9High cells were capable of forming secondary tumours at low numbers, 
demonstrating efficient tumour-initiating capacity and recapitulating the histology of 
the primary tumour source. These results could provide useful information for the 
development of PDAC targeted therapies.  
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SPT   Solid pseudopapillary tumors 
STK11   Serine/threonine kinase 11 
Strep   Streptomycin 
 
TACE   Tumour necrosis factor-α converting enzyme 
TAE   Tris acetate EDTA buffer 
TE   Tris-EDTA 
TEMs   Tetraspanin-enriched microdomains 
TFF2   Trefoil Factor 2 
TIC   Tumour initiating cell 
TGFβ   Transforming growth factor-β 
 
U   units 
Ub   Ubiquitin protein 
UPS   Ubiquitin-proteasome system 
 
V   Valine 
v/v   Volume per volume 
 
WHO   World Health Organization 
w/v   Weight per volume  
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YFP   Yellow fluorescent protein 
 
α    Alpha  
β    Beta  
β gal   Beta galactosidase 
δ   Delta 
µg   Microgram 
µL   Microlitre 
µm   Micrometre 
µM   Micromolar 
 
5-FU   Fluorouracil 
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Chapter 1. Introduction 
1.1  The mammalian pancreas 
Mammalian life is sustained by the complex coordination of internal organs, which, as 
systems, work together to perform crucial body functions. However, this intricacy is not 
only observed in organ systems, and sometimes, a single organ can serve as an 
equivalent representation of such complexity. The pancreas is probably one of the best 
examples of multifunctioning organs, where an exocrine and an endocrine compartment 
work in harmony to participate in different functions, but it might be one of the least 
understood. 
Residing in the abdominal cavity, the pancreas is a component of both digestive and 
endocrine systems. Topologically, the human pancreas is divided into three regions: 
head, body and tail. The head of the pancreas is located in the concavity of the 
duodenum, where it establishes a direct connection with the duodenum and bile duct 
(ampulla of Vater). The body is located below the stomach and the tail borders the 
spleen. In the mouse, the pancreatic organ is not as well defined, consisting of a soft and 
diffuse tissue mass divided into three lobes: the splenic lobe (corresponding to the 
human pancreatic tail), the gastric lobe (corresponding to the human pancreatic body) 
and the duodenal lobe (corresponding to the human pancreatic head and body) (Figure 
1a). Although pancreatic size and shape might differ between mammals, pancreatic 
composition remains conserved (Figure 1b). An exocrine and an endocrine 
compartment, each consisting of different cells, constitute the pancreas. The exocrine 
portion comprises 95% of the entire pancreatic gland and is represented by two main 
cell types: acinar and duct cells. Embedded in the exocrine pancreas, surrounded by 
acinar tissue, we find the endocrine pancreatic compartment organised in spheroidal 
structures entitled Islets of Langerhans. 
Acinar cells are arranged in aggregates named acini and are thought to be the main 
functional cell type within the exocrine gland, producing over 20 proenzymes and 
enzymes which are then secreted to aid digestion. These acini rest at the tips of an 
intricate network of channels lined by the second exocrine cell type, the ductal cells, 
which conduct the acinar-derived enzymes to the duodenum through the main 
pancreatic duct. The endocrine islets of Langerhans are crucial in blood sugar regulation, 
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as their main cellular components are beta (β)-cells, alpha (α)-cells, delta (δ)-cells and 
PP-cells, which produce and secrete insulin, glucagon, somatostatin and pancreatic 
polypeptide, respectively, hormones that are mainly involved in glucose homeostasis 
(Slack, 1995, Benitez et al., 2012, Puri and Hebrok, 2010). 
Given the distinct function and composition of each compartment, they are usually 
studied separately, impairing the comprehensive understanding of the organ as a whole. 
 
 
 
 
Figure 1 – Illustration of the human pancreas and its cellular components 
a) Schematic representation of the human pancreas. The pancreas (in yellow) is located 
in the peritoneal cavity surrounded by stomach (above), spleen (right) and intestine 
(left). The main pancreatic duct is connected to the liver by the common bile duct. The 
figure also illustrates the virtual subdivision of the human pancreas into 3 main regions: 
head; body; tail. b) Schematic illustration of the two pancreatic compartments and their 
cellular composition. The exocrine pancreas consists of a mass of acinar cells located at 
the tips of a network of ducts. The endocrine compartment is organized in islets of 
Langerhans embedded in the exocrine compartment. Figure adapted from Shih et al., 
2013 
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1.1.1 Pancreatic developmental biology 
Driven by the alarming outcomes of pancreatic diseases, considerable attention has been 
devoted to the understanding of pancreatic development,. 
The complex process of mouse pancreatic organogenesis can be subdivided into three 
distinct stages: primary transition (from embryonic day E9.5 to E12.5); secondary 
transition (from E12.5 to birth); and the postnatal period (from birth to onset of 
adolescence) (Pictet et al., 1972). 
Initial determination steps dictated by a notochord-induced repression of endodermal 
Sonic Hedgehog (Shh) allows the specification, at E8.5, of the position of the pancreatic 
buds in the foregut endoderm (Hebrok et al., 1998) (Figure 2a). The patterning of the 
endoderm and commitment to a pancreatic fate is dictated by extrinsic signals 
originating from surrounding tissues such as the cardiac mesoderm and endothelial cells. 
These molecular signals induce the formation of dorsal and ventral pancreatic buds that 
become morphologically evident at E9.5 (Spagnoli, 2007). Subsequent elongation, with 
concomitant stomach and duodenum rotation, leads to their fusion and consequent 
formation of the primordial unified pancreas. Concurrently, cellular proliferation leads 
to an increase in size and to a transient state of epithelial stratification, promoting 
microlumens to coalesce, giving rise to a primitive network of ducts composed of 
multipotent progenitors (Villasenor et al., 2010, Puri and Hebrok, 2010). 
On a molecular level, pancreatic specification signals induce the expression of 
transcription factors important for pancreatic induction and identity maintenance. Some 
of the transcription factors present in the primordial pancreas are restricted to the 
pancreatic domain, such as Pancreatic and duodenal homeobox (Pdx) 1, Pancreas 
transcription factor 1a (Ptf1a, also known as p48) and Sox9, while the expression of 
others (Gata4/6, Foxa1/2, Onecut1, Hes1, Tcf2, Prox1 and Mnx1) extends to the foregut 
endoderm (Figure 2a). It is not yet well known which transcription factors regulate 
pancreatic fate; however, amongst the above, Pdx1 and Ptf1a appear to be key for 
pancreatic identity.  Ectopic pan-endodermal expression of Pdx1 and Ptf1a, during 
Xenopus embryogenesis, converted duodenal domains into pancreatic endoderm. In the 
same study, morpholino antisense oligonucleotide (MO) injection against both 
transcription factors, in combination or individually assessed, led to the loss of exocrine 
pancreas (Solomon Afelik, 2006). Additionally, homozygous deletion of Pdx1 during 
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mouse embryonic development prevents pancreatic tissue formation, leading to lethality 
soon after birth with no additional abnormalities (Jonsson et al., 1995). 
During secondary transition, tightly controlled signals derived from the epithelium and 
mesenchyme regulate cell lineage determination of the pancreatic progenitors. In vivo 
analysis of fixed tissue, together with lineage tracing experiments, have demonstrated 
that, during the secondary transition, expansion and branching generates a topological 
organization of the pancreas that largely resembles that of the adult animal. In the 
beginning of the secondary transition, multipotent progenitors lose their potency and 
become committed to the acinar cell lineage at the tips while the stalk becomes 
composed of bipotent progenitors that develop towards endocrine and ductal cell fates 
(Shih et al., 2013) (Figure 2b). 
Knowledge of the specific regulatory cues is scarce, however, genetic studies have 
implicated Notch signalling as one of the main epithelium-induced regulators of early 
pancreatic growth and differentiation. Impairment of Notch signalling by deletion of 
Notch ligand delta-like gene 1 (Dll1) or its intracellular mediator, Recombination Signal 
Binding Protein for Immunoglobulin kappa J (RBP-J), in the murine embryonic 
pancreatic domain, accelerates the onset of endocrine over exocrine differentiation and 
promotes pancreatic growth arrest (Edlund et al., 1999). Similar observations were 
made by deletion of the Notch downstream effector Hairy/Enhancer of Split-1 (Hes1). 
Hes1-/- mice displayed pancreatic hypoplasia due to premature endocrine differentiation 
(Madsen et al., 2000). 
The influence of the microenvironment adds a layer of complexity to pancreatic 
organogenesis. Explant cultures of pancreatic primordium have demonstrated that the 
mesenchyme plays a crucial role in providing the environmental cues necessary for 
epithelium growth and differentiation. Cultured pancreatic buds devoided of 
mesenchyme failed to differentiate into the pancreatic cell lineages and displayed 
architectural abnormalities (Golosow and Grobstein, 1962). Although the effect of the 
mesenchyme on pancreatic development has long been observed, light is only recently 
being shed on the pathways involved. Critical pathways include FGF, Wnt and BMP 
(Shih et al., 2013). 
In response to the environmental signals, gene expression profiles change. Multipotent 
progenitors give rise to two main pancreatic precursors: acinar precursors located at the 
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tips of the pancreatic primordium, where they lose Pdx1 expression and acquire acinar 
determined signatures with expression of Ptf1a, carboxypeptidase A (Cpa) and c-myc 
(Zhou et al., 2007) and duct/endocrine precursors, identified by the expression of Pdx1, 
NK homeobox (Nkx) 6.1, Nkx6.2 and Sox9 (Figure 2b). The molecular mechanism 
underlying the dual fate determination has been suggested to rely on a cross-repressive 
interaction between Ptf1a and Nkx6.1/6.2. Immunofluorescence analyses have shown a 
temporal window where both transcription factors are expressed in the multipotent 
domains. Nkx6.1- and Nkx6.2-deficient mouse embryos exhibit ectopic Ptf1a 
expression in the trunk of the pancreatic primordium with a simultaneous reduction in 
the number of endocrine progenitors and an increase in acinar cell markers. Moreover, 
Nkx6.1 or 6.2 ectopic expression driven by the Pdx1 promoter (Pdx1-Nkx6.1/2) 
repressed Ptf1a expression and impaired acinar cell differentiation. Conversely, Pdx1-
Ptf1a ectopic expression blocked endocrine differentiation and devoided the pancreatic 
trunk of Nkx6.1 expression (Zhou et al., 2010). Once cells are committed to an acinar 
fate, these cells polarize, form aggregates at the tip of the primordial trunk and continue 
to mature and proliferate until adolescence (Desai et al., 2007). 
Still during secondary transition, pancreatic trunk bipotent progenitors undergo the last 
step of cell fate determination and become committed to endocrine progenitors or ductal 
exocrine lineages (Figure 2c). The key transcription factor that marks the onset of 
endocrine differentiation is Neurogenin 3 (Ngn3). It has been observed that, prior to 
endocrine cell delamination from the primordial ductal network, a subset of bipotent 
progenitors upregulate Ngn3, becoming committed to the endocrine lineage, while the 
remaining progenitors retain Sox9, Tcf2 and onecut1, determining duct cell fate. The 
importance of Ngn3 has been extensively demonstrated and highly studied, mainly due 
to the fact that a better understanding of endocrine specification could aid in the 
development of therapeutic tools for diabetes. Ngn3-deficient mouse pancreata exhibit a 
complete lack of endocrine lineages with concomitant aberrant ductal morphology 
(Magenheim et al., 2011). The ductal enlargement observed during that study was most 
apparent in areas where Ngn3-positive progenitors usually reside, emphasizing the 
preferential ductal lineage fate determination over endocrine fate when Ngn3 is lost, 
rather than loss of endocrine progenitors alone. Additionally, the authors demonstrated 
that the increased number of Ngn3-expressing cells during development, by gamma 
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secretase inhibitor treatment (previously shown to promote in vitro endocrine 
differentiation of embryonic pancreatic progenitors (Mason and Mahoney, 2010)), was 
accompanied by a thinning of the ductal network (Magenheim et al., 2011). 
Following Ngn3 expression, endocrine progenitors, expressing Pdx1, Ngn3 and Mafa 
(amongst other genes), exit the cell cycle, delaminate from the primitive ducts, further 
differentiate into the different pancreatic hormone-producing cells (β-, α-, δ- and PP-
cells) (Figure 2c) and aggregate in clusters designated Islet of Langerhans (Desgraz and 
Herrera, 2009).  
The knowledge of the mechanisms involved in pancreatic development constitutes a 
powerful tool in the understanding of the organ in the context of disease. However, 
thorough comprehension of disease mechanisms requires a deeper assessment of the 
adult scenario. 
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Figure 2 – Schematic representation of the main events in pancreatic embryogenesis 
a) Primary transition - Repression by Shh dictates the pancreatic bud position. The 
pancreatic bud is constituted of progenitors expressing transcription factors restricted to 
the pancreatic bud (Pdx1, Ptf1a, Sox9) and transcription factors whose expression is 
extended to the remaining endoderm (Gata4/6, Foxa1/2, Onecut1, Hes1, Tcf2, Mnx1). 
Primary transition terminates with the formation of a primordial trunk with multipotent 
progenitors. b) Secondary transition – The expression of Nkx6.1 suppresses Ptf1a and 
vice versa. Multipotent progenitors commit to acinar cells or bipotent trunk progenitors. 
Tip progenitors express Ptf1a, Cpa and c-Myc while trunk progenitors express markers 
of both endocrine and ductal cells (Pdx1, Nkx6.1, Nkx6.2, Sox9). c) Bipotent trunk 
progenitors differentiate between endocrine or exocrine lineages. Ngn3 expression 
specifies the endocrine fate.  
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1.1.2 The adult pancreas and organ plasticity 
Throughout pancreatic development, the primordial pancreas is exposed to a wide range 
of genetic, epigenetic and environmental factors, which modulate cellular responses that 
regulate organogenesis. During this period, epithelial sheets are composed of 
progenitors provided with delicate machinery capable of detecting and responding, with 
a high level of plasticity, to a complex signalling network. In most tissues, it is thought 
that the differentiated progeny matures and loses flexibility of cellular identity in 
response to environmental cues. However, genetic, and epigenetic, manipulations of 
developmental pathways in differentiated tissues have uncovered a latent ability of cells 
to de-differentiate or directly convert into a different lineage. Moreover, during disease 
development, it is observed that differentiated cells become more plastic and up-
regulate embryonic pathways (Graf, 2011).  
Regarding the murine pancreas, at the onset of puberty (weaning), the pancreatic 
topological organization and cellular differentiation are complete. While knowledge 
gained from the homeostatic organ suggests that the pancreas is generally quiescent, 
increasing evidence reveals that a large number of differentiated pancreatic cells have 
the capacity to change cellular fate and rapidly proliferate upon stimulation. 
 
In order to identify and understand pancreatic plasticity, injury models and gene 
expression modulation approaches have been developed to challenge the pancreas into 
unveiling its latent capabilities. The most commonly used injury models are: (1) 
pancreatic duct ligation (PDL), (2) partial pancreatectomy (Px), (3) β-cell depletion by 
drug treatment or genetically engineered mouse (GEM) models, and (4) induction of a 
pancreatic inflammatory response, i.e., pancreatitis by caerulein treatment. 
PDL consists of the ligation of the main duct near the tail. Ductal obstruction leads to 
accumulation of the pancreatic secretion, composed of the acinar-derived digestive 
enzymes, with consequent onset of cell death-triggered pancreatitis (Watanabe et al., 
1995). This method leads to a quick, and drastic, ablation of the acinar cell 
compartment, with consequent slower duct and islet cell destruction, and it has been 
extensively used to uncover certain plasticity in pancreatic cell fate. Partial 
pancreatectomy, as the name indicates, is the surgical removal of a portion of the 
pancreas. Removal of up to 90% of the rat pancreas has been demonstrated to promote a 
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drastic remodelling of the organ leading to tissue regeneration. β-cell depletion has also 
been shown to induce β-cell neogenesis from different pancreatic cell sources. 
Treatment with the cytotoxic agents streptozotocin or alloxan leads to selective β-cell 
death due to the drug’s glucose resemblance and subsequent uptake via Glut2 
transporters. Alternatively, GEM models can be used to specifically deplete this 
population by expression of diphtheria toxin (DT), or its receptor (DTR), driven by β-
cell specific promoters (Ferrer et al., 2007). Lastly, the induction of pancreatitis by the 
use of caerulein has also been used as a pancreatic injury. Caerulein is a cholecystokinin 
analogue, a peptide hormone involved in digestion, which induces the premature 
activation and release of acinar cell-produced digestive enzymes, leading to vast acinar 
cell death. Examples of the use of such strategies and their outcomes are discussed 
below. 
 
1.1.2.1 Endocrine cells 
As previously mentioned, the endocrine pancreas harbours a group of hormone-
producing cells, clustered into islet of Langerhans. During pancreatic organogenesis, 
through an intricate web of signalling events, a common post mitotic Ngn3-expressing 
progenitor is able to give rise to insulin producing β-cells, glucagon-producing α-cells, 
somatostatin-producing δ-cells and pancreatic polypeptide-producing PP-cells (Slack, 
1995, Benitez et al., 2012, Puri and Hebrok, 2010). Amongst all endocrine cells, the 
greatest efforts have been dedicated to the study of β-cell biology. β-cells constitute a 
key component in the control of glucose homeostasis due to their ability to sense 
variations in blood sugar levels and respond accordingly, by producing and secreting 
insulin. Insulin is a crucial hormone for survival as it is responsible for the cellular 
uptake of glucose from the blood, regulating the metabolism of carbohydrates and fat, 
and prevents glucose release from the liver. The lack of glucose regulation can cause 
hyper- or hypoglycaemia, leading to cardiovascular diseases, neuropathy, nephropathy, 
kidney failure, retinopathy and cataracts or brain related complications. In the absence 
of stimuli, β-cell mass remains unaltered. However, in the presence of a higher insulin 
requirement, such as pregnancy, autoimmune loss of β-cells (Type 1 diabetes), genetic 
insulin resistance or insufficient β-cell mass (type 2 diabetes) and obesity, the elevated 
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systemic glucose stimulates β-cells to initiate a proliferative program increasing cell 
mass by self-replication (Teta et al., 2007, Rieck and Kaestner, 2010). Notwithstanding 
the fact that β-cells re-enter the cell cycle to cope with insulin depletion-induced stress, 
in the case of diabetes, an alternative β-cell source is required for the continuous insulin 
demand. The search for new methods to obtain β-cells has demonstrated that non 
insulin-producing endocrine cells have the ability to alter their identity towards a β-cell 
fate. Such is the case for α-cell, a combinatory treatment of alloxan and PDL led to a 
dramatic β-cell neogenesis by α-cells in the mouse pancreas (Chung et al., 2010). 
Additional evidence was generated by specific β-cell deletion using GEM models.  In 
the lab of Pedro L. Herrera, β-cell depletion was achieved by expression of DTR under 
the control of the rat insulin promoter (RIP) followed by DT treatment. β-cell 
neogenesis was observed and lineage tracing analysis, where α-cells were labelled 
before DT exposure, allowed the identification of glucagon-expressing cells as the 
source of newly formed insulin-producing cells (Thorel et al., 2010). Recent evidence 
also implicates δ-cells as a source for β-cells following β-cell ablation during puberty 
(Chera et al., 2014).  
The ability of other endocrine cells to repopulate the endocrine gland after β-cell loss is 
interesting, and per se, demonstrates that pancreatic differentiated cells are capable of 
altering their identity upon stimulation.  
 
1.1.2.2 Acinar cells 
Acinar cells are the most abundant cell type in the exocrine pancreas. Constituting 95% 
of the exocrine gland, the acinar cells are roughly triangular in shape and cluster in 
globular structures, named acini, at the terminal ducts. Their role in digestion is 
achieved by continuous production and secretion of over 20 proenzymes and enzymes 
into the ductal network, which conducts them into the duodenum. Besides their 
functional and morphological differences compared with other pancreatic cells, acinar 
cells present a specific transcriptional profile that allows their identification by 
immunostaining. The most commonly used markers include: Ptf1a, Mist1, Elastase I 
(Ela1), Cpa1 and amylase. As the major constituent of the pancreas, unparalleled efforts 
have been undertaken to thoroughly assess their regenerative potential and possible use 
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in current diabetic-related medicine. In the adult animal, acinar cells have been shown 
to be characterized by a low proliferative potential during homeostasis (Desai et al., 
2007) and thus, similarly to the assumption made for the whole organ, were thought to 
have low regenerative potential. The first hint that these cells could be a valuable and 
abundant source for β-cell regeneration emerged from in vitro studies, where the rat 
pancreatic acinar cell line AR42J initiated insulin and GLUT2 protein expression, with 
concomitant c-peptide detection (a by-product of insulin hormone processing), when 
exposed to the signalling molecules betacellulin and activin A (Mashima et al., 1996). 
However, the conclusions taken from this study were still questionable, as the cell line 
used was derived from a chemical-induced exocrine pancreatic tumour and exhibits 
major physiological differences from true acinar cells (Christophe, 1994). 
In vivo models have since been used to address acinar cell plasticity. Initial studies ruled 
out acinar cells as a plastic pancreatic population. Desai and co-workers generated an 
acinar cell-specific transgenic mouse model where a tamoxifen-inducible mutated form 
of Cre recombinase (CreER) was expressed under the control of the Elastase1 promoter 
(Ela1 - acinar cell specific enzyme). In this model, the Cre recombinase is fused to a 
mutated ligand-binding domain of the human oestrogen receptor (ER) and, only in the 
presence of tamoxifen, it can translocate to the nucleus. Tamoxifen treatment, in mice 
harbouring a Rosa26-loxP-STOP-loxP (LSL) –LacZ, allowed the removal of the stop 
cassette, by recombination of the loxP sites, and linage tracing of acinar cells by LacZ 
expression. Px, PDL and pancreatitis induced by caerulein, failed to demonstrate LacZ-
labelled newly formed β-cells, indicating that mature acinar cells lose their ability to 
alter cellular fate during adulthood (Desai et al., 2007). As with most lineage tracing 
and surgical approaches, the efficiency of labelling, and/or the extent of the injury 
induced may compromise the outcome. Nonetheless, efforts to demonstrate acinar cell 
plasticity persisted and, in 2008, Zhou and co-workers were able to reprogram acinar 
into insulin-producing cells in vivo. For this study, a mixture of adenovirus co-
expressing one of the three key pro-endocrine developmental transcription factors (Pdx1, 
Ngn3 and Mafa), with nuclear GFP, was injected into the pancreas of acinar-specific 
lineage traced mice (Cpa1CreERT2; R26LSL- β galactosidase (βgal)). Soon after 
transduction, lineage traced cells up-regulated an endocrine program and exhibited 
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insulin content and secretion with co-expression of additional β-cell markers (Zhou et 
al., 2008). 
Additional evidence has been obtained for acinar cell plasticity without the need for 
genetic manipulation. It has been observed that, although inefficiently, long term assault 
via prolonged PDL, can induce pre-labelled acinar cells to convert into β-cells (Pan et 
al., 2013). Moreover, the in vivo treatment of adult alloxan-treated mice with ciliary 
neurotrophic factor and epidermal growth factor demonstrated that acinar cells could 
convert into β-cells, restoring normal glycaemia (Baeyens et al., 2013). These results 
support the assumption that Desai and co-workers might have missed the labelling of 
acinar cells capable of conversion, possibly due to the use of different Cre mouse lines, 
or that the extent of injury was not enough to induce an acinar-dependent endocrine cell 
regeneration. 
If acinar cells are capable of restoring endocrine tissue, although with limited capacity, 
it is reasonable to investigate their ability to regenerate the exocrine pancreas. In vitro 
strategies have highlighted the capacity of acinar cell explants to convert into ductal 
cells when cultured on nitrocellulose filters with stimulating factors (Githens et al., 
1994). Nowadays, there is far-reaching knowledge of their ability to acquire a ductal 
molecular profile and morphology upon injury in vivo. It has been extensively observed 
that PDL, Px and caerulein treatments stimulate intense ductal cell expansion upon 
acinar cell death (Slack, 1995). By the use of lineage tracers, it was possible to identify 
that the observed ductal expansion was, in fact, a transdifferentiation of acinar cells into 
ductal cells, denominated acinar-to-duct metaplasia (ADM) (Means et al., 2005). ADM 
will be extensively addressed in this thesis (see 1.6.2, page 74). 
 
1.1.2.3 Ductal cells 
Despite their proportionally small tissue representation, the ducts play a crucial role in 
pancreatic physiology. Ductal cells are responsible for the production of bicarbonate-
rich fluid which, combined with the acinar-derived enzymes, forms the pancreatic juice. 
Moreover, ductal cells are also responsible for the delivery of the pancreatic juice into 
the duodenum, to help digestion. The pancreatic ductal compartment consists of a 
convoluted network of ducts that can be subdivided according to their calibre and 
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histological features. Proximal to the bile duct, with the biggest calibre and initiating the 
network, is the main duct, composed of a columnar epithelium. Branching out of the 
main duct are the interlobular ducts constituted of cuboidal epithelia, which divide into 
intralobular and intercalated ducts containing flat cells. At the terminal end of the ductal 
network, a poorly characterized ductal cell, named centroacinar cells, is located 
(Reichert and Rustgi, 2011) (Figure 3). While ductal cells seem to differ 
morphologically between different segments, so far, their identification relies on 
common marker expression: cytokeratin 19 (CK19), Sox9, hepatocyte nuclear factor-1-
beta (Hnf1β) and the surface affinity for the dolichos biflorus agglutinin (DBA). 
 
 
Figure 3 – Schematic representation of the ductal network and cellular composition 
The ductal network is composed of ducts of different calibres and different histological 
features. The main duct has the largest calibre and is composed of columnar cells. 
Interlobular ducts have a reduced calibre, compared with the main duct, and are 
composed of cuboidal cells. Branching out of intelobular ducts are the intralobular ducts 
that give rise to the intercalated ducts. Both present flat cells. At the tips of the ductal 
network, centroacinar cells connect with the acinus. 
 
Despite their low proliferative index, similar to acinar and endocrine cells (Githens, 
1988), lessons from development have exposed the possibility of a higher plasticity for 
ductal cells compared with other pancreatic cell types. During pancreatic organogenesis, 
the population of progenitors sits in a primordial network, which culminates in the 
development of the ductal system. Therefore, the presence of a facultative stem cell 
population in the adult ductal compartment is hypothesised. Initial in vitro cultures of 
human ductal tissue demonstrated that cultured ductal cells reactivate an embryonic 
program, up-regulating Pdx1 and subsequently converting into insulin-producing cells 
able to respond to the presence of glucose (Bonner-Weir et al., 2000). In vivo evidence 
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of ductal plasticity was obtained after Px of rat pancreata. Bonner-Weir and co-workers 
observed, in 1993, that after 90% Px, part of the ductal compartment drastically 
increased proliferation with concomitant Pdx1 expression. Furthermore, during 
regeneration of the damaged organ, it was observed that 6% of the ductal cells in the 
main duct expressed insulin with 1% exhibiting insulin granules (Bonner-Weir et al., 
1993, Bonner-Weir et al., 2004). In a different study, the pancreatic tail of Balb/c mice 
was ligated, with, as observed for other models, a measurable regeneration of the β-cell 
population. The phenomenon was shown to be dependent on the expression of the 
endocrine fate determinant Ngn3. By tracing Ngn3 expression using Ngn3-nLacZ mice, 
the authors demonstrated that β-cell neogenesis was derived from the ductal cells given 
its co-expression with CK19 (Xu et al., 2008). Despite the numerous studies 
demonstrating the occurrence of insulin-expressing clusters near/within ducts upon 
injury, lineage-tracing analysis was still needed to unquestionably demonstrate the 
potential of ductal cells for β-cell neogenesis. 
Conflicting results have been presented regarding ductal cell plasticity. The use of duct 
cell specific, tamoxifen inducible, Cre-expressing mice, where Hnf1β (Hnf1β-CreER) 
and Sox9 (Sox9-CreERT2) promoter expression drive βgal labelling, pointed towards an 
absence of ductal cell-derived endocrine neogenesis. PDL and β-cell ablation were used 
as models of injury to promote β-cell regeneration. Notwithstanding observation of β-
cell mass expansion, no contribution from the pre-labelled ducts was detected (Solar et 
al., 2009, Kopp et al., 2011). On the other hand, the use of carbonic anhydrase II (CAII) 
or Ck19 genes driving a tamoxifen inducible Cre (CreER) have shown otherwise. In the 
first study, CAII-CreER; Rosa26-LSL-LacZ mice showed a marked increase in the 
number of labeled endocrine cells, after PDL, in the ligated pancreatic tail compared 
with controls (Inada et al., 2008). Genetic modulation of Fbw7 protein, a recognition 
component (F-box) of a Skp1-Cul1-Fbox (SCF)-type ubiquitin ligase, has also unveiled 
the ability of ductal cells to convert into insulin-expressing cells. Deletion of Fbw7 in 
ductal Ck19-expressing cells led to the conversion of a small number of labeled cells 
into functional β-cells. The authors demonstrated that Ngn3 protein is a direct target of 
Fbw7-dependent proteasomal degradation and thus, deletion of the ligase component 
led to Ngn3 accumulation and consequent ductal cell transdifferentiation (Sancho et al., 
2014). These contradictory results can be explained by the selective labelling of ductal 
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cells with the different Cre lines. Hnf1β-CreER and Sox9-CreERT2, although efficient, 
only labelled 65% of the ductal population. It is still an open question if the same ductal 
populations were labelled with the different Cre drivers or if progenitor-like ductal cells 
could have been selectively unlabelled. Moreover, Sox9 labelled cells showed Ngn3 
upregulation upon injury. 
As demonstrated by Sancho and co-workers, it is possible that the stability of the Ngn3 
protein was not enough for completion of the endocrine differentiation program 
(Sancho et al., 2014). Since the extent of the injury dictates the signals to which the 
cells are exposed, different levels of injury could culminate in different outcomes. 
Lastly, ductal cells were also shown to be able to generate acinar cells. By the use of a 
duct specific Cre mouse model (Sox9-CreER) with a Cre-dependent lineage tracer, the 
authors were able to identify traced acinar cells when tamoxifen treatment was 
performed in the adult mouse. In this study, it was not clear if this was a plasticity of the 
ductal cells converting into acinar cells or if a pool of progenitors residing within the 
ductal tree expresses Sox9 (Furuyama et al., 2011). This finding is still under debate 
(Carpentier et al., 2011). 
Nonetheless, the observations obtained so far for acinar, endocrine and ductal cells 
unveil a cellular plasticity within the pancreas that might compensate for cellular loss 
after sustained injury (Figure 4).  
 
Figure 4 – Pancreatic cellular plasticity 
Summary of the cellular plasticity observed for the different pancreatic compartments.  
Glucagon (α) and somatostatin (δ)-producing cells can transdifferentiate into insulin-
producing β-cells. Acinar cells can give rise to ductal cells and β-cells and ductal cells 
can give rise to acinar cells and β-cells.  
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1.2 Pancreatic cancer 
Cellular plasticity is an important feature of tissues exposed to damage and provides a 
unique tool for organ/tissue regeneration. However, the same mechanism used to 
repopulate different lineages after injury uncovers a cellular vulnerability to neoplastic 
hits. As mentioned before, all pancreatic cell types are provided with a cellular and 
genetic flexibility, which enables their tumourigenic transformation. Therefore, 
mimicking the pancreatic complexity, a whole spectrum of pancreatic tumours has been 
identified. The three most common pancreatic neoplasias will be described here. With 
defined histological features, resembling their normal counterparts, and characterized 
molecular alterations, pancreatic tumours can be presented as endocrine tumours 
(harbouring multiple endocrine neoplasia type 1-MEN1 mutations, amongst others) 
(Mingyi Chen, 2012), acinar cell carcinomas (harbouring APC/β-catenin mutations) and 
ductal adenocarcinomas (harbouring mutations in a wider range of genes, see 1.3.2, 
page 37 (Hezel, 2006) (Table 1). 
 
Pancreatic cancer 
type 
% of 
pancreatic 
cancers 
Histological 
presentation Genetic alterations References 
Endocrine tumours 
(Gastrinomas, 
Insulinomas, 
Glucagonomas, 
Somatostatinomas) 
1-2% 
Round to oval 
nuclei; Granules; 
Hormone 
production 
MEN1; VHL, NF-1; 
TSC; 
Loss of 1 and 11q; 
 Gain of 9q 
(Mingyi Chen, 
2012) 
Acinar cell 
carcinoma < 2% 
Polygonal shape; 
Zymogen granules APC/β-catenin 
(Stelow et al., 
2006b, Hezel, 
2006) 
Ductal 
Adenocarcinoma > 85% 
Ductal 
morphology; 
Desmoplasia 
KRAS; TP53, 
SMAD4, p16INK4A (Hezel, 2006) 
Table 1 - Summary of the histological features and genetic alterations of pancreatic 
tumours 
 
 For the purposes of this thesis, only pancreatic ductal adenocarcinomas, from now on 
referred to as PDAC, will be addressed.  
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1.3 Pancreatic Ductal Adenocarcinoma (PDAC) 
Comprising more than 85% of all pancreatic cancers, PDAC, whose name stems from 
its histological resemblance to ductal cells, is a devastating disease representing the 
fourth most common cancer-related death across the world (Hariharan et al., 2008). 
Contrasting with other tumour types, the increase in PDAC biology knowledge is not 
reflected in a improved patient outcome, where mortality mimics incidence rates (Jemal 
et al., 2008). Thus, although an overwhelming number of detailed and well-crafted 
studies have been conducted so far, much remains to be understood about the disease.  
 
1.3.1 Clinical data and disease management  
The absence of specific symptoms (abdominal pain and rare jaundice) and the 
aggressive nature of the disease, with early lymphatic and haematogenic dissemination 
to the lungs and liver (Schneider et al., 2008, Rhim et al., 2012), are the main 
contributors to the low prognosis of PDAC. Less than 4% of patients survive 5 years 
after diagnosis, due to presentation of unresectable cancerous tissue and presence of 
metastatic disease. Nonetheless, even in the manifestation of a localized tumour, a 
combination of surgery and chemotherapy only increases the 5-year survival to 20%, 
(Hezel, 2006). 
Increased susceptibility to PDAC has been documented for some environmental and 
genetic factors such as advanced age, chronic pancreatitis, smoking, obesity, long-
standing diabetes and familial history (Everhart, 1995, Fuchs, 1996, de Gonzalez et al., 
2003, Schenk et al., 2001), with some risk factors showing a stronger evidence over 
others. Hereditary PDAC has been reported, which accounts for approximately 10% of 
all PDAC cases. If little is known about the genetic alterations that confer increased 
PDAC risk in a hereditary context, less is known about the initial causative mutations. 
Nevertheless, germline mutations in the tumour suppressors INK4A, LKB1, MLH1, the 
hereditary pancreatitis-causing gene PRSS1 and the cystic fibrosis gene CFTR, have 
been reported (Whitcomb et al., 1996, Jaffee et al., 2002). Given the accentuated 
paracrine effect that exocrine dysfunctions, such as pancreatitis, might exert on normal 
tissue (by induction of reactive oxygen species and growth factor and cytokine-induced 
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responses), it is not surprising that familial pancreatitis, induced by mutations in the 
cationic trypsinogen gene PRSS1, appears to be the major risk factor, increasing PDAC 
risk by 50-fold in older patients (Lowenfels et al., 1997). The role of pancreatitis in 
PDAC onset will be discussed in detail in the thesis (see 1.5.2, page 71). 
Initial detection methods rely on imaging by computed tomography (CT) coupled with 
intravenous administration of contrasting agents. Additional imaging approaches might 
be required if negative results are obtained (Hidalgo, 2010). Serological marker 
detection usually represents the least invasive approach for tumour 
diagnosis/monitoring. However, the search for PDAC specific biomarkers has 
constituted a challenge. The haematogenic presence of the tumour-associated antigen 
CA19-9 has been described as a biomarker for PDAC presence (Forsmark et al., 1994). 
However, non-specificity reports and the high percentage of false negatives 
compromises its value (Chan et al., 2014). 
When PDAC is detected, staging is performed so that the therapeutic strategy can be 
outlined. Given the usually advanced stage of the disease at the time of diagnosis, and 
the complications of surgical procedures performed in aged patients, less than 15% of 
patients are candidates for surgical resection. Consequently, adjuvant and neoadjuvant 
therapies have been developed to improve prognosis. Response to chemotherapy has not 
been uniform for PDAC patients (Bittoni et al., 2014). Nonetheless, encouraging results 
have been obtained with pre-surgical FOLFIRINOX treatments, a combinatory 
treatment using fluorouracil (5-FU, pyrimidine analogue), irinotecan (topoisomerase I 
inhibitor), oxaliplatin (platinum-based antineoplastic agent, alkylating agent) and 
leucovorin (folinic acid) (Ferrone et al., 2015), or, more efficiently, Gemcitabine 
(nucleoside analogue) alone (Burris et al., 1997), or in a dual combination with either 
Erlotinib (HER1/EGFR tyrosine kinase inhibitor) (Moore et al., 2007) or cisplatin 
(platinum-based antineoplastic agent, alkylating-like agent) (Palmer et al., 2007). 
Despite all efforts to improve treatment, the drastic PDAC stromal reaction, which, 
notwithstanding its possible role in slowing down tumour progression (Wang et al., 
2014) forms a barrier impairing chemotherapy perfusion (Erkan et al., 2012), the low  
tumour vascularization (Olive et al., 2009) and the inherent cellular resistance to the 
drugs (Miranda-Lorenzo et al., 2014) compromise chemotherapy response. In order for 
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better neoadjuvant treatments to be generated, a deep understanding of PDAC 
molecular biology is crucial. 
1.3.2 PDAC molecular genetics 
Molecular analyses of patient derived PDAC have unravelled a comprehensive range of 
genetic alterations within these tumours. Advanced stage tumours are characterized by a 
marked aneuploidy, which might be the result of mutations in genomic stability 
regulator genes. Recent genetic analyses have identified at least 63 different gene 
alterations to be present and relevant in PDAC development/maintenance. Despite the 
fact that this overwhelming genetic variability culminates in the development of high 
inter- /intra-tumour heterogeneity, there is a consistency in the signalling pathways 
affected: apoptosis, DNA damage repair, cell-cell adhesion, invasion and cell cycle 
regulation (Jones et al., 2008). Some of the most common molecular abnormalities 
found in PDAC will be discussed below and include: mutations in the tumour 
suppressors TP53, SMAD4 and CDKN2A, mutations in the KRAS proto-oncogene and 
de-regulations of pancreatic embryonic signalling pathways.  
1.3.2.1 KRAS proto-oncogene and effector pathways 
KRAS, named after Kirsten rat sarcoma viral oncogene homolog, where it was first 
described (E H Chang, 1982), is a small GTPase protein, consisting of 188 amino acids 
(approximately 21kDa), and it is involved in the intracellular transduction of 
extracellular signals. KRAS activity is tightly regulated by a switch between an active 
and inactive state, depending on the type of guanoside N phosphate it is bound to. 
Activation occurs upon binding to guanosine triphosphate (GTP) promoted by guanine 
nucleotide exchange factors (GEFs). The active, GTP-bound, KRAS undergoes 
conformational changes allowing it to interact with downstream effectors. At the same 
time, KRAS also interacts with GTPase-activating proteins (GAPs), which induce the 
removal of GTP by enhancing KRAS intrinsic ability to hydrolyse GTP into guanosine 
diphosphate (GDP) (Figure 5). 
Upon stimulation of receptor tyrosine kinases (RTKs), and their consequent activation, 
the growth factor receptor binding (GRB2) adaptor protein, which under basal 
conditions is bound to the SOS domain of the GEF protein by the Src homology 3 
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(SH3) domain, is recruited to the plasma membrane and interacts with the RTK, via its 
SH2 domain. This leads to the proximity of the GEF with RAS and consequent 
formation of the RAS-GTP active complex (Rajalingam et al., 2007). When active, 
KRAS promotes transduction of cell surface-derived signals and activates a convoluted 
signalling cascade involving numerous pathways that culminate with a gene expression 
response that affects growth, differentiation and apoptosis (Figure 6). 
KRAS point mutations, leading to KRAS activation, are found in almost all PDAC (over 
90%) (Waddell et al., 2015) and mainly occur (98%) in codon 12 (exon 1), resulting in 
a amino acid change from Glycine (G) to either Aspartic acid (D) or Valine (V), 
referred to as G12D and G12V, respectively. These mutations impair the intrinsic 
hydrolytic activity, by blocking KRAS interaction with the GAP, which results in a 
constitutively active form of RAS with persistent signal transmission. Besides its 
overwhelming presence in late-stage PDAC, KRAS mutations are the first genetic 
alteration found in the early stages of tumour development, suggesting a key role in 
PDAC biology. Several mouse models have addressed PDAC requirement for KRas 
mutations showing that not only is it crucial for murine PDAC (mPDAC) initiation, it is 
also required for tumour maintenance. By means of a tetracycline inducible oncogenic 
KRas, it was possible to remove the oncogenic insult at different points. It was observed 
that silencing mutant KRas, at either early or late stages of tumour growth, halts 
mPDAC development with noticeable tumour regression (Collins et al., 2012a). 
Although the RAS protein is involved in the activation of numerous downstream 
signalling pathways, the canonical RAF/MEK/ERK and PI3K/PDK1/AKT pathways 
are the main ones involved in PDAC tumourigenesis (Eser et al., 2014).  
 
Figure 5 – The KRAS switch 
Illustration of the switch between the inactive and the active form of KRAS. Inactive 
KRAS is bound to GDP. Guanine nucleaotide exchange factors catalyse the dissociation 
of GDP and the binding of GTP molecules. GTP-bound KRAS is active and promotes 
downstream signal transduction. Inactivation of KRAS occurs by GTPase-activating 
proteins that increase the rate of GTP hydrolysis.  
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1.3.2.1.1 RAF/MEK/ERK pathway 
In a very simplified description, oncogenic KRAS activates the rapidly accelerated 
fibrosarcoma (RAF) serine/threonine-specific kinase, leading to consequent 
downstream phosphorylation and activation of the tyrosine/threonine kinase MEK (1/2). 
MEK activates, by phosphorylation, the extracellular signal-regulated kinase (ERK) 
protein (Seger and Krebs, 1995), and ERK phosphorylates downstream effectors 
modulating proliferation and other cellular functions (Figure 6). Members of this 
pathway are rarely mutated in PDAC. However, BRAF, a member of the RAF family, 
has been reported to be mutated in 7 to 15% of human PDAC. Interestingly, BRAF and 
KRAS point mutations are mutually exclusive, emphasizing the importance of this 
pathway for PDAC development. In the absence of KRAS mutations, BRAF mutations 
might be selected to activate the pathways (Calhoun et al., 2003).  Additionally, 
activation of the pathway downstream of RAS by the constitutive expression of mutant 
BRAF (BRAFV600E) in the embryonic pancreas, has demonstrated that this pathway 
alone is capable of PDAC formation, similarly to KRAS mutant mice (Collisson et al., 
2012). 
 
1.3.2.1.2 PI3K/PDK1/AKT pathway  
In a very brief overview, phosphatidylinositol 3-kinase (PI3K) is composed of a 
catalytic p110 and regulatory p85 subunits. Activation of PI3K leads to the conversion 
of phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-
triphosphate (PIP3), allowing PIP3 to subsequently bind and activate the complex 
phosphoinositide-dependent kinase 1 (PDK1)/AKT. This activation can be inhibited by 
the phosphatase and tensin homolog (PTEN) protein that dephosphorylates PIP3 to PIP2. 
Activated serine/threonine-specific protein kinase AKT promotes cell survival and 
proliferation through modulation of the activity of several downstream effectors. 
Activation of the PI3K/PDK1/AKT pathway can be accomplished in three different 
ways: (1) activated RTKs promote the binding of the PI3K-p85 domain to their 
phospho-YxxM motif triggering p110 activation; (2) GRB2 proteins bind to scaffolding 
proteins and the complex binds to p85; (3) interestingly, activation of the RAS pathway 
Chapter 1 Introduction 
 40 
also activates PI3K-p110 domain independently of p85 (Castellano and Downward, 
2011) (Figure 6). 
Despite the absence of point mutations in components of this pathway in human PDAC, 
strong evidence supports its crucial role in PDAC development and maintenance. It has 
been observed that PDAC cell lines and tumour tissue samples exhibit low expression 
of the tumour suppressor PTEN. Methylation-specific PCR analyses have suggested 
promoter methylation to be the main cause of PTEN downregulation. The consequent 
AKT activation was shown to lead to increased cell proliferation that could be 
counteracted by the PI3K inhibitor, LY294002 (Asano et al., 2004). Moreover, 
constitutive in vivo pancreatic expression of an active form of PI3K (PIK3CAH1047R/+), 
which presents a mutation in the catalytic domain of p110α, was demonstrated to 
generate PDACs, phenocopying the observations obtained with mouse models with 
KRas oncogenic pancreatic expression (Eser et al., 2013). These results were further 
strengthened by inhibition of this pathway in mutant KRas-derived murine PDAC. 
Genetic deletion of PDK1 (AKT activatior upon PIP2 to PIP3 conversion) abrogated 
KRasG12D-induced PDAC formation, while the loss of Craf, component of the 
RAF/MEK/ERK pathway, in KRasG12D mouse model of PDAC had no inhibitory effect 
in PDAC formation (Eser et al., 2013). 
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Figure 6 – RAS signalling via RAF/MEK/ERK and the PI3K pathway 
The figure provides a simplified overview of RAS canonical signalling and its 
interaction with the PI3K pathway. Activation of KRAS occurs by growth factor (GF) 
binding to receptor tyrosine kinases (RTK). Active KRAS (GTP) signals downstream to 
RAF/MEK/ERK. The PI3K signalling pathway can be activated by RAS or independent 
of RAS. Active PI3K promotes PIP3 formation from PIP2 and initiates downstream 
activation of PDK/AKT. PTEN can inhibit PI3K-dependent signalling.  
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1.3.2.2 The CDKN2A tumour suppressor 
The ability to escape checkpoints during the cell cycle is a very important feature of 
tumour cells. For this reason, cell cycle regulators are commonly altered in human 
cancers. Cell cycle initiation, and progression, roughly depends on the formation and 
activation of complexes containing the following proteins: cyclins and cyclin-dependent 
kinases (CDKs). These proteins are the main regulators of the cell cycle. Nonetheless, 
they are also a target for regulation by CDK inhibitors. Two inhibitor families have 
been described based on their structure and CDK specificity: the CIP/KIP family and, 
the focus of this sub-chapter, the INK4/ARF family (Lim and Kaldis, 2013). 
One of the most studied CDK inhibitors is the cyclin-dependent kinase inhibitor 2A 
(CDKN2A), which is involved in the inhibition of the G1/S phase transition of the cell 
cycle. This gene encodes 2 proteins: p16INK4a and p14ARF (or p19ARF in mice) derived 
from alternative splicing. The different proteins generated by the CDKN2A gene have 
independent functions in regulating cell cycle progression. While p16INK4a inhibits the 
phosphorylation of the Retinoblastoma (Rb) protein by the complex cyclin1-CDK4/6, 
which is required for G1-S progression in the cell cycle, p14ARF inhibits mouse double 
minute 2 homologue (MDM2)-dependent proteasomal degradation of p53, stabilizing it 
(Kim and Sharpless, 2006) (Figure 7). 
Preliminary indication of the involvement of CDKN2A in pancreatic cancer arose from 
the higher familial predisposition to PDAC development in CDKN2A germline 
mutation-harbouring siblings (Whelan et al., 1995). In depth analysis of sporadic PDAC 
revealed an overwhelming representation (over 80% of PDAC) of CDKN2A 
inactivation (Rozenblum et al., 1997). These mutations have been documented, in 
PDAC, to affect p16INK4a alone or both p16INK4a and p14ARF, while mutations affecting 
only p14ARF have never been observed. The occurrence of these mutations has only been 
described for advanced PDAC, positioning them as a later requisite for PDAC 
development. In line with the observation, the genetic ablation of both p16INK4a and 
p19ARF, in the mouse pancreas, had a drastic synergistic effect on PDAC progression 
when combined with KRAS embryonic oncogenic activation. However, deletion of the 
tumour suppressors alone failed to promote tumourigenesis excluding them as PDAC 
drivers (Aguirre, 2003).  
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Figure 7 – The CDKN2A tumour suppressor gene and encoded proteins 
The figure provides a simplified view of the two main protein encoded by the CDKN2A 
gene, products of alternative splicing. CDKN2A encodes p14ARF and p16INK4a. Protein 
p14ARF inhibits MDM2-dependent p53 proteasomal degradation. Protein p16INK4a 
inhibits CDK4/6-dependent Rb phosphorylation. This step is required to release 
inhibitory Rb function over E2F and promote consequent G1/S progression of the cell 
cycle.  
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1.3.2.3 The TP53 tumour suppressor 
The p53 protein, also referred to as the gardian of the genome, is a potent tumour 
suppressor involved in the regulation of a vast number of key cellular features. 
Activation of this protein can be initiated by different stimuli that induce cellular stress, 
leading to induction of numerous cellular responses including differentiation, DNA 
damage repair, cell cycle arrest, apoptosis and senescence, among others. Given the 
protein’s broad impact on cellular biology, extensive and thorough studies have been 
performed to understand how this protein is regulated and to shed light on the 
mechanisms by which it exerts its effect. However, a comprehensive knowledge is still 
yet to be achieved. p53 functions, mainly, as a transcriptional regulator, inducing or 
repressing gene expression upon activation. Stimuli lead to p53 binding to DNA with 
consequent promotion/repression of expression of downstream effectors involved in the 
above-mentioned cellular responses. Nevertheless, p53 has also been shown to harbor 
some transcriptionally-independent functions, mainly for apoptotic responses 
(Vogelstein et al., 2000). 
Regulation of p53 is a critical step for maintenance of cell viability. Levels of this 
protein are tightly controlled by transcriptional and post-translational mechanisms. The 
key p53 post-translational regulator is MDM2. The MDM2 gene encodes an E3 
ubiquitin-ligase protein. By promoting the addition of ubiquitin chains to the target 
protein, E3 ligases generate the critical signal for proteasome-dependent protein 
degradation. Hence, MDM2 facilitates p53 ubiquitination, inducing its degradation by 
nuclear and cytoplasmic proteasomal degradation (Figure 8). A further regulatory 
mechanism has been observed for MDM2, as it is able to physically bind to the NH2-
terminal domain of p53, directly inhibiting its transcriptional activity (Moll and 
Petrenko, 2003, Oliner et al., 1993). A third layer of complexity is achieved with p53’s 
ability to transcriptionally regulate MDM2. This creates an autoregulatory negative 
feedback loop with p53 regulating MDM2 expression and MDM2 regulating p53 
protein stability and function (Figure 8). Thus activation of a p53-dependent response 
can be achieved by the induction of post-translational modifications that promote 
conformational changes allowing the protein to evade MDM2-dependent degradation. 
Conversely, activation can also be promoted by induction of changes on the MDM2 
protein impairing its ability to recognise p53 (Moll and Petrenko, 2003).  
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The protein p53 was initially implicated in tumour progression due to the observation 
that a familial condition caused by p53 mutations, Li-Fraumeni syndrome, led to 
increased susceptibility to tumour development. It was later described that this disease 
is a rare autosomal-dominant disorder that relies on germline inactivating mutations of 
the p53 and CHEK2 genes, the latter being able to stabilize p53 (Marielle WG Ruijs, 
2009, Srivastava et al., 1990). Additional evidence from mouse models indicated that 
the absence of p53 protein, by generation of a mouse harbouring a homozygous p53 
null allele, greatly increases spontaneous tumour susceptibility (Donehower et al., 1992). 
Nowadays, it is known that aberrant expression of p53 is one of the most common 
features of human cancers, with point mutations being observed in 50% of these 
tumours (Freed-Pastor and Prives, 2012).  
Mutations in p53 are also extremely common in PDAC patients. While no p53 mutation 
has been observed in early phases of disease development, more than 80% of the later 
stage tumours harbour p53 aberrant expression (Rozenblum et al., 1997). The late 
presentation of p53 mutations, together with their high incidence in PDAC and the fact 
that Li-Fraumeni syndrome patients do not present pancreatic cancer, led to the 
suggestion that this gene could be more important for PDAC progression rather than 
initiation. Confirming the hypothesis, whole body genetic ablation of p53, both 
heterozygous and homozygous, using mouse models, failed to give rise to pancreatic 
tumours. However, it drastically promoted the formation of malignant lymphomas and 
sarcomas (Donehower et al., 1992). Moreover, the expression of a gain of function 
mutant form of p53 (Trp53R172H), present in human PDAC, failed to induce PDAC 
formation by itself. Nonetheless, it demonstrated a drastic synergistic effect when 
concomitantly expressed with oncogenic KRasG12D (Hingorani et al., 2005).  
PDAC is characterized by an intricate landscape of abnormalities. Detailed analyses of 
human samples have documented a step-wise acquisition of chromosomal aberrations 
that would initiate the activation of cell cycle checkpoints and, consequently, hinder cell 
survival and proliferation. Thus, it is likely that p53 inactivation confers a clear growth 
advantage on tumour cells. 
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Figure 8 – MDM2-p53 regulation (feedback loop) 
Simplified illustration of p53 regulation and the feedback loop. The E3 ligase MDM2 
targets p53 for proteasomal degradation. MDM2 is also able to directly bind to p53, 
inhibiting its transcriptional activity. The protein p53 functions mainly as a 
transcriptional regulator, repressing cell cycle progression genes and promoting the 
expression of apoptotic genes and of its own regulator MDM2. 
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1.3.2.4 SMAD4 and TGFβ signalling 
SMAD4 (mothers against decapentaplegic homolog 4), also known as “deleted in 
pancreatic carcinoma locus 4” (DPC4), is a fundamental component of the transforming 
growth factor-β (TGFβ) family. The TGFβ signalling pathway plays a crucial role in 
modulating key cellular responses including tissue morphogenesis, apoptosis, 
proliferation and differentiation. The TGFβ pathway can be activated by various 
different ligands, including bone morphogenetic proteins (BMPs), growth and 
differentiation factors (GDFs), anti-müllerian hormone (AMH), activin, nodal and 
TGFβ (Weiss and Attisano, 2013). However, for the purpose of understanding the 
pathway and its involvement in pancreatic cancer, a simplified view will be provided. 
Two types of cell surface serine/threonine kinase receptors detect TGFβ signals, type I 
and type II. Upon external signal stimulation, and consequent formation of a 
heterotetrameric complex, the receptor II, which is constitutively phosphorylated, 
phosphorylates receptor I, activating it for signal transduction. Signal transduction is 
carried out by type I receptor substrates called SMAD proteins, referred to as SMADs 
from hereafter. There are different types of SMADs responsible for signal transduction 
of specific signals and with different modes of action: receptor-regulated SMADs, 
coSMADs and antagonistic SMADs. SMAD1, 2, 3, 5 and 8 are designated receptor-
regulated SMADs, as they are direct substrates of the TGFβ-family receptor. Regarding 
their function, while SMAD2 and SMAD3 are involved in signalling stimulated by 
TGFβ's, activins, and nodals, SMAD1, SMAD5 and SMAD8 transduce BMP-derived 
stimuli. On the other side of the spectrum, antagonistic SMAD6 and SMAD7 inhibit the 
activating function of receptor-regulated SMADs. Despite the distinctive roles of 
receptor-regulated SMADs, all of them associate with a coSMAD to be able to 
translocate to the nucleus and regulate transcription. The only known coSMAD is 
SMAD4, making it a key component of the TGFβ signalling pathways  (Figure 9) 
(Massagué, 1998). 
Another important feature to be mentioned is the ability of this pathway to stimulate 
activation of other equally important signalling pathways, such as the RAS signalling 
pathway. RAS pathway activation occurs independently of SMADs. Despite being a 
serine-threonine kinase, TGFβ receptor II can also autophosphorylate tyrosine residues, 
although inefficiently. Moreover, it can also be tyrosine-phosphorylated by Src proteins. 
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This tyrosine phosphorylation constitutes a docking site for the SH2 domain of the 
GRB2 adaptor protein, initiating the RAS signalling cascade (Figure 9) (Zhang, 2009). 
As the name indicates, DPC4 (SMAD4) is frequently lost in pancreatic cancers. It was 
initially observed that 90% of PDAC harbours allelic loss at chromosome 18q. Detailed 
genetic mapping of a wide range of pancreatic tumours enabled the identification of a 
consensus lost region at 18q21.1, where SMAD4 is located (Hahn et al., 1996). 
Following the identification of the tumour suppressor, it has been observed that SMAD4 
is lost in about 30% of PDAC, although its expression is reduced in about 55% of 
PDACs due to additional inactivating mutations (Iacobuzio-Donahue et al., 2000b). 
Loss of SMAD4 expression is a late event in PDAC tumourigenesis (Wilentz et al., 
2000), thus attributing a tumour progression-related role to the protein. Supporting the 
hypothesis is the observation that blocking the TGFβ signalling pathway, by genetic 
deletion of either TGFβ receptor type II or SMAD4 in mouse pancreas, has no effect in 
tumour formation, unless in combination with oncogenic KRAS, where it accelerates 
tumour onset (Ijichi et al., 2006, Bardeesy et al., 2006b). 
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Figure 9 – TGFβ and BMP signalling 
Simplified illustration of TGFβ and BMP signalling. Upon receptor activation receptor-
regulated SMADs (green) get phosphorylated and associate with the coSMAD4 (pink). 
This complex is translocated to the nucleus where it transcriptionally regulates several 
cellular functions. The signal can be blocked by the inhibitory activity of antagonistic 
SMADs 6 and 7. Type II receptors can also, inefficiently, activate the RAS pathway.  
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1.3.2.5 NOTCH pathway and FBW7 regulation 
During tumourigenesis, cells acquire the ability to re-enter cell cycle and modulate their 
own growth, as well as the microenvironment. It is thought that tumourigenesis roughly 
recapitulates embryonic development. Hence, it is not surprising to find de-regulated 
embryonic pathways in cancer cells. One important pathway activated in PDAC is the 
Notch signalling pathway (Jones et al., 2008). 
The NOTCH pathway is a highly conserved pathway responsible for the mediation of 
short-range signals, whose function is crucial during embryonic development and 
adulthood. Although it is mainly known to participate in cell fate decisions, NOTCH is 
also involved in survival and cell cycle regulation, under specific signals.  It is 
functional in different cell types, promoting different cellular responses. Therefore, and 
highlighting its importance, genetic alterations in this pathway lead to a long list of 
human disorders and cancers (Andersson et al., 2011). 
There are 4 Notch receptors, NOTCH1, NOTCH2, NOTCH3 and NOTCH4. These 
receptors are located at the cell surface and are composed of: (1) extracellular EGF-like 
repeats (EGF-LR) enabling receptor/ligand interactions; (2) LIN-NOTCH repeats 
(LNR) adjacent to the membrane which modulate the interaction between the receptor’s 
extracellular and intracellular domains; (3) a RBPJ-associated molecule (RAM) domain 
(4) six intracellular ankyrin repeats (which enable protein-protein interaction) flanked 
by nuclear localisation signals (NLS); (5) a PEST domain responsible for rapid protein 
degradation, preventing the signal peptide from long lasting signal transmission; and (6) 
a transactivation domain (Figure 10a). NOTCH receptors respond to two types of 
ligands: Delta-like and Jagged/Serrate. NOTCH ligands are transmembrane proteins and 
thus, in order for Notch signal activation, cell-cell contact is required. There are 3 Delta-
like ligands, Delta1, Delta3 and Delta4, and 2 Jagged ligands, Jagged1 and Jagged2. 
Although structurally different, both ligand types share a Delta Serrated and Lag2 
(DSL) domain that mediate the interaction between the ligand and the EGF-like repeats 
of the receptors. Upon ligand/receptor interaction, the receptor exposes an extracellular 
cleavage site susceptible to the protease activity of the transmembrane proteases 
ADAM10 (A desintegrin and metalloprotease 10) and ADAM17, also known as TACE 
(tumour necrosis factor-α converting enzyme). This step is followed by another 
cleavage mediated by a membrane protein, designated ɣ-secretase, leading to the release 
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of the NOTCH receptor intracellular domain (NICD) to the cytoplasm. NICD contains 
nuclear localisation signals allowing it to be translocated to the nucleus, where it binds 
to RBP-J (Fiúza and Arias, 2007). In the absence of activated Notch, RBP-J is bound to 
DNA exerting a repressive effect on gene transcription. However, upon Notch 
activation, NICD binds to RBP-J, inducing the recruitment of transcription co-activator 
mastermind-like (MAML). The formation of the complete complex ultimately leads to 
transcription of NOTCH targets; the best studied so far being the transcriptional 
repressors HES (1 and 5) and HEY1 (Figure 10b). Following transcription, HES and 
HEY lead to repression of differentiation and promotion of proliferation (Borggrefe and 
Oswald, 2009). 
As mentioned before, the NOTCH pathway is implicated in tumourigenesis. Similarly, 
the role of NOTCH in PDAC biology has been described.  By comparing normal tissue 
expression with pancreatic precursors, Miyamoto and co-workers have detected that 
several members of the pathway were upregulated in early stages of PDAC, both at the 
RNA and protein level, with consequent upregulation of the transcriptional target HES1. 
Moreover, ectopic NOTCH activation in normal pancreas explant cultures led to the in 
vitro generation of PDAC precursors – ADM (see 1.6.2, page 74) (Miyamoto et al., 
2003). Additionally, it has been documented that a panel of PDAC cell lines treated 
with ɣ-secretase inhibitor (GSI) have reduced proliferation indexes and reduced colony 
formation ability in soft agar compared with untreated cultures. When GEM models 
harboring a heterozygous deletion of the tumour suppressor p53 with concomitant KRas 
oncogenic activation in the embryonic pancreas were treated with GSI after precursor 
lesions were observed, they exhibited a reduction in the progression from precursors to 
PDAC (Plentz et al., 2009). 
Given the broad cellular responses that NOTCH modulates, its regulation has to be 
extremely tight. Different responses might be achieved depending on the level of 
activation. This hypothesis was originated due to the observation that, unlike most 
signalling pathways, the NOTCH pathway does not exhibit an intracellular signal 
amplification. Instead, a stoichiometric relationship is observed, where one ligand binds 
to the receptor, releasing one downstream effector. Additionally, post-translation 
regulation ensures a proper signal transduction by enhancing activation or inducing 
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repression of the pathway. For the purposes of this thesis, only proteasome-mediated 
regulation by the protein FBW7 will be discussed. 
The FBW7 protein is an F-box component of the S-phase-kinase-associated protein-1 
(SKP1)-cullin-1 (Cul1)-Fbox protein (FBP) (SCF)-type E3 ubiquitin ligases, members 
of the ubiquitin-proteasome system (UPS).  The UPS is an important pathway that 
allows quick and regulated protein degradation. Due to its ability to alter protein levels, 
it is crucial for cellular homeostasis and signal response. The initiation of the pathway is 
dependent on the activation of ubiquitin protein (Ub) by an E1 Ub-activating enzyme, in 
an adenosine triphosphate (ATP)-dependent manner. The activated Ub is then 
transferred to an E2 Ub-conjugating enzyme. Lastly, an E3 ligase promotes the transfer 
of the activated Ub to a specific substrate, establishing the protein degradation signal 
(Ravid and Hochstrasser, 2008).  
Protein degradation is a highly selective event, relying on the identification of specific 
substrates. In the case of SCF-type E3 ligases, the F-box protein provides such 
specificity. Although different classes of F-box proteins have been described, only 
FBWs will be discussed. As the name indicates FBWs are WD-40 repeat containing-F-
box proteins. These repeats form a circularized β-propeller that recognizes serine and 
threonine phosphorylation signals at specific consensus sequences (phosphodegrons) 
(Cardozo and Pagano, 2004).  
The list of substrates of the FBW7-containing E3 ligase is ever-growing. Some of the 
substrates identified include c-Myc, cyclin E, NOTCH, c-Jun, and Mcl-1 (Figure 10b). 
Given its main targets, FBW7 has been described as a potent tumour suppressor and 
plays a major role in cell differentiation, proliferation and maintenance of genomic 
stability. FBW7 deletion and the consequent increase in downstream targets has been 
implicated in several human cancers (Cheng and Li, 2011, Sancho et al., 2010). 
However, its relevance in PDAC biology has been poorly addressed. The first report of 
FBW7 deregulation in PDAC was submitted by Calhoun and co-workers, who have 
identified that 6% of PDAC present cyclin E overexpression partially due to 
inactivating mutations in the FBW7 gene (Calhoun et al., 2003). Additional studies also 
described a link between the RAS pathway and FBW7 by demonstrating that Ha-RAS 
activation inhibits FBW7-dependent cyclin E degradation (Minella et al., 2005).  
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Nonetheless, FBW7 involvement in PDAC biology, as well as its role in mediating 
NOTCH de-regulation in PDAC, is still an open question. 
 
Figure 10 – The NOTCH signalling pathway and FBW7 
a) Schematic representation of the domains present in the NOTCH receptor. EGF-LR – 
EGF-like repeats. LNR – LIN-NOTCH repeats. RAM - RBPJ-associated molecule 
domain. NLS – Nuclear localisation signal. ANK – ankyrin repeats. TAD – 
transactivation domain. PEST – protein degradation domain b) Simplified illustration of 
the NOTCH signalling pathway and FBW7-dependent degradation of substrates. 
NOTCH ligands are present at the surface of neighbouring cells, thus, cell to cell 
contact is crucial. Upon binding of the NOTCH receptor (via EGF-LR) to the DSL 
region on the ligand, the transmembrane domain gets cleaved by ADAM10/ADAM17 
and ɣ-secretase. The intracellular domain (NICD) is released to the cytoplasm, 
translocated to the nucleus and forms a complex with RBPJ and MAML. This 
transcription-activating complex leads to expression of transcriptional repressors 
(HES1/5 and HEY). FBW7 provides a post-translational regulation of NOTCH and 
additional proteins by proteasome-dependent degradation.  
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1.4 Morphological clinical presentation of PDAC and precursor 
lesions 
At the time of diagnosis, PDAC patients already exhibit an advanced stage of the 
disease. Low response to chemotherapy and high aggressiveness impair any chance of 
patient survival. Great knowledge has been gained on the molecular requirements for 
PDAC development and maintenance. However, despite the use of this information in 
the improvement of chemotherapy, little success has been obtained (Bittoni et al., 2014). 
Therefore, better understanding of the initial events leading to PDAC onset and the 
comprehension of its precursor lesions are crucial to improve early detection and 
change current survival figures. 
Following the development achieved for other tumour types, a progression model has 
been proposed for pancreatic cancer (Hruban et al., 2000a). Based on morphological 
and histological analysis, lesions with increased cellular atypia have been described. 
These lesions were postulated as precursors of PDAC based on their genetic alteration 
landscape (Cubilla and Fitzgerald, 1976). Observations made so far have identified 4 
types of neoplastic precursors which can present a convergent evolution towards 
PDAC: intraductal papillary mucinous neoplasia (IPMN); pancreatic mucinous cystic 
neoplasm (MCN), intraductal tubular papillary neoplasm (ITPN) and pancreatic 
intraepithelial neoplasia (PanIN) (Hruban et al., 2007).  
These lesions have been detected and documented before nomenclature was established. 
Hence, it is very common to find different references to these morphological entities, 
such as “lesions”, “metaplasias”, “hyperplasias” and “dysplasias”. The absence of a 
universal classification hampered the identification and consequent distinction of these 
independent precursors. To address this issue, the “Pancreas Cancer Think Tank” 
meeting, involving several experts, was held in 1999 to generate a standard 
categorization (Kern et al., 2001). A consensus nomenclature, and mode of operation 
for diagnosis, was generated. Nevertheless, there is still great controversy and difficulty 
in the distinction between lesions. 
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1.4.1 Intraductal Papillary Mucinous Neoplasm (IPMN) precursor 
IPMNs were initially described as rare mucin-secreting pancreatic cancers. Nowadays, 
they are classified as infrequent cystic pancreatic lesions. On a morphological and 
histological level, IPMNs, as the name indicate, are characterized by a columnar 
epithelium with a papillary architecture and detectable mucin (Muc) production, 
identified by either immunohistochemistry or alcian blue/periodic acid-Schiff stain 
(AB/PAS). They consist of large legions (≧1cm), usually detectable by medical 
imaging techniques, such as computed tomography (CT) and magnetic resonance 
imaging (MRI), and are thought to generated from the increased proliferation of the 
main pancreatic duct epithelium or major branches. Concerning their clinical 
significance, it has been observed that one third of patients harbouring IPMNs progress 
to invasive carcinoma. As mentioned before for precursor lesions in general, there is an 
on-going discussion for the classification of these lesions (Cooper et al., 2013). Several 
subtypes of IPMNs have been described based on histological features and mucin 
expression. However, the diversity reported might be overestimated as some of the 
identified lesions have similar features but appear to be classified under different names.  
According to World Health Organization (WHO) Classification of Tumours of the 
Digestive System, there are four types of IPMNs with different grades of dysplasia:  
Gastric, Intestinal, Pancreatobiliary and Oncocytic (Hamilton and Aaltonen, 2000) 
(Table 2). Given the variable classification, several attempt were made to fully 
characterize IPMN subtypes (Yonezawa et al., 2008, Cooper et al., 2013, Distler et al., 
2014), which will be summarised below: 
 
Gastric IPMN, the most common subtype and presenting low-grade dysplasia, is 
characterized by a papillary columnar epithelium with mild atypical nuclei located 
basally and supranuclear mucin production. While other IPMN are thought to be mainly 
formed from the main duct, the gastric type is found on branching ducts. It is very 
similar to another low-grade precursor, PanIN-1 (see 1.4.4, page 59), being separated 
from this lesion on the basis of size and location within the ductal network. Gastric 
IPMN are larger lesions than PanINs. Regarding mucin production, these lesions 
express Muc5ac (a secreted mucin) and Muc6 (membrane mucin) but do not express 
Chapter 1 Introduction 
 56 
Muc1 and Muc2 (membrane-associated mucins). From a clinical point of view, the 
gastric subtype rarely progresses to invasive carcinoma (Figure 11a).  
 
Intestinal IPMN, originating in the main duct and with low to intermediate dysplasia, 
resembles colorectal villous adenoma for its morphological appearance and mucin 
expression. These lesions are characterized by long papillae composed of columnar 
epithelium with oval and elongated nuclei. The level of dysplasia is higher compared to 
the gastric type, thus, it is not surprising that their association with invasive carcinoma, 
mainly to colloid (mucinous noncystic) pancreatic carcinoma, is greater (20 to 40%). 
Regarding mucin expression for immunologic diagnosis, intestinal IPMNs express the 
intestinal marker CDX-2, Muc2 and Muc5ac, being negative for Muc1 and Muc6 
(Figure 11b). 
 
Pancreatobiliary IPMNs present high-grade dysplasia, being commonly associated with 
invasive carcinoma, and are characterized by the presence of complex branching 
papillae, lined by a cuboidal epithelium containing round nuclei. Similarly to the 
intestinal type, pancreatobiliary IPMNs have their origin in the main duct. These lesions 
exhibit Muc1 and Muc5ac expression, being negative for Muc2 (Figure 11c). 
 
Oncocytic IPMNs, the rarest type of IPMNs, are very similar to the pancreatobiliary 
type regarding histo- and morphologic features, with a complex branching of the 
epithelium. However, they exhibit a large number of goblet cells and cells with denser 
cytoplasm. Inconsistent data has been gathered regarding their mucin production. 
However, they appear to express Muc5ac and Muc6 (Figure 11d). 
IPMN subtype Origin (duct) Immunologic diagnosis Level of dysplasia 
Gastric Branching Muc5ac+ Muc6+ low/mild 
Intestinal Main Muc5ac+ Muc2+ CDX-2+ high 
Pancreatobiliary Main Muc5ac+ Muc1+ high 
Oncocytic Main Muc5ac+ Muc6+ high 
Table 2 - Summary of IPMN subtypes and main features 
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Figure 11 – Histological features of IPMN subtypes 
a) H&E of gastric IPMN showing papillary columnar epithelium with basally oriented 
nuclei and abundant supranuclear cytoplasm. b) H&E of intestinal IPMN showing long 
papillae composed of columnar epithelium and pseudostratified nuclei. c) H&E of 
pancreatobiliary IPMN showing branching papillae lined by cuboidal cells. d) H&E of 
oncocytic IPMN showing complex arborizing papillae composed of cuboidal and 
columnar cells. Adapted from Tanaka et al., 2012 with permission from Elsevier (see 
Chapter 6, Appendix) 
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1.4.2 Pancreatic Mucinous Cystic Neoplasm (MCN) precursor 
MCN lesions are the least common neoplastic precursors found in pancreatic cancer 
patients, although they are the largest (median size between 60 and 100 mm). Similar to 
IPMNs, MCNs are cystic lesions with high mucin production presenting Muc5ac and 
Muc2 expression. However, they have no detectable connection to the ductal network 
and occur in the body or tail of the pancreas. Detection of these lesions is usually 
accidental and presents a favourable prognosis. Nevertheless, reports have suggested a 
worse prognosis in comparison to IPMNs (Hamilton and Aaltonen, 2000). 
Histologically, MCNs present a flat columnar epithelium with occasional papillae and a 
fibrous pseudocapsule (Figure 12). Cells have expanded cytoplasm with nuclei located 
basally and supranuclear mucin production. The level of dysplasia can vary from low to 
high and progression culminates in PDAC. They can be readily distinguished by the 
presence of an ovarian-like stroma, which is their main diagnostic feature (Distler et al., 
2014, Cooper et al., 2013, Yonezawa et al., 2008).  
 
 
Figure 12 – Histological features of MCN lesions 
H&E of MCN showing flat columnar epithelium and underlying ovarian type stroma. 
Adapted from Distler et al., 2014. For permission of use see Chapter 6, Appendix.  
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1.4.3 Intraductal Tubular Papillary Neoplasm (ITPN) precursor 
Recently, as a consequence of sub fragmenting the IPMN category, a new precursor 
lesion has been included to the list by the WHO, entitled intraductal tubular papillary 
neoplasm. Abundant, and localized tubular nodules, with little mucin production, 
characterize this neoplasm. These lesions are highly dysplastic and somewhat resemble 
the pancreatobiliary IPMNs. However, the prognosis is relatively favourable. The recent 
established nomenclature, and its underrepresentation within exocrine neoplasias (0.9%), 
impairs the proper definition of this lesion. Nonetheless, reports so far indicate that it is 
located in the main duct or major branches and can be found throughout the pancreas 
(head, body and tail). Cells can be cuboidal or columnar, arranged in a cribriform 
epithelium, with round nuclei. Although mucin production is low, as assessed by the 
almost absent AB/PAS stain, membrane-associated mucins present in PDAC are also 
present in the pre-neoplastic precursor, such as Muc1 and, less frequently, Muc6 
(Cooper et al., 2013). 
 
1.4.4 Pancreatic Intraepithelial Neoplasia (PanIN) precursor 
By far the most common pre neoplastic PDAC precursor, and the most thoroughly 
studied, is the pancreatic intraepithelial neoplasia. Being the first documented pre-
neoplastic lesion, the variability in its classification is not unexpected. Similarly to the 
approach undertaken for other precursors, a consensus was generated for diagnosis and 
classification of PanINs (Hruban et al., 2001). According to several reports, PanINs are 
microscopic lesions (<5mm) that occur mainly in intralobular ducts.  
A sub classification for PanINs has also been proposed and, despite the fact that, in 
broad terms, all PanINs express the same mucins (Muc1, Muc6 and Muc5ac), they can 
be distinguished by their increased degrees of architectural and cytological atypia 
(Table 3) (Yonezawa et al., 2008, Hamilton and Aaltonen, 2000). 
 
PanIN1 is the earliest stage of PanIN development with low-grade dysplasia. In the 
human it can be subdivided into two different types (1A and 1B) according to its 
architecture. However, such distinction is not made in the mouse where only PanIN1 is 
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reported. As mentioned before, PanIN1 resembles the gastric IPMN, but can be 
distinguished from these lesions based on their smaller size. 
 
PanIN1-A is characterized by a flat epithelium composed of cells with a prominent 
enlargement of the cytoplasm (columnar) towards the lumen and nuclei located basally 
(Figure 13). Abundant mucin is produced and, thus, it can be clearly identified at early 
stages of development by AB/PAS stain. It is a fairly common lesion being observed in 
40% of the pancreata not presenting invasive carcinoma (Figure 13). 
 
PanIN1-B presents a papillary or pseudostratified architecture with the same 
histological and molecular features observed in PanIN1-A (Figure 13). 
 
PanIN2 lesions are characterized by a columnar epithelium with papillary architecture. 
Dysplasia is greater than in the previous PanINs, with increased nuclear abnormalities, 
such as loss of polarity and nuclear enlargement (Figure 13). Similarly to the lower-
grade PanINs, PanIN2 is highly mucinous and readily detected by AB/PAS stain. 
Moreover, proliferation is not evident, although some rare mitoses are reported. 
 
PanIN3 is characterized by the presence of a papillary, micropapillary or true cribriform 
epithelium. Fragmentation and budding of epithelial clusters towards the lumen is 
occasionally detected in combination with necrosis. Loss of polarity concomitant with 
nuclear positioning near the lumen is frequently observed (Figure 13). It is a highly 
proliferative lesion but mitoses are abnormal. These lesions present a lower mucin 
production compared to other lesions. If not absent, they exhibit low AB/PAS stain and 
Muc5ac. PanIN3 is present in nearly all PDAC specimens reported so far. However, 
their observation in the absence of invasive carcinoma has not been reported. Due to 
their high frequency and prominent dysplasia, a distinction between pre-neoplastic and 
neoplastic is close to impossible. It has been suggested that these lesions actually 
constitute a PDAC extension. Hence, they are also referred to as “carcinoma in situ” 
(Hruban et al., 2007, Cooper et al., 2013). 
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PanIN grade Histo/Cytological features Markers 
1A 
Flat columnar epithelium 
Supranuclear mucin, 
Round to oval nuclei 
Muc5ac 
AB/PAS 
1B 
(micro) Papillary columnar epithelium 
Supranuclear mucin 
Round to oval nuclei 
Muc5ac 
AB/PAS 
2 
Papillary columnar epithelium 
Nuclear abnormalities 
Pseudo-stratification 
Muc5ac 
AB/PAS 
3/"carcinoma in situ" 
Papillary to cribriform cuboidal 
epithelium 
Severe nuclear abnormalities 
Budding of clusters 
Frequent mitosis 
Loss of polarity 
- 
Table 3 - Summary of histological and cytological features of human PanINs 
 
 
Figure 13 – Histological features of PanIN lesions 
H&E showing histological features of human PanIN lesions. PanIN1A presents a flat 
epithelium with columnar cells and nuclei located basally. PanIN1B (black arrow) 
constitutes a papillary variant of PanINA. PanIN2 present papillary architecture with 
moderate cytological atypia. PanIN3 presents loss of nuclear polarity and papillary 
architecture with cuboidal and columnar cells. Images are not in the same scale. 
Adapted from Distler et al., 2014.For permission of use see Chapter 6, Appendix. 
 
Despite the efforts made for a unanimous classification of PanINs, some inconsistencies 
have been pointed out. Importantly, PanINs are found in almost all pancreata analysed 
for other pancreatic diseases besides PDAC (Cooper et al., 2013), which questions the 
true prognostic power of these lesions to predict PDAC development. 
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1.4.5 PDAC progression model 
Regardless of the type of tumour and the field of expertise, cancer progression models 
constitute a valuable tool for the understanding of the tumourigenic process by 
dissecting and simplifying complex events. Vogelstein has provided a crucial 
contribution to the elaboration of such a approaches, using colorectal cancer as his 
model of choice (Vogelstein and Kinzler, 1993). 
Epidemiological data, together with in vitro and in vivo approaches, have been used to 
understand how a normal cell undergoes transformation. Initial evidence indicated that 
cancer incidence increases with age. Furthermore, exposure to carcinogenic cues, such 
as radiation, were shown not to have an immediate effect on tumour formation. Tumour 
manifestation occurs with long latency, indicating that one damaging hit (mutation) is 
not sufficient for cancer development. Instead, a prolonged survival of the mutation-
containing clone, with further acquisition of genetic alterations, would explain this 
observation (Miller, 1980). In vitro and in vivo experiments with genetic transfer and 
ectopic expression, respectively, of oncogenes have also demonstrated the increased 
tumorigenic power of cooperation.  It has been observed that some oncogenes have little 
to no effect on tumour formation when present on their own. However, the concomitant 
expression of one additional hit promotes a synergetic response, thus highlighting that 
additional hits promote the acquisition of greater tumourigenic features (Land et al., 
1983). Interestingly, the gradual acquirement of genetic alterations can be correlated 
with morphological and histopathological features. It has been observed for human 
cancers that higher-grade tumours present a wider panel of genetic alterations when 
compared with lower-grade neoplasms. Moreover, human cancer data has demonstrated 
the presence of more than one genetic alteration in more aggressive tumours when 
compared with less aggressive/progressed ones (Alexandrov et al., 2013). 
The beauty of these models is the ability to infer cause/consequence relationships and 
make predictions based on current stages. Thus the proposal of a human tumour 
progression model, and consequent verification by mouse model strategies, constituted 
a pillar in colorectal cancer patients’ prognosis, as it provided critical information for 
the development of better genetic screening and chemoprevention approaches 
(Vogelstein and Kinzler, 1993). 
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The establishment of a model requires an unequivocal identification of lesions 
preceding the neoplasm. The identification of early lesions for cancers of accessible 
regions, such as the cervix and colon, is relatively non-invasive and thus possible to 
easily screen. However, other types of tumours, such as PDAC, require invasive 
approaches impairing access. Consequently, screening is not performed in the absence 
of symptoms. Therefore, the PDAC progression model has been inferred based on 
exhaustive assessments of PDAC resection specimens, pancreata of non-cancerous 
patients and mutational analysis (Hruban et al., 2000b, Hruban et al., 2000a). 
The triggering forces for the proposal of the PDAC progression model were: (1) the 
identification, in non-cancerous patients, of hyper proliferative ducts, commonly found 
in cancer; (2) the consequent observation that these proliferative ductal regions 
exhibited a higher level of atypia when present in cancer patients (Cubilla and 
Fitzgerald, 1976); and (3) the documentation that highly dysplastic lesions commonly 
occurred within regions presenting mild atypia (Furukawa et al., 1994). The model was 
re-enforced by the identification of a similar phenomenon in conditions with increased 
risk of pancreatic cancer development. Such was the case for pancreatitis and the 
presence of hyper-proliferative ducts (Yanagisawa et al., 1993). Although powerful and 
informative, the cases reported until then were only based on morphological features 
and thus, sensitive to misinterpretation. It was also possible that these abnormal ducts 
were just hyperplastic and reactive to environmental cues. A correlation with tumour 
development was only implied.  
Genetic tools provided the missing link between these structures and PDAC 
development. Assessment of the mutational landscape of these putative precursor 
lesions led to the observation that they harbour a simpler, although, similar genetic 
profile as their tumour counterpart (Kanda et al., 2012, Yanagisawa et al., 1993, Caldas 
et al., 1994). Microdissection of the different precursor lesions, of different grades, with 
follow up genetic analysis have allowed the elaboration of a progression model that 
correlates the sequential acquisition of genetic alterations with the increase in 
morphological and cytological dysplasia (Hruban et al., 2000a, Hruban et al., 2000b, 
Kanda et al., 2012). 
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In summary: KRAS mutations are the most common genetic alterations found in human 
PDAC. Not only are KRAS mutations the most common, they are also the earliest 
mutation, detected in 30% of PanIN1 lesions increasing to approximately 75% 
representation in PanIN3 (Feldmann et al., 2007). This is also the case for the remaining 
precursor lesions where it was observed that one third of the early IPMNs present KRAS 
mutations, culminating in 50% of invasive IPMN. Additionally, MCNs also harbour 
KRAS mutations in 20% of early lesions to 89% in malignant lesions (Delpu et al., 
2011). 
Another equally prevalent abnormality in PDAC is epidermal growth factor receptor 
(EGFR) and human epidermal growth factor receptor 2 (Her-2/neu) overexpression. 
From the immunohistochemical analyses of PDAC and adjacent duct hyperplastic 
lesions, it was observed that, in contrast to the absence of expression in normal ducts, 
82% of the flat hyperplastic ducts exhibit high levels of Her-2/neu expression which 
increases in proportion with the increase in atypia (Day et al., 1996). 
Other mutational events present in PDAC have also been identified in pre-neoplastic 
lesions. However, their absence in low-grade precursors suggests a role in the 
progression of dysplasia and excludes their involvement in tumour initiation. Such is 
the case for SMAD4, CDKN2A and p53, amongst other less represented molecular 
alterations. 
As a surrogate for CDKN2A mutations, the expression of p16INK4a has been analyzed. It 
has been observed that, although in cancer-associated PanINs p16 INK4a expression is 
low, PanINs in the context of pancreatitis present normal expression until later stages 
(low expression observed in 0% of PanIN1-A, 11% of PanIN1-B, 16% of PanIN2 and 
40% for PanIN3) (Rosty et al., 2003). P53 mutations are also detected at later stages of 
tumour development. Mutations in this gene are barely seen in early precursors, such as 
PanIN1 (0%), but are evident in a subset (12%) of PanIN3 (Delpu et al., 2011).  Lastly, 
SMAD4 mutations have also been observed in precursor lesions. Despite their absence 
in PanIN1 and 2, SMAD4 mutations, and consequent reduced expression, is observed in 
30% of high-grade PanIN3 (Hong et al., 2011).  
 
Given that PanINs are the most abundant precursor lesion, the pancreatic progression 
model (Figure 14), proposed by Hruban and co-workers (Hruban et al., 2000a) is now 
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accepted worldwide and used as a starting point for further in-depth analyses. 
Nonetheless, the fact that the data obtained for the generation of the model was based 
on fixed resected tissue, and the lack of screening methods, hinders the complete 
understanding of these lesions and their immediate role in tumour formation. In fact, the 
results obtained with the analysis of KRAS mutations have been controversial. While 
some have reported a high percentage of ductal lesions harbouring KRAS mutations, 
others show that this event only occurs in a small proportion of low-grade precursors 
(Lüttges et al., 1999, Löhr et al., 2005). This suggests that, either oncogenic KRAS 
might not be the only driving force for PDAC development, or that low-grade lesions 
do not necessarily progress to PDAC. Instead, they might be indicative of increased risk 
of development. Furthermore, the predictive power of PanIN presence is also being 
investigated. It has been observed, in a short-term study (10 years follow up), that the 
presence of PanIN lesions in the surgical margins upon PDAC resection does not 
correlate with increased risk of relapse (Konstantinidis et al., 2013). Additionally, 
PanINs have also been observed in the presence of other pancreatic neoplasms, such as 
acinar cell carcinomas (ACCs), MCNs, pancreatic endocrine tumours (PETs), 
cystadenomas (SCs), and solid pseudopapillary tumours (SPTs) (Stelow et al., 2006a). 
The ubiquitous presence of PanINs challenges their status as PDAC precursors, 
suggesting a broader relevance and origin in pancreatic insults. Thus, the successive 
evolution from low-grade lesion to PDAC is still under debate. 
 
Figure 14 -  PDAC progression model based on human data 
Illustration of the histological and architectural features of PDAC and its precursor 
lesions. Normal ducts are thought to acquire mutations leading to the generation of 
PanIN1A-1B, which progress to PanIN2, PanIN3 and PDAC.  
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1.4.6 PDAC cell of origin hypothesis (clinical data-based assumption) 
The identification of a cancer’s cellular origin has immeasurable benefits for the clinic 
as it provides unique information about tumour molecular origins/dependencies.  
PDAC is usually a moderately differentiated tumour with glandular, duct-like structures 
surrounded by abundant stroma. On a histological level, it presents large/medium 
tubular structures that can be papillary or cribriform. While its precursors are usually 
mucinous with a columnar epithelium, PDAC is less mucinous, presenting cuboidal 
cells with variable-sized nuclei. If well differentiated, neoplastic duct structures can be 
difficult to distinguish from normal ducts. These tumours retain some of the markers 
present in ductal cells, such as CK7, 8, 18 and 19, Muc1 and HNF1β, but also 
upregulate others, such as the embryonic transcription factor Pdx1 and 
carcinoembryonic antigen (CAE) (Hamilton and Aaltonen, 2000). Moreover, early 
studies detected hyperplastic ducts before and during PDAC onset. Given the 
morphological resemblance of PDAC and PanIN cells with pancreatic ductal cells, and 
the observation of hyperproliferative ducts before, and upon tumour formation, it was 
proposed that PDAC would have its origin in a ductal cell. Recent findings have 
challenged this hypothesis, as it will be discussed in this thesis (see 1.6.2, page 74). 
 
1.5 Genetically engineered mouse models (GEMs) of PDAC 
Great discoveries and deep understanding of PDAC biology and genetics can be 
achieved based on analyses of tumour resected fixed tissue. Clinical observations have 
provided the driving force for the understanding of the genetic and environmental 
components leading to PDAC. However, correlation analyses have to be challenged and 
put to the test so that stronger statements can be made. While in vitro studies are useful 
for isolated questions, the big picture can only be obtained by modulating cellular 
responses in their own environment. Animal models are powerful tools to shed light 
into the mechanisms of pathogenesis. 
Initial pancreatic cancer models used to understand PDAC biology were based on 
xenografts, where human tumour cells are transplanted in the mouse (subcutaneous or 
orthotopic tumours). Considering the injected cells are already coming from an 
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established tumour, issues such as the cell of origin and mechanisms of tumour 
initiation are difficult to address. Additional approaches took advantage of carcinogens 
to induce tumourigenesis. The results obtained with these approaches, although 
histologically mimicking the human disease, failed to clarify the events under a precise 
molecular alteration (Bardeesy et al., 2001). The generation of GEMs completely 
revolutionized cancer research. Deletion or ectopic expression of specific genes can, 
nowadays, be easily achieved. A great contribution was the generation of a Cre 
recombinase-dependent genetic manipulation. The Cre-based system provides an 
incomparable genetic tool that allows the irreversible induction of a genetic alteration 
by the recombination, and consequent excision, of DNA sequences flanked by loxP 
recognition sites (Sauer, 1998). Cre is expressed under the control of a tissue-specific 
promoter allowing tissue-specific genetic modulation. Similar to the specificity 
provided by Cre models, other approaches have been developed that serve a similar 
purpose. Lastly, the possibility to regulate Cre function provided another layer of 
control. This was achieved by fusing Cre to a mutated ligand-binding domain of the 
human oestrogen receptor (ER). Only in the presence of tamoxifen (an oestrogen 
agonist/antagonist), Cre is translocated to the nucleus and mediates loxP recombination 
and DNA excision (Feil et al., 1996). 
 
In the pancreatic cancer field, mouse models have been crucial to the understanding of: 
(1) the role of oncogenes and tumour suppressors in PDAC; (2) progression from 
normal tissue to neoplasia; (3) the cellular origin of pancreatic tumours; (4) the impact 
of the environment, such as inflammation, in PDAC development; and (5) the interplay 
between genetic and environmental insults. These finding are explored below and will 
be subdivided into embryonic or postnatal models.  
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1.5.1 Lessons from embryonic GEMs of PDAC 
In this chapter, a summary of the most common GEM models used (Table 4) and the 
main findings obtained will be discussed. 
 
The role of oncogenes and tumour suppressors in PDAC - Progression Model 
Studies have identified several genetic and epigenetic alterations to be present in both 
PDAC and its pre-neoplastic precursors. While these changes are observed, a 
cause/consequence relationship was not solid. GEM models have helped to clarify the 
role of these molecular aberrations and, thus, to better understand the step-wise 
progression of the disease.  
Initial attempts to create a GEM model for PDAC were made by ectopically expressing 
oncogenic KRasG12D under the control of the Ck19 (duct marker in adult pancreas; 
progenitor population during development) or Elastase 1 (Ela1 - acinar cell marker in 
embryonic development and adulthood) promoters (Grippo et al., 2003, Brembeck et al., 
2003). However, in both cases, KRas oncogenic expression was dependent on the 
regulation of the respective promoters used, and thus, the levels of expression did not 
mimic the human scenario. 
In 2003, Hingorani and co-workers generated a more physiologically relevant mouse 
model where KRas oncogenic expression was regulated by its own promoter (Hingorani 
et al., 2003). In this model, an oncogenic KRasG12D sequence, preceded by a loxP-
STOP-loxP (LSL) cassette, was knocked-in after the promoter region of the KRas locus 
and upstream of the coding sequence. This mouse model was then crossed to a Pdx1-
Cre deleter strain. In this model, the expression of the transcription factor Pdx1 at E8.5, 
in embryonic pancreatic progenitors, drives Cre expression, promoting the excision of 
the STOP cassette and transcription of the oncogenic KRasG12D. For the first time, a 
multi-step carcinogenesis of PDAC was documented, closely recapitulating the human 
disease. These animals developed murine PanINs (mPanINs) as early as 2 weeks of age. 
As proposed for the human disease, these mPanIN lesions progressed from grade 1 to 3 
and culminated with focal murine PDAC (mPDAC) development close to one year of 
age (Hingorani et al., 2003). Similar results were obtained using the Ela1-tTA/tetO-Cre 
model (Cre expression is promoted by tTa regulated by the Elastase promoter, in the 
absence of doxycycline) in combination with another endogenously regulated 
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oncogenic KRas (KRas+/LSLG12Vgeo) (Guerra et al., 2007). Since Elastase expression starts 
in the embryo, at E16.5, tumourigenesis begins before birth, in embryonic acinar cells. 
Doxycycline untreated KRAS+/LSLG12Vgeo; Ela1-tTA/tetO-Cre mice developed focal low-
grade mPanINs at 3 months, meeting the consensus classification described by Hruban 
and co-workers in the 2006 pancreatic GEM model report (Hruban, 2006). Over time, 
these lesions increased in grade and, at one year of age, half of the mice presented 
PDAC, supporting the progression model. These studies confirmed the common KRAS 
mutation found in humans (G12D) as being sufficient for PDAC initiation and 
progression. Nonetheless, the long latency of tumour onset also confirmed the observed 
need for additional molecular abnormalities for tumour development.  
It is known from the clinic that PDAC harbours more than just KRAS mutations. Given 
their absence in low-grade lesions and presence in the established tumour, these 
additional molecular alterations were suggested to be involved in the progression from 
pre-neoplastic to neoplastic disease. Such is the case for alterations in the genes 
CDKN2A, p53 and SMAD4. Similarly, GEM models were created that either 
deregulated these genes alone, or in combination with KRas constitutive activation. In 
summary, deletion of either p16INK4A/p19ARF (Ink4a/Arflox/lox), p16 INK4A or p53, in 
KRasG12D; Pdx1-Cre or KRas+/LSLG12Vgeo; Ela1-tTA/tetO-Cre mice, led to a drastic 
acceleration of tumour formation with no observable effect in the absence of oncogenic 
KRas (Bardeesy et al., 2006a, Aguirre, 2003, Guerra et al., 2011). Similarly, deletion of 
Tgfβ receptor 2 (Tgfbr2lox/lox), with concomitant expression of oncogenic KRasG12D in 
the embryonic pancreas (Ptf1a-Cre), significantly accelerated PDAC onset while having 
no effect in tumour formation when deleted alone (Ijichi et al., 2006). These mouse 
models have shed light on the importance and role of the tested oncogenes and tumour 
suppressors. Moreover, they have strengthened the proposed progression model by 
demonstrating the time-wise requirement for genetic alteration. An increasing number 
of genes and pathways are being put to the test using similar approaches, providing an 
extremely detailed understanding of the key players involved in PDAC tumourigenesis 
(Hanlon et al., 2010, Eser et al., 2013, Pérez-Mancera et al., 2012). 
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Molecular 
alterations Driver Target cell 
PanIN 
onset  
PDAC 
onset  Reference 
KRas+/LSL-G12D Pdx1-Cre Progenitor (E8.5) 2w 1y 
(Hingorani et 
al., 2003) 
KRas+/LSL-G12D p48/Ptf1a-Cre Progenitor (E9.5) 2w 1y 
(Hingorani et 
al., 2003) 
KRas+/LSLG12Vgeo Ela1-tTA/tetO-Cre No Dox 
Acinar 
progenitor 
(E16.5) 
3m 50% 1y 
(Guerra et 
al., 2007) 
KRas+/LSL-G12D 
Ink4a/Arflox/lox Pdx1-Cre 
Progenitor 
(E8.5) No info 7/11w 
(Aguirre, 
2003) 
KRas+/LSL-G12D 
Ink4a/Arflox/lox  lox/+ Pdx1-Cre 
Progenitor 
(E8.5) No info 2/8m 
(Bardeesy et 
al., 2006a) 
KRas+/LSL-G12D 
p53lox/lox or lox/+ Pdx1-Cre 
Progenitor 
(E8.5) No info 1.5/5m 
(Bardeesy et 
al., 2006a) 
KRas+/LSL-G12D 
p16lox/lox Pdx1-Cre 
Progenitor 
(E8.5) No info 4.5m 
(Bardeesy et 
al., 2006a) 
KRas+/LSL-G12D 
p53lox/lox 
p16lox/lox or lox/+ 
Pdx1-Cre Progenitor (E8.5) No info 6/7w 
(Bardeesy et 
al., 2006a) 
KRas+/LSLG12Vgeo 
p53lox/+ 
Ela-tTA/tetO-Cre 
No Dox 
Acinar 
progenitor 
(E16.5) 
No info 6m (Guerra et al., 2007) 
KRas+/LSL-G12D 
Tgfbr2lox/lox or lox/+ p48/Ptf1a-Cre 
Pancreatic 
progenitor 
(E9.5) 
3w  2/6m (Ijichi et al., 2006) 
Table 4 - Summary of the most commonly used prenatal PDAC GEM models and their 
respective phenotypes 
Table summarising the most commonly used mouse models of PDAC targeting the 
pancreas of pre-natal mice. w – weeks. m – months. y – years 
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1.5.2 Lessons from postnatal GEMs of PDAC 
PDAC is more prevalent in the aged population, thus it is very improbable that the 
driving mutations occur during human embryogenesis. The likeliest scenario is the 
acquisition of somatic mutations during adulthood. Hence, embryonic GEMs are limited 
in their capacity to fully mimic the human disease. Moreover, embryonic models do not 
answer the longstanding question of the cell of origin of PDAC (see 1.6.2, page 74). 
Thus, conditional modulation of gene expression constitutes an invaluable tool for 
investigating PDAC in the adult (Table 5). 
 
Tumourigenic resistance of the adult pancreas (possible stem cell-like pool?) 
A plethora of studies have demonstrated that KRasG12D activation in pancreatic 
progenitors is sufficient to drive tumourigenesis by induction of mPanIN lesions. 
Nonetheless, progenitor cells are thought to harbour the required activated mechanisms 
to rapidly respond to oncogenic hits. Thus, it does not answer the question of whether 
KRas oncogenic mutations would be able to transform an adult population. In order to 
address this issue, the activation of the oncogenic hit has been induced in the adult 
pancreas. Studies have addressed the ability of both adult acinar and ductal cells to give 
rise to PDAC. However, ductal-specific targeting has been unsuccessful (see 1.6.2, page 
74). Thus, the main findings obtained so far targeted adult acinar cells. Guerra and co-
workers have activated KRasG12V in acinar cells of an adult mouse. KRas+/LSLG12Vgeo; 
Ela1-tTA/tetO-Cre mice (tet-off system) were treated with doxycycline until 2 months 
of age (P60) to prevent Cre-dependent recombination. After doxycycline removal, mice 
were followed up to one year with no detectable histological aberration (Guerra et al., 
2007). In a follow up study, the concomitant homozygous deletion of p53 or 
p16INK4A/p19ARF, with KRASG12V expression, in adult acinar cells, also failed to induce 
any neoplastic growth (Guerra et al., 2011). These results suggest a high refractory 
nature of the adult organ to tumourigenesis. It is known that inflammation constitutes a 
high PDAC susceptibility state. Thus, the authors repeated the approaches with parallel 
induction of pancreatic inflammation (pancreatitis). Pancreatitis was induced with 
caerulein, a cholecystokinin analogue, treatment that promotes the premature activation 
and uncontrolled release of the acinar digestive enzymes, with consequent damage to 
the pancreas, mainly to acinar cells. The inflammatory environment acted 
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synergistically with KRas mutations to promote the formation of pre-neoplastic 
precursors and rare focal murine PDAC at 8 months post-Cre expression (Guerra et al., 
2007). Human PDAC aetiology had already established pancreatitis as a main risk 
factor. Nonetheless, theses studies have re-classified pancreatic inflammation as a 
crucial component of PDAC development.  
In contrast to the above-mentioned studies, it has been observed that adult acinar cells 
are, in fact, able to give rise to KRASG12D-dependent murine PanIN initiated mPDAC 
development (Habbe et al., 2008). This observation can be explained by: either the non-
comparable tumourigenic capacity of different KRas mutations (G12D vs G12V); the 
use of different Cre lines and consequently the different population targeted, or due to 
the different age of induction (6 weeks versus 8 weeks of age).  
 
 Molecular 
alterations Cre Driver 
Target 
cell Observation Reference 
A
ci
na
r 
KRas+/LSLG12Vgeo Ela1-tTA/tetO-Cre  Dox up to P60 
Adult 
acinar 
P60 
ADM, PanIN and PDAC 
development  require 
pancreatitis 
(Guerra et al., 
2007) 
KRas+/LSLG12Vgeo 
p53lox/lox or 
Ink4A/Arflox/lox 
Ela1-tTA/tetO-Cre 
Dox up to P60 
Adult 
acinar 
P60 
ADM, PanIN and PDAC 
development  require 
pancreatitis 
(Guerra et al., 
2011) 
KRas+/LSL-G12D Ela-Cre
ERT2Tg/+ 
Tamox at 6w 
Adult 
acinar 
6w 
PanIN without requirement of 
pancreatitis 
(Habbe et al., 
2008) 
KRas+/LSL-G12D Mist1Cre
ERT2/+ 
Tamox at 6w 
Adult 
acinar 
6w 
PanIN without requirement of 
pancreatitis 
(Habbe et al., 
2008) 
KRas+/LSL-G12D 
p53lox/lox CPA1-CreER 
Adult 
acinar 
P60 
PanIN and PDAC development 
in the presence of pancreatitis 
(Friedlander et 
al., 2009) 
E
nd
oc
ri
ne
 
KRas+/LSL-G12D 
alone or in 
combination w/ 
p53lox/lox 
RIP-CreER 
Adult 
β-cells 
P30/P60 
No transformation without 
caerulein. Chronic pancreatitis 
induced PDAC only in double 
mutants. 
(Friedlander et 
al., 2009) 
D
uc
t 
KRas+/LSL-G12D Ck19-CreER Tamox at 6w 
Adult  
duct 
6w 
No transformation. 
Rare PanIN 
Unspecific Cre diver. 
(Ray et al., 2011) 
KRas+/LSL-G12D Sox9-CreER
 
Tamox at P10 
Postnatal 
duct 
P10 
No transformation 
Rare PanIN 
Possible unspecific Cre line. 
(Kopp et al., 
2012) 
Table 5 - Summary of the most commonly used postnatal PDAC GEM models and their 
respective phenotypes 
Table summarising the most commonly used mouse models of PDAC targeting the 
pancreas of postnatal mice. P – postnatal day. w – weeks. Dox – Doxycycline. Tamox - 
tamoxifen 
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1.6 PDAC cell of origin 
A great part of understanding the nature of any tumour is the knowledge of the cells 
from which it originates. The awareness of the cell of origin has already been shown to 
provide crucial information regarding the initial stages of tumour development in 
different organs, as well as the molecular mechanisms involved in early tumourigenesis 
(Gangopadhyay et al., 2013, Jordan, 2007, Barker, 2014). Additionally, the 
identification of a more tumourigenic population can provide valuable insight into the 
biology of the organ homeostasis and regeneration. The search for pancreatic adult 
progenitor cells and PDAC cell of origin has been restless. An increasing amount of 
evidence points to the existence of cells with different tumourigenic potential, urging 
for a different handling in the clinic. 
 
1.6.1 PDAC heterogeneity and tumour molecular subtypes 
PDAC, as described before, is a disease that exhibits an extremely poor prognosis. This 
unfortunate phenomenon can be partially attributed to its extremely aggressive nature 
coupled with the lack of distinctive symptoms. Nonetheless, effective therapies should 
be capable of tumour remission, which is not the case. An important factor for evasion 
of chemotherapy is the heterogeneity of the tumour (Dexter and Leith, 1986). In fact, 
detailed genetic analyses have broadened the panel of molecular alterations detected in 
PDAC. In 2008, a comprehensive analysis of deletions, amplifications, mutations and 
gene expression of 24 PDAC patient samples identified an average of 63 genetic 
alterations whose functions spread over 12 signalling pathways (Jones et al., 2008). 
Furthermore, whole genome sequencing and copy number variation studies on 100 
tumour samples from PDAC have reinforced the great genetic variation present in these 
tumours. Chromosomal rearrangements were frequent and led to the deregulation of 
genes known to be important for PDAC development, as well as the identification of 
new potential drivers. Genetic instability was found to be extremely important to the 
chemotherapy outcome and thus, PDAC was sub-classified into 4 different categories 
according to their chromosomal structure: stable; locally rearranged, scattered and 
unstable (Waddell et al., 2015). In a different study, a distinctive classification was 
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made where a combined analysis of publicly available transcriptional datasets of 
resected PDAC with the laboratory’s own microdissected PDAC gene expression 
microarray data, was performed. In this study, a 62-gene molecular PDAC signature 
(PDAssigner) was obtained, that assigned particular expression profiles to different 
tumour subtypes with distinct clinical outcomes and responses to therapy. The subtypes 
were named “classical” (with a better prognosis), “exocrine-like” (with an intermediate 
prognosis) and “quasi-mesenchymal” (with the worst registered prognosis) due to the 
main functions of the genes expressed in each signature. Hence, the “classical” type 
expressed epithelial genes and genes commonly involved in adhesion, the “exocrine-
like” type exhibited high expression of genes involved in production and secretion of 
acinar cell digestive enzymes and the “quasi-mesenchymal” was shown to express high 
levels of genes associated with the mesenchyme (Collisson et al., 2011). At this point a 
complete understanding of the underlying reason for the different subtypes is not 
obvious. A correlation with KRAS dependency was proposed, but it does not segregate 
the samples into 3 different groups. One possible explanation for the different 
expression is that the expression is reminiscent profile of the cell of origin. It has been 
hypothesised that PDAC could arise from different pancreatic cellular compartments 
and thus the consequent tumours would be expected to fall into different profiles.  
 
1.6.2 Pancreatic cellular compartment of origin 
As mentioned above, the human data obtained for PDAC and its pre-neoplastic lesions 
has suggested that PDAC arises from ductal cells. Nevertheless, the cellular 
compartment of origin of PDAC is still a subject of pronounced debate. Using the 
knowledge of the detailed marker expression of the different pancreatic compartments, 
it was possible to generate GEM models that are specific for distinctive cell lineages 
(Table 5). 
Up to the initiation of the currently presented study, attempts to provide solid proof of a 
duct cellular origin had failed to demonstrate the tumourigenic capacity of these cells. 
Encouraging data on the ductal origin was originally provided by the deletion of Pten, 
an antagonist of the PI3K/PDK1/AKT pathway, in the embryonic pancreas. Ptenlox/lox; 
Pdx1-Cre mice exhibit an acceleration of the previously observed KRasLSL-G12D/wt; Pdx1-
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Cre model. This acceleration was suggested to be due to centroacinar cell expansion, a 
specialized type of ductal cells, and consequent transformation (Stanger et al., 2005). 
Nevertheless, Pdx1-Cre targeting is not specific to the ducts and thus the finding was 
later put to the test. 
Specific ductal cell targeting was achieved with the use of Ck19-CreER or Sox9-CreER 
mice. Both Ck19 and Sox9 have been proposed to be exclusively expressed in the 
ductal network. Crossing KRasLSL-G12D/wt with Ck19-CreER or Sox9-CreER failed to 
generate PDAC. The only observation, in both studies, was the presence of extremely 
rare PanINs, detected long after tamoxifen-induced recombination (Ray et al., 2011, 
Kopp et al., 2012). Thus, the current results discouraged PDAC as having its origin in 
the ductal compartment and triggered an extensive search for the cell of origin. 
It has been extensively demonstrated that plasticity is a characteristic of all pancreatic 
cells (see 1.1.2, page 26). Since the ductal cell of origin hypothesis was not confirmed, 
attention has been focused on the remaining cellular compartment. In order to narrow 
down the responsible compartment, Friedlander and co-workers used cell-specific Cre 
drivers that restricted the KRAS oncogenic activation to endocrine β-cells (RIP-CreER) 
and acinar cells (CPA1-CreER) (Friedlander et al., 2009). Two observations were made 
from this study. Firstly, it was reinforced that inflammation is important for promotion 
of tumour development, as the absence of a caerulein treatment failed to give rise to 
tumours in both compartments. Secondly, while β-cells required the concomitant 
homozygous deletion of p53 and caerulein treatment to induce rare mPDAC, acinar 
cells responded strongly with KRasG12D alone and inflammation. Furthermore, the use 
of the RIP-CreER model showed some labelled exocrine cells. Thus, it seemed that 
acinar cells constituted the main cellular source for PDAC. 
Although it seems counterintuitive, several studies had previously focused on the PDAC 
tumourigenic capacity of acinar cells. It had been previously reported that c-myc ectopic 
expression in acinar cells, by means of a Ela1-myc transgene, culminated in the 
formation of acinar cell carcinomas in half of the mice, while the other half presented a 
mass of duct-like cells which progressed to ductal adenocarcinomas (Sandgren et al., 
1991). In a following study, a similar approach expressing TGFα (Ela1-TGFα) was 
undertaken. It was observed that acinar cells from transgenic mice would progressively 
gain a ductal morphology with parallel upregulation of ductal markers (Wagner et al., 
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1998). This observation was then named acinar-to-duct metaplasia (ADM, conversion 
of an acinar cell into a ductal cell) and was thought to precede PanIN formation leading 
to PDAC. In accordance with these observations, it was demonstrated that soon after 
KRasG12D activation in the embryonic pancreas, ADM was the predominant 
morphological change. Interestingly, normal acinar cells near the ADM ductal clusters 
also presented ductal cell markers. Moreover, in the same study, a time course analysis 
demonstrated that early mPanIN lesions retain some acinar markers suggestive of an 
acinar cell origin or a partial acinar contribution to the pre-neoplastic lesion (Zhu et al., 
2007).  
Nowadays, it is known that KRas mutations induce ADM in vivo and in vitro (Shi et al., 
2012). Furthermore, caerulein-induced pancreatitis promotes extensive ADM, which 
might at least partially be the cause of the acceleration of acinar-derived PDAC 
observed in caerulein-treated KRas+/LSLG12Vgeo; Ela1-tTA/tetO-Cre mice (Guerra et al., 
2007).  
In summary, despite the ductal morphology, the greatest amount of evidence supports 
an acinar cell origin for PDAC via ADM-PanIN-PDAC progression (Figure 15). 
Nonetheless, a ductal cell origin cannot be excluded solely based on the studies 
performed so far. 
 
Figure 15 – PDAC progression model based on GEM data 
Illustration of the histological and architectural features of PDAC and its precursor 
lesions. Acinar cells undergo a transdifferentiation step, named Acinar to ductal 
metaplasia – ADM, and acquire a ductal morphology. These duct-like structures 
progress towards PDAC via the intermediate development of murine PanIN1, PanIN2 
and PanIN3.  
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1.6.3 Tumour-initiating cells 
Tumour-initiating cells (TICs), commonly referred to as cancer stem cells (CSCs), are 
an interesting, yet, still controversial concept. Tumours can be roughly seen as a 
hierarchical organization, where, over time, mutations in a cell or in a small group of 
cells confer a growth advantage over the neighbouring population.  
Xenograft-based studies have demonstrated that a high number of tumour cells is 
required to establish the new tumour, upon transplantation (Polyak and Hahn, 2006). 
While cell death is expected due to implantation procedures and crosstalk with the host, 
it would be estimated that, if all tumour cells have the same tumourigenic potential, that 
a smaller number of cells would be required for tumour formation. Hence, the theory of 
cancer stem cells emerged, as the subpopulation of cells within tumours with a unique 
capacity to initiate and maintain tumour development, and it has been a subject of 
discussion ever since (Jordan et al., 2006). 
A plethora of studies have been conducted in order to identify a cancer population 
responsible for tumour generation and maintenance. As a result, the establishment of 
subpopulations with high tumourigenic capacity, self-renewal ability and increased 
proliferative index have been detected for tumours of different organs, such as the brain, 
intestine, breast and the haematopoietic system (Barker, 2014, Gangopadhyay et al., 
2013, Wang and Dick, 2005).  
 
1.6.4 Clinical relevance of cancer stem cells 
CSCs are of extreme importance given their unique role in tumour initiation. However, 
many other features enhance their importance and relevance in therapeutic outcome. 
Chemotherapy drugs are developed based on the molecular information provided by 
cancer cell lines and patient biopsy samples. This means that the average molecular 
aberrations are detected while lowly represented changes are diluted out. CSCs 
constitute a minority in the tumour. Thus, while chemotherapies are designed for the 
molecular dependencies of the bulk tumour, they usually fail to target the CSC 
subpopulation. Tumour recurrence, despite evident remission after chemotherapy, has 
been a common finding, reported extensively (Vidal et al., 2013). Resistance to 
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chemotherapy can be attributed to several factors such as selection of resistant clones 
and microenvironment protection, amongst others. Nevertheless, CSCs have been 
shown to efficiently evade chemotherapy, in vitro and in vivo, by numerous 
mechanisms, such as dormancy, efflux pump-mediated drug exclusion or adapted 
molecular regulation (Rich and Bao, 2007). 
An additional layer of importance is given concerning the metastatic process. A parallel 
connection between CSCs and epithelial to mesenchymal transition (EMT) has been 
suggested. EMT is a biological process by which epithelial cells acquire a more 
mesenchymal phenotype, as a consequence of changes in the transcriptional profile. 
This enhances the migratory and invasive nature of these cells, allowing them to leave 
the primary tumour and colonize distant sites. It has been observed in different cancers 
that the CSC population harbours an increased metastatic potential, with a more 
pronounced EMT phenotype. Specific pharmacological targeting of these cells greatly 
reduces their invasive and colonization capacity (Sampieri and Fodde, 2012).  
Great knowledge has strengthened the relevance of CSCs in pathogenesis. Thus, the 
identification of such cells, and the understanding of their biology, might have 
immeasurable benefits for the development of better chemotherapeutic strategies.  
 
1.6.5 Pancreatic cancer stem cells 
PDAC is an extremely heterogeneous disease with poor response to chemotherapy. As 
discussed above, both heterogeneity and drug resistance can be attributed to the 
comprehensive molecular alterations and chromosome instability observed in these 
tumours, coupled with the intense desmoplastic reaction and low vascularity that 
accompanies tumour formation (Olive et al., 2009, Samuel and Hudson, 2011). 
However, evidence for a pool of cells with distinct and enhanced tumour-initiating 
potential has been documented (Hermann et al., 2007).  
The embryonic progenitor cells of the developing pancreas are equipped with extremely 
efficient molecular machineries capable of great plasticity. However, the regenerative 
capacity is greatly reduced after birth (Solar et al., 2009, Pan et al., 2013). Analogously, 
the ability to generate PDAC in mouse models decreases with age. When KRas 
mutations are targeted to the pancreatic embryonic progenitors, by the use of Pdx1-Cre 
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or Ptf1a-Cre mice, pre-neoplastic mPanIN lesions can be observed as soon as two 
weeks after birth, with PDAC onset at one year of age (Hingorani et al., 2003). 
Oncogenic insults in young mice, soon after birth, greatly delayed tumour onset as seen 
by Guerra and co-workers. Activation of oncogenic KRasG12D 10 days after birth 
initiated the tumourigenic program in acinar cells (KRas+/LSLG12Vgeo;Elas-tTA/tetO-Cre, 
doxycycline up to P10) with detectable early-grade mPanINs only at 6 months and rare 
focal PDAC one year post Cre-mediated recombination. The effect of age on 
tumourigenesis is even more obvious in adult mice. In the same study, the KRasG12V 
mutation was induced in adult acinar cells (P60) where no pathogenesis was observed 
up to one year, even with concomitant homozygous deletion of p53 (Guerra et al., 2007). 
These results nicely point to an exhaustion or reduction in the tumour-initiating 
population with age.  
Tumour formation can be induced in the adult pancreas, however it requires the 
concomitant presence of an inflammatory environment (Guerra et al., 2011). It has been 
described before that pancreatitis-induced regeneration relies on the repression of 
exocrine programs and the re-activation of embryonic pathways with simultaneous re-
expression of embryonic markers, such as Pdx1 (Jensen et al., 2005). Thus, it is 
reasonable to conjecture that adult PDAC tumourigenesis is dependent on the presence 
of stem cells/committed progenitors or the reactivation of stem cell programs.  
The search for tumour-initiating cells led to the development of technical strategies that 
could test, both in vivo and in vitro, the phenotypic tumourigenic differences between 
these cell populations. Currently accepted cancer stem cell assays rely on the 
identification of surface markers that enable the physical separation of this population 
versus the remaining tumour cells. This allows the comparison of the two populations 
regarding their ability to self-renew and give rise to differentiated progeny. Most 
commonly used in vitro assays compare the cellular capacity to grow as spheroids in 
non-adherent conditions where tumour-initiating cells overcome anoikis. Additionally, 
recent strategies have been developed, which rely on the ability of tumour-initiating cell 
to form organoids in soft matrices (Clarke et al., 2006). While in vitro approaches allow 
the high-throughput study of this specialized subpopulation, as the name indicates, the 
ultimate test for a tumour-initiating property is their unique ability to generate tumours 
in recipient mice, when isolated from the bulk, non-tumour-initiating population. Thus, 
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for a cell to be proposed as a tumour-initiating cell, it has to generate in vivo tumours in 
recipient mice, following injection of a small number of cells, and to recapitulate the 
cellular heterogeneity present in the primary tumour (Clarke et al., 2006). 
The increasing evidence for cellular heterogeneity within PDAC tumours triggered the 
search to define the tumour-initiating population. Cell surface marker screening of 
human PDAC samples demonstrated heterogeneity in expression of CD44, CD24, and 
Epithelial-specific antigen (ESA), previously described cancer stem cell markers. 
Transplantation into Non-obese diabetic/ Severe combined immunodeficient 
(NOD/SCID) mice indicated that CD44+CD24+ESA+ cells had the highest tumour 
initiating potential, where as few as 100 cells were capable of PDAC initiation, 
phenocopying the primary human tumour (Lee et al., 2008). In a different study, 
Hermann and co-workers identified a subpopulation expressing prominin1 (also known 
as CD133). The orthotopic transplantation of these isolated cells was able to generate 
tumours with as little as 500 cells, while their negative counterpart failed to do so even 
when 106 cells were transplanted. Tumours generated after serial transplantation of 
CD133+ cells maintained the histological features observed in the first generation 
tumours, indicating a stem cell-like capacity to give rise to differentiated progeny. 
Moreover, as suggested for most cancer stem cells, the CD133+ population was shown 
to be more resistant to common PDAC chemotherapy (Gemcitabine). Interestingly a 
double positive population for CD133 and C-X-C chemokine receptor type 4 (CXCR4) 
was present at the migratory front of the tumour. Orthotopic transplantation of 
CD133+CXCR4+ versus CD133+ cells demonstrated that both populations presented the 
same tumourigenic capacity, but tumour cells circulating in the blood were only 
detected when xenografts were performed with the double positive population. These 
results indicate that the tumour-initiating population described in this study contained a 
metastatic group of cells. This suggests that the tumour-initiating population is the one 
responsible for metastasis from PDAC tumours, highlighting the need for specific 
targeting of PDAC TICs (Hermann et al., 2007). 
Despite the encouraging results, immunohistochemical analysis of these CD133, CD44 
markers in human neoplastic pancreas indicates that cells positive for either CD133, 
CD44 or both might be more represented than what was initially reported (Matsuda et 
al., 2012, Immervoll et al., 2011). Moreover, some caveats in the studies mentioned 
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above, such as the possible inclusion of stromal cells in the cellular fraction that was 
negative for the selected tumour-initiating marker, might compromise the findings 
proposed. Thus, it is still not clear if CD133 or CD44 can identify a tumour-initiating 
population in the pancreas, or even if one exists. 
 
1.7 Aim of this Thesis 
Pancreatic ductal adenocarcinoma has been extensively studied. However, regardless of 
the great amount of molecular and histological knowledge gained so far, prognosis has 
remained poor with only 4% of the patients surviving more than 5 years (Hezel, 2006). 
It is becoming increasingly obvious that attention has to be focused on the initial stages 
of tumour development, when the disease is still manageable. In the study presented 
here, I aimed to investigate the origins of PDAC in the different pancreatic exocrine 
compartments at early stages of tumour development to better understand the 
contributions of each compartment to PDAC development. Additionally, I aimed to 
specifically identify the PDAC tumour-initiating cell for the future development of 
targeted chemotherapeutic strategies. 
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Chapter 2. Materials & Methods 
2.1 Materials 
2.1.1 Reagents and Consumables 
The consumables and reagents used for the development of this study were acquired 
from the companies listed or the Cancer Research-UK London Research Institute (LRI) 
Central Services: 
 
0.5 ml, 1.5 ml, 2 ml tubes   Eppendorf (Cambridge, UK) 
100bp DNA ladder    Life Technologies (NY, USA) 
1 kb DNA ladder    Life Technologies (NY, USA) 
1 ml, 5 ml, 50 ml syringes    BD Plastipak (Oxford, UK) 
5 ml, 10 ml, 25 ml serological pipettes Corning (Corning, USA) 
15 ml, 50 ml tubes     Corning (Corning, USA) 
18G, 19G needles       BD Microlance (Oxford, UK) 
6 cm diameter dishes (adherent cells)  Corning (Corning, USA) 
10 cm diameter dishes (adherent cells) Corning (Corning, USA) 
25 cm2 flasks (adherent cells)   Corning (Corning, USA) 
75 cm2 flasks (adherent cells)   Corning (Corning, USA) 
150 cm2 flasks (adherent cells)   Corning (Corning, USA) 
25 cm2 flasks (suspension culture)   Sarstedt (Leicester, UK) 
75 cm2 flasks (suspension culture)   Greiner bio-one (Stonehouse, UK) 
6-well plate (flat bottom)   BD Falcon (Oxford, UK) 
24-well plate (flat bottom)    BD Falcon (Oxford, UK) 
96-well plate (flat bottom)    BD Falcon (Oxford, UK) 
96-well plate (non-sterile)    Nunc (Rochester, USA) 
LS MACS columns     Miltenyi Biotec (Sussex, UK) 
QuandroMACS separator   Miltenyi Biotec (Sussex, UK) 
3,3,5-Triiodo-L-trhyronine    Sigma-Aldrich (Poole, UK)  
4-hydroxytamoxifen    Sigma-Aldrich (Poole, UK)  
ABC Kit Vector Laboratories   Vector Laboratories (Peterborough, UK) 
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Adenovirus     Gene Transfer Vector Core (Iowa USA) 
Advanced DMEM/F12   Life Technologies (NY, USA) 
Agarose     Bioline (London, UK)  
Alcian Blue     Sigma-Aldrich (Poole, UK)  
Ammonium chloride    LRI/CR-UK (London, UK) 
Ammonium persulfate   Sigma-Aldrich (Poole, UK)  
Ampicillin     Sigma-Aldrich (Poole, UK)  
B27 Supplement    Life Technologies (NY, USA) 
Bovine Pituitary Extract   BD Biosciences (Oxford, UK) 
Bovine serum albumin   Sigma-Aldrich (Poole, UK) 
Bromophenol blue    Sigma-Aldrich (Poole, UK)  
Caerulein     Sigma-Aldrich (Poole, UK) 
Calcium Chloride     Sigma-Aldrich (Poole, UK) 
Cell strainer (45 µm Nylon)   BD Falcon (Oxford, UK) 
Cell strainer (70 µm Nylon)   BD Falcon (Oxford, UK) 
Cholera Toxin     Sigma-Aldrich (Poole, UK) 
Collagenase type V    Sigma-Aldrich (Poole, UK) 
Collagenase P     Roche (Welwyn Garden City, UK) 
Collagen Rat Tail type I   BD Biosciences (Oxford, UK) 
Coverslips     Menzel-Glaeser (Braunschweig, Germany) 
DAB solution      BioGenex (Burlingame, UK) 
DAPI      Sigma-Aldrich (Poole, UK)  
ddH2O      LRI/CR-UK (London, UK)  
Dexamethasone    Sigma-Aldrich (Poole, UK) 
DirectPCR Lysis Reagent   Viagen Biotech (Los Angeles, USA)  
Disodium tetraborate    AppliChem (Darmstadt, Germany) 
DMEM     Life Technologies (NY, USA) 
DyeEx® 2.0 Spin Kit    QIAGEN (Crawley, UK) 
EDTA      Sigma-Aldrich (Poole, UK) 
EGF (human)      PeproTech (London, UK)  
Embedding cassetes    Tissue Tek (Basingstoke, UK) 
Eosin Y     Sigma-Aldrich (Poole, UK) 
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Ethanol     Fisher Scientific (Loughborough, UK)  
Ethidium Bromide    Sigma-Aldrich (Poole, UK) 
FACS tubes     Becton Dickinson (Oxford, UK)  
FGF-basic (human)     PeproTech (London, UK)  
FGF10 (human)     PeproTech (London, UK) 
Fluorescent Mounting Medium  DAKO (Ely, UK) 
Foetal calf serum (FCS)    PAA (Yeovil, UK) 
Gastrin     Sigma-Aldrich (Poole, UK) 
GoTaq PCR DNA Polymerase  Promega (Southampton, UK) 
Glucose      Sigma-Aldrich (Poole, UK) 
Glycerol     Sigma-Aldrich (Poole, UK)  
Glycine     Sigma-Aldrich (Poole, UK) 
Goat serum      Sigma-Aldrich (Poole, UK) 
Harris Hematoxylin (Shandon)  Fisher Scientific (Loughborough, UK) 
HBSS Ca2-/Mg2-     Invitrogen (Paisley, UK) 
Histo-Clear     Fisher Scientific (Loughborough, UK) 
Hydrochloric acid    Fisher Scientific (Loughborough, UK)  
Hydrogen peroxide    Sigma-Aldrich (Poole, UK) 
Illustra GFX DNA Purification Kit GE Healthcare (Little Chalfont, UK)  
Industrial methylated spirit (IMS)  LRI/CR-UK (London, UK)  
Isopropanol     Fisher Scientific (Loughborough, UK) 
ITS+ premix     BD Biosciences (Oxford, UK) 
MACs separation columns, 25 MS  Miltenyi Biotec (Surrey, UK) 
Marvel skimmed milk powder  A1 Laboratory Supplies Ltd (Enfield, UK) 
Matrigel, Growth Factor Reduced   BD Biosciences via VWR 
Mayer`s hematoxylin    LRI/CR-UK (London, UK) 
Magnesium Chloride    LRI/CR-UK (London, UK) 
N-2 supplement    Life Technologies (NY, USA) 
N-Acetylcysteine    Sigma-Aldrich (Poole, UK) 
Neutral buffered formalin (NBF)  LRI/CR-UK (London, UK) 
Nicotinamide     Sigma-Aldrich (Poole, UK) 
Nu-Serum IV     BD Biociences (Oxford, UK) 
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Paraffin wax     Tissue Tek (Basingstoke, UK)  
Paraformaldehyde    Sigma-Aldrich (Poole, UK)  
PBS      Life Technologies (NY, USA) 
Peanut oil     Sigma-Aldrich (Poole, UK)9 
Penicillin/Streptomycin   Life Technologies (NY, USA)  
Periodic Acid-Schiff    Sigma-Aldrich (Poole, UK) 
Phenol Chloroform Isoamyl Alcohol 24:24:1 Sigma-Aldrich (Poole, UK) 
Proteinase K     Melford Laboratories (Ipswich, UK)  
Rainbow markers    GE Healthcare (Little Chalfont, UK)  
Rat tail Collagen type I   BD Biosciences (Oxford, UK) 
Ribonuclease     Sigma-Aldrich (Poole, UK)  
RNase-Free DNase Set   QIAGEN (Crawley, UK 
RNeasy Mini-kit    QIAGEN (Crawley, UK)  
Sodium Acetate    Sigma-Aldrich (Poole, UK)  
Sodium Chloride    LRI/CR-UK (London, UK)  
Sodium Fluoride    Sigma-Aldrich (Poole, UK) 
Soybean trypsin inhibitor    Sigma-Aldrich (Poole, UK) 
Superfrost Ultra Plus charged slides  Menzel-Glaeser (Braunschweig, Germany) 
Superscript III cDNA synthesis kit  Life Technologies (NY, USA) 
SYBR Green     Life Technologies (NY, USA) 
Taq PCR Core Kit    Qiagen (Crawley, UK) 
Tamoxifen      Sigma-Aldrich (Poole, UK) 
Tris      Sigma-Aldrich (Poole, UK)  
Trisodium Citrate    Sigma-Aldrich (Poole, UK)  
Trypan Blue     Sigma-Aldrich (Poole, UK)  
Trypsin     Life Technologies (NY, USA) 
Vi-Cell™ sample vial    Beckman Coulter (High Wycombe, UK) 
Waymouth’s MB725/1 Medium  BD Biosciences (Oxford, UK) 
Xylene      LRI/CR-UK (London, UK) 
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2.1.2 Media and Buffers 
Blocking Buffer (IF/IHC)    final concentration: 
Bovine serum albumin   1% 
Goat/Donkey Serum    10% 
Triton X-100     0.4% 
PBS      89.6% 
 
Citrate Buffer 
Sodium citrate     2.94 g  
HCl (0.2 M)      18 ml  
ddH2O     up to 1 l 
 
DMEM (complete Media) 
DMEM     445 ml 
(+ 4.5 g/l glucose, + l-glutamine, + pyruvate) 
FCS      50 ml 
1% (v/v) Penicillin/Streptomycin (10000 U/ml) 5 ml 
 
DNA Extraction Buffer  
DirectPCR Lysis Reagent (mouse tail) 95 µl 
Proteinase K (10 mg/ml)    5 µl 
 
Harri’s hematoxylin 
Hematoxylin     2.5 g 
Absolute alcohol    25 mL 
Potassium alum    50 g 
ddH20      500 mL 
Sodium iodate     0.5g 
Glacial acetic acid    20 mL 
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G solution – 1 L (stock)   volume (final concentration): 
HBSS      1L 
CaCl2 (0.119 M)    0.4 mL (47.6 µM) 
Glucose     0.9 g 
 
MACS sorting buffer – 50 mL  volume (final concentration): 
PBS endotoxin free    49.8 mL  
BSA      0.25g (0.5% w/v) 
EDTA (0.5M)     200 µL (2 mM) 
FACS Buffer – 500 mL   volume (final concentration): 
PBS endotoxin free    490 mL 
FCS      10 mL (2% v/v) 
 
Pancreatic ducts 2D media - 50mL (stock) volume (final concentration): 
Advanced DMEM/F12   45.72 mL 
Nu-Serum (100x stock)   2.5 mL (1x) 
Bovine Pituitary Extract (3 mg/ml stock) 420 µL (25 µg/mL) 
ITS+ premix (100x stock)   250 µL (1x) 
EGF (100 µg/mL stock)    10 µL (20 ng/mL) 
Cholera Toxin (1 mg/mL stock)  5 µL (100 ng/mL) 
3,3,5-Triiodo-L-thyronine (50 µM stock) 5 µL (5 nM) 
Dexmethasone (20 µg/mL stock)  1 mL (1 µM) 
Glucose      0.25g (5 mg/mL) 
Nicotinamide     66mg (1.22 mg/mL) 
Penicillin/Streptomycin (100x stock)  500 µL (1x) 
 
Pancreatic organoid media - 50mL (stock) volume (final concentration): 
Advanced DMEM/F12   37.275 mL 
B27 (100x stock)    1mL (1x) 
N-Acetylcysteine (625 mM stock)  100 µL (1.25 mM) 
Gastrin (10 µM stock)   50 µl (10 nM) 
EGF (100 µg/mL stock)   25 µL (50 ng/mL) 
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RSPO1-conditioned media (100% stock) 5 mL (10%) 
NOGGIN-conditioned media (100% stock)  5 mL (10%) 
FGF10 (100 µg/mL stock)   50 µL (100 ng/mL) 
Nicotinamide (500 mM stock)  1 mL (100 mM) 
Penicillin/Streptomycin (100x stock)  500 µL (1x) 
 
Phosphate buffered saline (PBS)  final concentration:  
KCl      3 mM  
NaCl      136 mM  
Na2HPO4 c$2O    8 mM  
KH2PO4     15 mM 
 
Protein loading buffer (Laemmli buffer) final concentration 
Tris-HCl (pH 6.8)     63 mM 
SDS (w/v)      2% (w/v) 
Glycerol (v/v)     10% (v/v) 
bromophenol blue (w/v)    0.0025% (v/v) 
β-mercaptoethanol (v/v)    2.5% (v/v) 
 
Sodium acetate buffer 
1 M sodium acetate    99 ml 
1 M acetic acid    960 µl  
ddH2O      up to 1 l 
 
Tris-EDTA buffer (10mM Tris Base, 1mMEDTA, 0.05% Tween, pH9.0) 
Tri base      1.21g 
EDTA      0.37g 
ddH2O      1000mL 
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10X Waymouth’s (100mL)   volume (final concentration) 
10X Waymouth’s powder   14g (1X) 
7.5% (w/v) Sodium Bicarbonate  30mL (2.25% (w/v)) 
Adjust the pH to 7.3 
 
 
1X Waymouth’s complete media (100mL)  volume (final concentration) 
1X Waymouth’s     98.725 mL 
Trypsin Inhibitor (40mg/mL)   250 µL (0.1mg/mL) 
Dexamethasone (4mg/mL)   25 µL (0.001mg/mL) 
FCS      1 mL (1%) 
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2.1.3 Oligonucleotides 
The primers indicated in the tables below were used in the present study for mouse 
genotyping PCR (table 1), mouse Q-PCR (table 2) and generating the southern blotting 
probes (table 3) 
 
Table 6 - Mouse genotyping primers 
Gene/alelle Primer Sequence PCR product 
Fbxw7 
Wild type allele 
(wt) 
Floxed allele (F) 
Deleted allele 
(𝛥𝛥) 
Forward: 
5’– CAGTGGAGTGAAGTACAACTCTGG – 3’ 
Reverse: 
5’– GCATATTCTAGAGGAGGGTATCGG – 3’ 
Deleted reverse: 
5’ – GGCCAGCCTGGTCTGTATAGAG – 3’ 
wt: 288 bp 
F: 388 bp 
𝛥𝛥: 744 bp 
 
Cre 
Forward: 
5’ – CGGTCGATGCAACGAGTGATGAGG – 3’ 
Reverse: 
5’ – CCAGAGACGGAAATCCATCGCTCG – 3’ 
Cre: 600 bp 
p53 
Wild type allele 
(wt) 
Floxed allele (F) 
Deleted allele 
(𝛥𝛥) 
Forward: 
5' – CACAAAAACAGGTTAAACCCAG – 3’ 
Reverse: 
5' – GAAGACAGAAAAGGGGAGGG – 3’ 
Delta: 
5’– AGCACATAGGAGGCAGAGAC – 3' 
wt: 288 bp 
F: 370 bp 
𝛥𝛥: 612 bp 
KRasLSL-G12D 
Wild type allele 
(wt) 
Floxed allele 
(LSL) 
Recombined 
allele (Lox) 
1: 5' – GTCTTTCCCCAGCACAGTGC – 3’ 
2: 5' – CTCTTGCCTACGCCACCAGCTC – 3’ 
3: 5' –AGCTAGCCACCATGGCTTGAGTAAGTCTGCA 
- 3’ 
wt: 622 bp 
 
LSL: 500 bp 
 
Lox: 650 bp 
Rosa26-LSL-
YFP 
Wild type (wt) 
Floxed (mut) 
Recombined 
(Lox) 
1: 5’– GCGAAGAGTTTGTCCTCAACC – 3’ 
2: 5’– AAAGTCGCTCTGAGTTGTTAT – 3’ 
3: 5’– GGAGCGGGAGAAATGGATATG – 3’ 
wt: 600 bp 
mut: 300 bp 
Lox: 650 bp 
Pten 
Wild type allele 
(wt) 
Floxed allele (F) 
Deleted allele 
(𝛥𝛥) 
Forward: 
5' – CCATCACACTAAGGTCTGTGG – 3’ 
Reverse1: 
5' – ACTCCCACCAATGAACAAAC – 3’ 
Reverse2: 
5’– CCAGTAGTGATAGAACGGAAGTC – 3' 
wt: 135 bp 
F: 346 bp 
𝛥𝛥: 410 bp 
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Table 7 - Mouse Q-PCR primers 
Gene Primer Sequence 
Cd9 
Forward: 5’ – ATATTCGCCATTGAGATAGCC – 3’ 
Reverse: 5’ – TGGTAGGTGTCCTTGTAAAACTCC – 3’ 
Cd44 
Forward: 5’ –  GGCTCATCATCTTGGCATCT – 3’ 
Reverse:5’ – GCTTTTTCTTCTGCCCACAC – 3’ 
Ck19 
Forward: 5’ – TGACCTGGAGATGCAGATTG – 3’ 
Reverse: 5’ – CCTCAGGGCAGTAATTTCCTC – 3’ 
EpCam 
Forward: 5’ –  AGAATACTGTCATTTGCTCCAAACT – 3’ 
Reverse: 5’ – GTTCTGGATCGCCCCTTC – 3’ 
Pdx1 
Forward: 5’ –  GAAATCCACCAAAGCTCACG – 3’ 
Reverse: 5’ –  CGGGTTCCGCTGTGTAAG – 3’ 
Ptf1a 
Forward: 5’ –  GGGACGAGCAAGCAGAAGTA – 3’ 
Reverse: 5’ –  CGCGGTAGCAGTATTCGTG – 3’ 
Pol II 
Forward: 5’ –  AATCCGCATCATGAACAGTG – 3’ 
Reverse: 5’ –  TCATCCATTTATCCACCACCT – 3’ 
Sox 9 
Forward: 5’ – GTACCCGCATCTGCACAAC – 3’ 
Reverse: 5’ –  CTCCTCCACGAAGGGTCTCT – 3’ 
Fbw7 (exon 5) 
Forward: 5’ – TTCATTCCTGGAACCCAAAGA – 3’ 
Reverse: 5’ –  TCCTCAGCCAAAATTCTCCAGTA – 3’ 
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2.1.4 Antibodies 
Table 8 - Primary Antibodies 
Primary 
Antibody 
(reactivity) 
Species 
(details) 
Application, 
(Dilution, 
antigen 
retrieval) 
Supplier, Cat Number 
APC Rat isotype 
control 
Rat monoclonal 
(IgG2b, κ) 
FACS 
(1:500,na) 
BD (Oxford, UK), 553991 
CD9 (mouse) 
Rat monoclonal 
(KMC8.8 IgG2a) 
IHC-p (1:100, 
TE), IHC-IF 
(1:100, TE), 
FACS 
(1:500,na) 
Santa Cruz (CA, USA), sc-
18869 
CD44-APC 
(mouse) 
Rat monoclonal  
(IM7, IgG2b, κ) 
FACS 
(1:500,na) 
BD (Oxford, UK), 559250 
CD44S 
(mouse) 
Rat monoclonal 
(A020, IgG2b) 
IHC-p (1:100, 
SC), IHC-IF 
(1:100, SC), 
FACS 
(1:1000,na)  
Chemicon/Millipore 
(Watford, UK), MAB2137 
CD45-PE 
(mouse) 
Rat monoclonal  
(30-F11, IgG2b, 
κ) 
FACS 
(1:500,na) 
BD (Oxford, UK), 9012-
9459 
CK19 
(mouse) 
Rat monoclonal 
(IgG2a, κ) 
IHC-p (1:100, 
SC) IHC-IF 
(1:100, SC)  
DSHB (Iowa, USA), 
Troma-III 
DBA-Biotin 
(mouse) 
- 
MACS 
(1:100,na) 
Vector Laboratories 
(Peterborough, UK), B-
1035 
DBA-Fluorescein 
(mouse) 
- IHC (1:100,SC) 
Vector Laboratories 
(Peterborough, UK), FL-
1031  
DBA-Rhodamine 
(mouse) 
- 
IHC-IF 
(1:100,SC) 
Vector Laboratories 
(Peterborough, UK), RL-
1032 
E-Cadherin 
(mouse) 
Rabbit 
monoclonal (IgG) 
IHC-p (1:400, 
SC) 
Cell Signalling, (Hitchin, 
UK), 3195 
GFP 
Goat polyclonal 
(IgG) 
IHC-p (1:300, 
SC) IHC-IF 
(1:100, SC) 
Abcam (Cambridge, UK), 
ab6673 
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HNF1beta 
(human/mouse) 
Rabbit polyclonal 
IHC-p (1:200, 
SC) IHC-IF 
(1:200, SC) 
Sigma-Aldrich (Poole, 
UK), HPA002083 
Hes1 (mouse) Rabbit polyclonal IHC-p 
Chemicon/Millipore 
(Watford, UK), AB5702 
Phosphorylated 
histone 3 (mouse) 
Rabbit polyclonal 
IgG 
IHC-p (1:100, 
SC) 
IF-p (1:100, 
SC) 
Santa Cruz (CA, USA), sc-
8656-R 
Ptf1alpha 
(human/mouse) 
Rabbit polyclonal IHC-p (1:1000) 
Beta Cell Consortium 
(Tennessee, USA), 
AB2153 
pERK (p44/42 
MAPK) 
Rabbit, polyclonal IHC 1:100 
Cell Signalling, (Hitchin, 
UK), 4370 
Rat IgG2a 
isotype control 
Rat monoclonal 
(IgG2a) 
IHC-p (1:100, 
TE), IHC-IF 
(1:100, TE), 
FACS (1:500,na 
Santa Cruz (CA, USA), sc-
3883 
Β-catenin Rabbit polyclonal 
IHC-p (1:200, 
SC) 
Sigma-Aldrich (Poole, 
UK), C2206 
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Table 9 - Secondary Antibodies 
Secondary 
Antibody 
Species Application, 
Dilution 
Supplier, Cat Number 
Alexa Fluoro 488, 
anti Mouse 
Donkey anti-
Mouse IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A21245 
Alexa Fluoro 488, 
anti Mouse 
Goat anti-
Mouse IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A11029 
Alexa Fluoro 488, 
anti Rabbit 
Donkey anti-
Rabbit IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A21206 
Alexa Fluoro 488, 
anti Rabbit 
Goat anti-
Rabbit IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A11008 
Alexa Fluoro 546, 
anti Mouse 
Goat anti-
Mouse IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A10036 
Alexa Fluoro 546, 
anti Rabbit 
Donkey anti-
Rabbit IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A10040 
Alexa Fluoro 568 
anti Mouse 
Donkey anti-
Mouse IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A10037 
Alexa Fluoro 568 
anti Rabbit 
Donkey anti-
Rabbit IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A11011 
Alexa Fluoro 555 
anti Rat 
Goat anti Rat 
IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A21434 
Alexa Fluoro 647 
anti Rat 
Goat anti Rat 
IgG 
IHC-IF (1:200) 
FACS (1:2000) 
Life Technologies (NY, 
USA) A21247 
Biotin-conjugated 
anti-Goat 
Rabbit, anti-
Goat IgG 
IHC-p 1:250 Vector Laboratories 
(CA, USA) BA-5000 
Biotin-conjugated 
anti-Mouse 
Horse anti-
Mouse IgG 
IHC-p 1:400 Vector Laboratories 
(CA, USA) BA-2000 
Biotin-conjugated 
anti-Rabbit 
Goat anti-
Rabbit IgG 
IHC-p 1:250 Vector Laboratories 
(CA, USA) BA-1000 
Biotin-conjugated 
anti-Rat 
Rabbit, anti-
Rat IgG 
IHC-p 1:250 Vector Laboratories 
(CA, USA) BA-4000 
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2.2 Methods 
2.2.1 Animal work 
2.2.1.1 Housing and animal care 
All mice used during the course of this study were housed in the Biological Resource 
Unit, at either Lincoln’s Inn Fields or Clare Hall sites, of the London Research Institute.  
Mice were culled by Schedule 1 Methods, in accordance with the Animal Scientific 
Procedures Act 1986 (revised in 1997), via cervical dislocation followed by 
exsanguination through the severing of a major blood vessel.  New-borns were culled 
by decapitation and death confirmed by verification of onset of rigor mortis. All 
scientific procedures performed during the course of this study were approved by the 
London Research Institute Animal Ethics, following UK home Office guidelines. 
2.2.1.2 Mouse lines 
 
Mouse Line Reference 
Ck19-CreER (Means et al., 2008) 
Ela1-CreER (Desai et al., 2007) 
Fbw7F/F (Hoeck et al., 2010) 
Hnf1β-CreER (Solar et al., 2009) 
KRasLSL-G12D/wt (Jackson, 2001) 
Nu/Nu (Flanagan, 1966) 
p53F/F (Marino et al., 2000) 
Pdx1-Cre (Hingorani et al., 2003) 
PtenF/F (Lesche et al., 2002) 
Rag2KO (Hao and Rajewsky, 2001) 
Rosa26-LSL-YFP (Srinivas et al., 2001) 
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2.2.1.3 Tamoxifen preparation and injections 
For an inducible regulation of Cre recombinase expression, CreER mouse models were 
used. In these mice, Cre recombinase is fused to a mutated ligand-binding domain of the 
human oestrogen receptor. Thus, Cre is expressed but unable to translocate to the 
nucleus. Cre function is dependent on hydroxytamoxifen (metabolic product of 
tamoxifen) administration.  A 20 mg/mL of tamoxifen solution was prepared by 
dissolving the tamoxifen powder in peanut oil. To promote dissolution, the mixture was 
subjected to 3 cycles of 15-minute incubations at 50C℃ followed by 15 minutes on a 
rotating wheel. To induce Cre-dependent recombination of the floxed alleles present in 
the various genotypes used, mice were intraperitoneally injected once a day (for two 
consecutive days) with 5 µL/g bodyweight of the 20 mg/mL stock solution.  
 
2.2.1.4 Hydroxytamoxifen preparation  
When local pancreatic induction of Cre recombinase fucntion was required, the 
intraperitoneal injection of tamoxifen was substituted by the intrapancreatic injection of 
4-hydroxytamoxifen (see surgery section). A 10 mg/mL solution of 4-
hydroxytamoxifen was prepared by dissolving 10 mg of 4-hydroxytamoxifen in 1 mL of 
peanut oil. Dissolution was promoted by cooled sonication of the mixture for 2 cycles 
of 30 minutes (30 s on/off cycle) using a BioRuptor water bath. Mice were subjected to 
surgery (see 2.2.1.7, page 97) and 100 µL of the 10 mg/mL 4-hydroxytamoxifen 
solution was injected directly into the tail of the pancreas. 
 
2.2.1.5 Acute pancreatitis – caerulein treatment 
To induce acute pancreatitis, mice were subjected to a short caerulein treatment. A stock 
solution of caerulein was prepared to a final concentration of 100 µg/mL by dissolving 
1 mg of caerulein in 10 mL of PBS. Working solutions were obtained by dissolving the 
stock solution to a concentration of 10 µg/mL in PBS. Mice were intraperitoneally 
injected 6 times a day, at hourly intervals, for 2 days. Per injection the caerulein dose 
was as follows: 5 µl per gram of body weight of caerulein (50 µg/kg of body weight). 
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2.2.1.6 Chronic pancreatitis – caerulein treatment 
To induce chronic pancreatitis, mice were subjected to a long caerulein treatment. A 
stock solution of caerulein was prepared to a final concentration of 100 µg/mL by 
dissolving 1 mg of caerulein in 10 mL of PBS. Working solutions were obtained by 
dissolving the stock solution to a concentration of 10 µg/mL in PBS. Mice were 
intraperitoneally injected 3 times a day, at hourly intervals, for 3 consecutive days, for 4 
weeks. Per injection the caerulein dose was as follows: 5 µl per gram of body weight of 
caerulein (50 µg/kg of body weight). 
2.2.1.7 Surgery – Intrapancreatic/ductal injection of cells/ substances 
Twenty-four hours before the surgery Rimadyl (Carprofen-based anagesis) was added 
to the water. Two mL of 50 mg/ml Rimadyl solution were added to 1 L of water. On the 
day of the surgery, mice 8 to 12 weeks of age (genotype depending on the experimental 
goal, specified in result section) were subcutaneously injected with Rimadyl 1 hour 
before surgery. For the subcutaneous injection of Rimadyl, a 1:10 dilution was prepared 
with a stock solution of 50 mg/mL. Mice were injected with 1µ of the solution per gram 
of body weight. Following anaesthesia by Isoflurane inhalation, the abdominal and 
splenic areas were shaved and their eyes protected with Lacri-lube. The shaved area was 
thoroughly cleaned with Medihex-4 (surgical scrub) and a sterile incise drape was used 
to cover the non-shaved parts. With sterile surgical scissors, a small incision was 
performed in the skin and the peritoneal wall exposed. After opening the peritoneum, 
the pancreas was located and either a tumour cells suspension in growth factor reduced 
matrigel (50 µL) or (2) 4-hydroxytamoxifen (100 µL) were injected in the pancreatic 
tail. Having concluded the procedure, the peritoneal was sutured with absorbable 
sutures and the skin closed with clips. A dose of 0.05 mg/Kg of Vetergesic was 
subcuteneosly injected immediately after surgery and the mice placed in a clean cage on 
a heating pad until recover. The next day, mice were subcutaneously injected with 
Rimadyl as before and the drinking water was supplemented Rimadyl for three days. 
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2.2.1.8 Limiting-dilution transplantation assay of cells in mouse flanks 
To assess the tumour initiating capacity of CD9High-expressing cells, epithelial tumour 
cells were obtained either from primary tumours of GEM models or from GEM tumour-
derived organoids. In both cases, tumour cells were identified by GFP expression, 
enabled by the presence of the lineage tracer R26-LSL-YFP. Following fluorescence 
activated cell sorting for CD9 expression and CD45 exclusion (pan-immune cell 
marker), serial dilutions of single GFP+CD9HighCD45- cells were prepared (200, 2000, 
20.000 and 200.000 cells) in 50 µL of growth factor-reduced matrigel and injected in 
the flank of age and gender matched NuNu immunodeficient mice. To control for 
tumour development and tumor-initiating potential of the selected population, the 
negative counterpart (GFP+, CD9LowCD45- cells) were injected in the opposite flank. 
Tumour measurements were performed twice a week and volume was calculated using 
the following equation: volume = (1/2)*length*width*height (Tomayko and Reynolds, 
1989). Tumours were collected when one of the flanks exhibited a tumour of 1cm3 in 
volume or when location of the tumour presented a health hazard.  
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2.2.2 Primary cell manipulation 
2.2.2.1 Primary pancreatic wild type and tumour cell isolation 
To isolate primary pancreatic wild type and tumour cells, a modified version the 
protocol described before (Reichert et al., 2013) was applied. The mouse was culled by 
cervical dislocation followed by exsanguination, according to the Home Office 
guidelines. The pancreas was dissected out carefully, including the tail, body and head 
of the pancreas, as well as the connection with the bile duct. The dissected pancreas was 
immediately put in 5 mL of cold G solution (see 2.1.2, page 86) and kept on ice. Under 
the primary tissue culture hood, the pancreas was placed on paraffin and mechanically 
dissociated with curved scissors. The minced pancreas was then transferred to a 50 mL 
falcon with 15 mL of collagenase V (1 mg/mL in DMEM plus 1% (v/v) 
Penicillin/Streptomycin (10,000U/mL with no FCS). Following a 20 minute incubation 
in a water bath at 37°C with gentle shaking, 15 mL of ice-cold G solution were added to 
stop the reaction. The digested pancreas was centrifuged at 300g for 5 minutes with no 
break, the supernatant discarded and then incubated in Trypsin-EDTA for 5 minutes at 
room temperature. To stop the reaction, 2 mL of Soybean Trypsin Inhibitor were added, 
followed by 15 mL of ice-cold G solution and centrifugation for 5 minutes at 300g. The 
supernatant was ressuspended in 10mL of PBS with 2% (v/v) FCS and passed through a 
70 µm filter. At this point, the isolated single cells could be used for different 
applications such as, direct culture, Dolichos biflorus agglutinin magnetic bead cell sort 
(DBA-MACS), xenograft experiments, fluorescent activated cell sorting/analysis or 
biochemical experiments (see respective sections). 
 
2.2.2.2 Dolichos biflorus agglutinin magnetic bead cell sort (DBA-MACS) 
Pancreatic ductal cells present DBA lectin in their cell surface allowing the isolation of 
these cells by magnetic bead cell sorting. In order to isolate pancreatic ductal cells, a 
modified version of the protocol described before (Reichert et al., 2013) was applied. 
Following pancreatic cell isolation, as described above, single cells were ressuspended 
in 3ml of MACS sorting buffer (0.5% BSA and 2mM EDTA in endotoxin free PBS) 
with 1:200 DBA-FITC conjugated antibody. The suspension was incubated for 10 
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minutes, at 4 ℃ in the dark, with mild shaking and then 2.8 mL of MACS sorting 
buffer were gently mixed. Following centrifugation at 300 g for 5 minutes with no 
break, the cell pellet was ressuspended in 360 µL of Sorting buffer plus 40 µL of anti-
FITC-Microbeads and incubated for 15 minutes at 4 ℃ with gentle shaking.  Cells were 
washed by adding 4 mL of MACS sorting buffer and centrifuging the suspension at 300 
g for 5 minutes with no break. After discarding the supernantant, cells were 
ressuspended in 2 mL of MACS orting buffer and kept on ice until the separation 
columns were ready for use. For primary pancreatic wild type and tumor cells DBA-
MACS, LS MACS columns were used. The preparation of columns consisted on 
placing them on a QuadroMACS separator and adding 3 mL of MACS sorting buffer. 
After the buffer had flowed through the columns by gravity, the cells suspension was 
then applied to the buffered columns. At this point the labelled cells are retained in the 
columns by magnetic forces. The columns were washed three times by adding 2 mL of 
MACS sorting buffer and allow flow by gravity. After the lst washing, the columns 
were removed from the stand and placed in collection tubes. To allow separation of the 
cells from the columns, 3 mL of MACS sorting buffer were added to the columns and 
with the plunger, flushed to the tube. At this point the isolated ductal cells were used for 
different purposes. 
 
2.2.2.3 Flow cytometry and Fluorescent activated cell sorting (FACS) 
Following primary pancreatic cell isolation as described above, cells could then be used 
for flow cytometry analysis or cell sorting. Single cells were ressuspended in endotoxin 
free PBS with 2% (v/v) FCS (FACS buffer) and then split into the different control and 
test samples (unstained, secondary antibodies alone, primary plus secondary antibodies, 
and/or conjugated primary antibody, and FMOs (fluorophore minus one, where all 
combinations of the fluorophores used, minus one, are included for specific signal 
detection purposes). Cells were pelleted into a 96-well plate (round bottom) for 3 
minutes at 300 g, the supernatant was discarded by rapidly inverting the plate, and the 
cells ressuspended in 100 µL FACS buffer with the appropriate primary antibody 
(specific dilutions were used for different antibodies, see 2.1.4, page 92). All primary 
antibodies were incubated for 30 minutes on ice. Following incubation, cells were 
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pelleted at 300 g for 3 minutes, at room temperature, and washed 3 with 100 µL of 
FACS buffer. Secondary antibody was diluted in FACS buffer and 100 µL were added 
to the cells. Incubation was performed in the dark for 30 minutes at 4℃. Cells were 
washed 3 times in FACS buffer and ressuspended in FACS buffer containing DAPI 
0.003 mM (1 µL per mL of buffer from 3mM stock). A sortings were performed in one 
of the three flowing machines: FACS ARIA fusion, FACS Aria or Influx, using the diva 
software and adjusting the flow pressure to 20psi. Flow cytometry was performed using 
Fortessa Diva and analysis was carried out using FlowJo 9 software. 
 
2.2.2.4 2D primary pancreatic ductal cell culture 
Pancreatic ductal cells were grown in 2D, on top of a rat tail type I collagen matrix, on a 
6-well plate. The matrix had to be prepared the day before, as to allow the collagen to 
set. For each well of the 6-well plate, a 1.5 mL of collagen solution were prepared by 
mixing 2.31 mg/mL of cold rat tail collagen solution with 0.0165 mL of 1M NaOH 
(1.65% (vol/vol)) and 100 µL of 10X sterile PBS (10% (vol/vol)), and toping up with 
sterile ice-cold deionized water. The solution was poured into a well of a 6-well plate 
and allowed to set O.N. in the incubator (37 ℃). The next day, and after primary 
pancreatic cell isolation and DBA-MACS (see 2.2.2.2, page 99), the isolated ductal 
cells were ressuspended in PDAC media composed of Advanced DMEM/F12 
supplemented with 1X Nu-serum, 25 µg/mL of bovine pituitary extract, 1x ITS+ premix, 
20 ng/mL of EGF, 100 ng/mL of cholera toxin, 5 nM of 3,3,5-Triiodo-L-thyronine, 1 
µM of Dexmethasone, 5 mg/mL of glucose, 1.22 mg/mL of Nicotinamide and 1x P/S. 
The media was changed every other day to maintain the culture. Both wild type and 
tumour primary pancreatic ductal cells grow very slowly in these conditions and thus, 
this methods was only used to maintain the cells for long periods of time. 
 
2.2.2.5 2D primary pancreatic ductal cell passaging 
To remove the pancreatic ductal cells from the collagen matrix, the collagen sheet was 
transferred into a 50 mL falcon tube with 10 mL of collagenase type V in DMEM (1 
mg/mL). Following 15 minutes incubation at 37℃ in a water bath, the cells were 
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pelleted at 300 g for 5 minutes at 4 ℃. The supernantant was discarded, 1 mL of 1X 
trypsin was added and a 5-minute incubation at room temperature took place. To stop 
the reaction, 2 mL of soybean trypsin inhibitor were added, followed by 25 mL of ice-
cold G solution. Cells were pelleted as before and either re-plated (see 2.2.2.4, page 
101) or used for various purposes. 
 
2.2.2.6 3D primary pancreatic ductal cell culture - organoid 
Following primary pancreatic cell isolation and, in some specified cases, DBA-MACS, 
the isolated cells were ressuspended in 100% Growth factor reduced matrigel and 
placed in a 24-well plate as 50 to 100 µL drop. The matrigel solidifies at warm 
temperatures so, to allow the formation of a matrix, the 24-well plates were then 
incubated for 15 minutes at 37 ℃. After the matrigel was set, organoid media 
composed of Advanced DMEM/F12 supplemented with 1x B27, 1.25 mM N-
Acetylcysteine, 10 nM Gastrin, 50 ng/mL EGF, 10% RSPO1-conditioned media, 10% 
NOGGIN-conditioned media, 100 ng/mL FGF10, 100 mM Nicotinamide and 1X P/S, 
was added. Cells were passaged once a week. 
 
2.2.2.7 3D primary pancreatic ductal cell passaging 
 To obtain a single cell suspension of the organoid cultures, the matrigel-embedded 
organoids were ressuspended in 15 mL of endotoxin free PBS. Organoids were pelleted 
for 5 minutes at 1500 rpm, to assure the matrigel goes to the bottom of the tube, and the 
PBS discarded. Dissociation was carried out for 10 minutes with 500 µL of 1mg/ml 
trypsin at 37 °C, and immediately inactivated with 1 mL of 1X soybean trypsin inhibitor. 
A washing step was performed with an additional 15ml of endotoxin free PBS and 
single cells were either ressuspended in matrigel for further expansion or passed by a 40 
µm cell strainer and used for downstream experiments. 
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2.2.2.8 Explant culture of mouse primary acinar cells 
It has been demonstrated that acinar cells have the ability to in vivo transdifferentiate 
into duct-like cells upon injury and in the context of pancreatitis and tumour formation. 
Recently, this phenomena was mimicked in vitro, allowing the culture of explants of 
acinar tissue which undergo ADM (Means et al., 2005). Before starting the procedure 
the cell culture plates were coated with an ice-cold rat tail collagen I solution composed 
of 5.5mL of 4.5g/mL Rat tail Collagen I solution, 550 µL of 10X Waymouth’s medium 
and 336.7 µL of 0.34N NaOH. Each well of a 6-well plate was covered with 800 µL of 
the aforementioned collagen solution and placed in the incubator until needed 
(approximately 3h). 
In order to obtain the acinar explants, the mouse of interest was culled by cervical 
dislocation followed by exsanguination, as mentioned above. With the help of sterile 
tweezers, the pancreas was dissected out, including the tail, body and head of the 
pancreas. The dissected pancreas was immediately put in 20 mL of ice-cold HBSS with 
1x P/S and kept on ice. Under the primary tissue culture hood, the pancreas was placed 
on a 1.5 mL eppendorf, minced with sharp scissors and transferred to a 50mL falcon 
tube containing 30 mL of ice-cold HBSS 1x P/S. Centrifugation at 2000rpm at 4 °C for 
2 minutes was carried to remove any floating fat or mesenteric tissue that could have 
been extracted during the pancreas dissection. After discarding the supernatant, the 
remaining pancreatic tissue was enzymatically digested in 5mL of 2 mg/mL collagenase 
P, dissolved in HBSS, in a 37°C water bath for 15 minutes with occasional shaking. The 
digestion was stopped by adding 5 mL of ice-cold HBSS supplemented with 5% FCS 
and the digestion was centrifuged for 2 min at 4 °C at 2000 rpm. Following 2 washing 
steps with 10m L ice-cold HBSS supplemented with 5% FCS, the pellet was 
ressuspended in 5mL of the same solution and filtered twice. Initially it was passed 
through a 500 µm sterile cone-mesh followed by a 105µm mesh. These filtering steps 
allow the purification of small acinar cell aggregates by removal of big cell clumps. The 
acinar cell aggregate suspension was then added, in a drop-wise manner, on top of a 
HBSS solution supplemented with 30% FBS and centrifuged at 1000rpm at 4°C for 2 
minutes. This density-based separation step allows the elimination of any acinar or duct 
single cells that could contaminate and compromise the explant culture. The pellet was 
ressuspended in Waymouths complete medium and either used immediately for culture 
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or Ad-CMV-Cre infected and then embedded. Acinar aggregates were embedded in 
collagen by mixing equal volumes of the cell suspension and collagen solution (700 µL 
10x Waymouth’s medium supplemented). The mixture was added to the pre-coated 
plates (2 mL of embedding suspension per well of a 6-well plate), the plates were 
carefully placed at 37°C in the incubator for the collagen to set for 1 hour and 3 mL of 
Waymouth’s media were added. Cultures were followed under the microscope, the 
media was changed every two days and duct structures harvested after 7 days of culture. 
 
2.2.2.9 Harvest of acinar explant-derived duct structures 
As mentioned above, culturing KRasG12D mutation-harbouring acinar explants under 
the above conditions induces the formation of ring structures composed of pancreatic 
duct-like cells. The structures take an average of 7 days to form and, once formed, they 
can be harvested for further culture or downstream biochemical applications. To harvest 
the cells, the media was aspirated and the collagen sheet was placed in a 15mL tube 
with 5mL of 1mg/mL collagenase P solution in HBSS. Following a 15 minute 
incubation at 37°C in a water bath, the digestion solution was centrifuged at 2000rpm 
for 5 minutes at 4°C. The cell pellet was washed once with ice-cold PBS and cells 
ressuspended in appropriate buffer or media, depending on the downstream application. 
 
2.2.2.10 Adeno virus transduction 
To induce in vitro Cre recombinase-mediated excision of loxP site, cells harbouring 
alleles flanked by loxP sequences (e.g. LSL-KRasG12D) were transduced with Adeno-
CMV-Cre-GFP virus. This procedure was performed in duct-derived organoids and 
acinar cells aggregates harbouring the following alleles: p53F/F; KRasLSL-G12D/wt; R26-
LSL-YFP. For ductal cell infection, duct-derived organoids were dissociated into single 
cells (see 2.2.2.7, page 102), the single cell suspension was incubated with 0.375 µl of 
either Adeno-Cre-GFP or Adeno-GFP (Gene Transfer Vector Core) in 1.5ml of 
organoid media for 1hour at 37°C. Following transduction, cells were pelleted, 
ressuspended in matrigel and a drop of 25 µl was placed in the center of each well of a 
24-well plate. A 15 minute incubation at 37°C was carried out to set the matrigel and 
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500 µl of organoid media were added with the same amount of fresh Ad-CMV-Cre-GFP 
virus. Acinar cell aggregates were infected immediately after their isolation from 
primary tissue, as described for ductal cells. Following transduction, the cell suspension 
was mixed in a 1:1 ratio with collagen solution (as described for expant culture), placed 
on top of rat tail collagen I pre-coated plates and allowed to set for 1h at 37°C before 
adding Waymouth’s media. In both cases, media was changed 24h later. Infection 
efficiency was estimated by quantifying the percentage of GFP expressing cells, and the 
efficiency of recombination assessed by DNA isolation and genotyping for the floxed 
and delta alleles. All infection steps were carried out in a Category II Containment Suite 
 
2.2.2.11 In vitro self-renewal assessment – organoid formation 
Assessment of in vitro self renewal ability was performed as described in (Huch et al., 
2013). Pancreatic duct cells were either isolated from primary tumours by DBA MACS. 
Isolated cells were incubated with CD9 primary antibody (1:500) for 30 minutes on ice. 
Following 3 washes with ice-cold PBS with 2% FCS, a 30 minute incubation with a 
secondary antibody (1:2000) was performed on ice and in the dark. Cells were washed 
three times with PBS with 2% FCS, passed through a 40 µm cell strainer and DAPI was 
added (1:1000) from a stock solution of 3 mM. Fluorescence activated cell sorting 
allowed the separation between the CD9High and CD9Low populations. One hundred cells 
of each population was sorted directly into wells of a pre-cooled 96-well plate 
(100cells/well) containing 20 µL of ice-cold matrigel. Or 1000 cells were plated into 
single wells of a 24-well plate. Following sorting, the matrigel was allowed to set at 
37°C for 15 minutes and organoid media was added. Organoids were counted and 
measured using ImageJ 10 days later.  
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2.2.3 Cellular and molecular biology 
2.2.3.1 Histology - Tissue processing 
For histological studies, tissues were collected from recently sacrificed mice and placed 
in 10% neutral buffered formalin (NBF) solution overnight (approximately 16h) for 
protein cross-linking and consequent tissue fixation. The next day, the NBF solution 
was replaced by 70% ethanol. The fixed and dehydrated tissue was paraffin embedded 
sectioned in 3 or 4 µm paraffin sections, for pancreas or tumour analysis, respectively, 
using a manual microtome (RM2235 Leica) and placed in a 37°C water bath to unfurl. 
Sections were mounted on Superfrost Ultra Plus charged slides (Menzel-Glaeser) and 
incubated in the oven for 15 minutes to increase adherence. 
 
2.2.3.2 Hematoxylin and eosin (H&E) stain 
Histological enquiry based on tissue morphological features was carried out by analysis 
of hematoxylin and eosin stains. This procedure takes advantage of the affinity of 
certain compounds for particular cellular structures. Hematoxylin is a dark blue 
coloured basic compound that binds acidic or basophilic structures, namely nucleic 
acids, giving the nucleus a blue colour. Eosin is a pink compound that binds basic or 
eosinophilic structures, namely proteins, staining the cytoplasm and membranes pink. 
To perform the stain, 3 or 4 µm paraffin section sections, for pancreas and tumours, 
respectively, were obtained and de-waxed in xylene two times for 10 minutes. Re-
hydration was carried out by incubations in water solutions with decreasing ethanol 
concentration: 2x in 100% ethanol for 3 minutes, 1x in 95% (v/v) ethanol for 3 minutes, 
1x in 80% (v/v) ethanol for 3 minutes, 1x in 50% (v/v) ethanol for 3 minutes and 1x in 
running water for 5 minutes. Nuclear staining was performed by incubating the 
hydrated sections in Harri’s hematoxylin solution for 5 minutes and washed in running 
tap water for 5 minutes. Differentiation was performed for 5 seconds in 1% (v/v) acid 
alcohol (1% HCL in 70% alcohol) and sections were washed in running tap water for 5 
minutes. Cytoplasm staining was accomplished by incubation of the section in 1% (w/v) 
eosin Y and final washing in running tap water for 5 minutes.  Before mounting, the 
section were dehydrated through graded alcohols: 2x in 70% (v/v) ethanol for 3 minutes, 
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and 2x in 00% ethanol for another 3 minutes. At the final step sections were cleared 
twice in xylene for 3 minutes and mounted with DPX mounting medium (Raymond A. 
Lamb). All H&E stains were performed by the experimental histopathology facility. 
 
2.2.3.3 Histological analysis 
Histological analysis, the identification of tumour progression and the classification of 
mPDAC from different GEM models was performed with the help of London Research 
Institute’s experienced consultant histopathologist Professor Gordon Stamp. 
 
2.2.3.4 Immunohistochemistry 
For protein detection in the embedded tissues, thin sections were obtained and re-
hydrated as performed for H&E stains. Antigen retrieval was performed to expose the 
masked epitopes and different antibodies required different antigen retrievals (see 2.1.4, 
page 92). The most common antigen retrieval performed was a heat-based treatment 
with 10 mM Sodium citrate buffer pH 6.2. In sum, dissolving 2.94 g of sodium citrate in 
water and adjusting the pH with HCl to 6.2 performed a 1L 10 mM of sodium citrate 
solution. Sections were submerged in this solution and microwaved for 10 minutes at 
full power, avoiding boiling. Following the heat treatment, section were placed in a sink, 
under a barely running tap for 5 minutes to both cool and dilute the buffer solution to 
prevent salt crystallisation. Slides were washed with PBS and the endogenous 
peroxidase was blocked by a 10-minute treatment in 1.6% (v/v) solution of hydrogen 
peroxide in PBS (13.3mL of 30% (v/v) H2O2 in 250 mL final volume of PBS) 
terminated by a 5-minute incubation in dH2O. To stain the slides, the excess fluid was 
carefully wiped from the slide and a barrier around the tissue section was drawn using a 
hydrophobic pen. Section were first blocked for 45 minutes with a blocking solution 
composed of PBS supplemented with 10% (v/v) donkey serum, 1% BSA (w/v), 0.4% 
(v/v) Triton X-100 and then incubated either overnight at 4°C or 1h at room temperature 
with the primary antibody diluted in the blocking solution. Slides were kept in a humid 
chamber until the end of the incubation. Following primary antibody incubation, the 
appropriate secondary antibody conjugated with biotin was used. The secondary 
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antibody dilution depended on the antibody used (see 2.1.4, page 92), antibodies were 
diluted in the blocking solution and incubated, at room temperature for 45 minutes. 
Before the end of the secondary antibody incubation, the Avidin-Biotin Complex 
(ABC) solution was prepared by adding 9 µL of reagent A and B from the 
VECTASTAIN ABC kit to 1mL of PBS. The sections were incubated with ABC 
solution for 30 minutes in a humid chamber, at room temperature, and then washed 3 
times for 3 minutes in PBS. For developing the staining, the Peroxidase substrate kit 
DAB from Vector was used. This last step was performed under a microscope to closely 
monitor the signal strength. The DAB solution was performed as instructed by the kit. 
Two drops of Buffer solution were added to 5mL of distilled water. The solution was 
mixed and 4 drops of DAB substrate solution were added. After mixing, 2 drops of 
provided hydrogen peroxide solution were added and the DAB solution was mixed 
again. DAB solution was applied to the washed slides, the signal monitored and the 
reaction stopped my immersing the slides in distilled water. To counterstain the nuclei a 
light hematoxylin protocol was followed. Slides were immersed in hematoxylin (120mL 
Mayer’s Hematoxylin and 80mL of dH2O) for 1 minute and then washed with tap water 
for 5 minutes. Lastly, the slides were dehydrated through incubations in 70% and 100% 
IMs, cleared in xylene and mounted with DPX.  
 
2.2.3.5 Immunofluorescence 
For immunofluorescence analysis, thin sections were obtained and re-hydrated as 
performed for H&E stains. Antigen retrieval was performed to expose the masked 
epitopes and different antibodies required different antigen retrievals (see 2.1.4, page 
92). Following antigen retrieval (as described for immunohistochemistry), the sections 
were washed with PBS a barrier was drawn around the tissue section using a 
hydrophobic pen. Section were first blocked for 45 minutes with a blocking solution 
composed of PBS supplemented with 10% (v/v) serum of the species of the secondary 
antibody to use, 1% BSA (w/v), 0.4% (v/v) Triton X-100 and then incubated either 
overnight at 4°C with the primary antibody diluted in the blocking solution. Slides were 
kept in a humid chamber until the end of the incubation. Following primary antibody 
incubation, the appropriate secondary antibody conjugated with the fluorophore of 
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interest was used. The secondary antibody dilution depended on the antibody used (see 
2.1.4, page 92), antibodies were diluted in the blocking solution together with DAPI 
(0.003 mM) for DNA stain, and incubated, at room temperature for 2 hours. Following 
incubation with the secondary slides were washed 3 times for 5 minutes in PBS and 
incubated in 0.1 % (w/v) Sudan Black B in 70% (v/v) ethanol to reduce 
autofluorescence. Slides were washed 3 times in PBS for 5 minutes, mounted with 
DAKO mounting media and kept in the dark until imaging. 
 
2.2.3.6 Alcian Blue and Periodic acid-Schiff stain  
To detect mucinous structures in pre-neoplastic lesion of PDAC the alcian blue and 
periodic acid-schiff stain was performed for being extensively used to detect these 
lesions. Alcian blue (AB) is a polyvalent basic dye that stains acidic polysaccharides 
and mucopolysaccharides. Tissues that stain positive for this dye are called 
alcianophilic and acquire a dark blue colour. The Periodic acid-Schiff (PAS) stain 
detects polysaccharides and mucosubstances. Tissues that stain positive for this method 
acquire a purple/magenta colour. The AB/PAS stain is a combination of both methods 
where AB is performed first. It is important to bear in mind that acid mucin that are also 
PAS-positive will not stain for PAS after the AB stain is performed.  
To perform the stain in paraffin section, the paraffin was first removed by xylene 
treatment twice for 5 minutes. The tissue was incubated in 100% IMS for 3 minutes 
twice and incubated once in 70% IMS for 3 minutes. After washing in tap water, the 
slides were incubated for 5 minutes in alcian blue solution (1% (w/v) Alcian blue – 1 g 
in 100 ml of 3%(v/v) acetic acid). Slides were then washed intensively in tap water and 
then distilled water before the performing the PAS satin. Following washes, slides were 
incubated in 1% (w/v) periodic acid in distilled water for 5 minutes and washed again in 
distilled water. The Schiff reagents was obtained from Fisher and the tissue was 
incubated in the solution for 15 minutes with a follow up washing step of 10 minutes in 
running tap water. The nuclei were counterstained with Mayers hematoxylin for 1 
minute. The stain was differentiated in 1% acid alcohol for a few second (arbitrary time, 
dependent on monitoring) and washed in tap water for 5 minutes. For mounting, the 
Chapter 2 Materials and Methods 
 
 110 
tissue was dehydrated in ethanol and cleared in xylene as mentioned before (see 2.2.3.2, 
page 106), and slides were mounted with coverslips using DPX mounting medium.  
 
2.2.3.7 DNA isolation from tissue for genotyping 
For genotyping, murine tissue fragments (ear or tail snips) were incubated in 100 µL of 
DirectPCR Lysis Reagent (Viagen) supplemented with 3 µL of Proteinase K (10mg/mL, 
Melford) overnight at 56 °C in a shaking platform. The next day, the enzyme was 
inactivated by a 45-minute incubation at 85 °C. Samples were vortexed and centrifuged 
at full speed for 15 minutes (eppendorf Centrifuge 5415 D). For genotyping purposes, 2 
µL of extracted DNA solution were used for PCR. DNA solution was kept at -20 °C. 
 
2.2.3.8 DNA isolation from tissue embedded in paraffin blocks for genotyping 
To extract DNA from tissue embedded in paraffin block, sections 10-20 10 µm section 
were obtained in one eppendorf tube. Paraffin was removed by adding 1 mL xylene and 
incubating the tube at 55°C for 15 minutes.  Following incubation the samples were 
centrifuged and the supernatant discarded. A second xylene incubation was performed 
to ensure complete removal. Before the next step, tubes were opened to release pressure. 
Following xylene incubations and, 1 mL of 100% ethanol was added to the pellet and 
the samples were incubated for 15 minutes. Tubes were centrifuged, the supernatant 
discarded and an additional ethanol washing step was performed. Following 
centrifugation, the supernatant was carefully discarded and the tubes were left opened to 
allow the pellet to air dry. One mL of Proteinase K (final concentration of 0.5 mg/mL) 
in digestion buffer (100nM NaCl, 10mN Tris-HCl pH8, 25mM EDTA pH8 and 0.5% 
SDS) was added to the dry pellet and the samples were incubated overnight at 55°C. 
The next morning DNA precipitation was performed. An equal volume of 
phenol/chloroform/isoamyl alcohol (Ameresco) was added to the digestion solution. 
The tubes were centrifuged for 2 minutes and the upper aqueous phase was collected to 
a new tube. The previous step was repeated. Following removal of the aqueous phase, 
330 µL were removed to a new tube and ammonium acetate (7.5M) was added (1/2 of 
the original volume). Additionally, 2.5 times the volume were added of 100% ethanol. 
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The solution was incubated at -20°C overnight. The next morning, the solution was 
centrifuged for 20 minutes at 4 °C at maximum speed (eppendorf Centrifuge 5415 D), 
the ethanol was decanted and the pellet was allowed to air dry. The dry pelleted was 
eluted in 20 µL of TE buffer overnight at 4°C. For genotyping, 200 to 500 µg/mL of 
DNA were used. 
 
2.2.3.9 Polymerase Chain Reaction (PCR) 
After DNA isolation, genotyping PCR was performed using approximately 2 µL of the 
isolated DNA. 
A mixture of 20 µL of final volume was prepared containing the following components: 
1x Coral Load PCR Buffer   2 µL (10X stock) 
1x Solution Q (DMSO based)  4 µL (5X stock) 
dNTPs (0.25 mM)     0.2 µL (25mM stock) 
Forward primer (1 µM)   0.2 µL (100 µM stock) 
Reverse primer (1 µM)   0.2 µL (100 µM stock) 
Taq-polymerase (0.2 U)   0.2 µL (5 U/µL stock) 
ddH2O      11.2 µL 
DNA      2 µL 
 
 The list of primers can be found in Table 6 (page 90). PCR program below: 
(1) Initial denaturation:  94 °C for 3 minutes 
(2) Denaturation within cycle: 94 °C for 30 seconds 
(3) Annealing:    55 °C for 45 seconds 
(4) Extension within cycle:  72 °C for 45 seconds 
(5) Repeat 2, 3 and 4 34 times (35 cycles total) 
(6) Final extension:   72 °C for 10 minutes 
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2.2.3.10 Agarose gel electrophoresis  
PCR products for Fbw7, Rosa26-LSL-YFP, Cre, p53, Rosa-CAG-Tomato and Pten were 
separated on a 1.5% (w/v) agarose (Bioline) gel. The KRasLSL-G12D PCR product was 
separated using a 3% (w/v) agarose gel. The gel was prepared diluting the appropriate 
amount of agarose in 1X TAE and dissolving by heat treatment. Following cooling 
down of the solution, ethidium bromide (10 mg/mL, Sigma-Aldrich) was added (1 µL 
per 100 mL of gel solution). The PCR producr was loaded in totality and the gel was 
subjected to 120 V until a clear separation was observed. To determine band size, 10 µL 
of 1 Kb DNA Ladder (Invitrogen) was loaded in parallel.  
 
2.2.3.11 RNA isolation 
For large amounts of material RNA extraction was performed using the RNeasy Mini- 
or RNeasy Midi-kit (QIAGEN) according to the manufacturer’s instructions. Cells were 
obtained from cultured condition or from primary tissue and lysed by physical rupture 
using an 18-gauge needle (BD) and passing the material through it several times. On-
Column DNase digestion was performed using the RNase-Free DNase Set (QIAGEN). 
RNA concentrations and quality were measured using the NanoDrop spectrophotometer 
(Thermo Scientific. The ratio of OD260/OD280 between 1.8 and 2.0 were considered as 
indicative of a non-contaminated RNA sample. RNA was immediately used for cDNA 
synthesis or stored at -80 °C. 
 
For small amounts of tissue, such as RNA extraction after cell sorting of primary 
tumours for microarray purposes (1-50x103 cells), the MagMAXTM-96 Total RNA 
Isolation Kit (Ambion) was used. This protocol is a bead based isolation where 
nucleotide-binding beads bind to both DNA and RNA, thus, DNase treatment is 
essential. RNA extraction was performed according to the manufacturer’s instructions. 
All solutions are provided. Final RNa elution was performed with 20 µL of Elution 
buffer and the quality and concentrations were analysed using a Bioanalyser using Nano 
or Pico chips (Agillent Technologies). 
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2.2.3.12 cDNA synthesis 
RNA amounts were standardised using RNase-free water and cDNA suntehsis was 
performed using the Superscript III First-Strand cDNA synthesis kit (Invitrogen). 
Random hexamer primers were used (Invitrogen). For each sample, 500 ng of RNA 
were used as a template for cDNA synthesis. 
The cDNa synthesis mix was composed of (Kit components): 
Hexamer primers:   4 µL 
5X RT Buffer    8 µL 
Protector RNase inhibitor  1 µL 
dNTPs     4 µL 
Reverse transcriptase enzyme  1 µL 
RNA     500 ng 
DEPC water    (up to 40µ) 
 
Tubes were placed in 25°C for 10 minutes, followed by one hour at 50°C and 5 minutes 
at 85°C. The synthesised cDNA was diluted 1:10 with DEPC water and stored at -20°C 
for downstream applications.  
 
2.2.3.13 Quantitative real-time PCR 
For quantitative real-time (Q-PCR) analysis, cDNa was diluted 1:10 in DEPC-treated 
ddH2O. 4 µL of diluted cDNA were used per Q-PCR reaction, which was conducted in 
triplicates. Q-PCR was performed measuring Express SYBER®GreenER on an 
ABI7500 (Applied Biosystems). Data were analysed using the SDS software (Applied 
Biosystems). Primers were designed using the Universal ProbeLibrary Assay Design 
Center from Roche, avoiding intronic regions. Normalization was performed against 
values of Polimerase II, Actin and Tubulin. 
List of Q-PCR primers can be found in Table 7 (page 91). 
To exclude primer dimer and unspecific amplification, a “no template control was 
included” and dissociation and standing curves were performed. To retrieve Ct values, 
the threshold was set within the exponential phase of the amplification plots.  
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Components of each reaction: 
Express Syber®GreenER    10 µL 
Primer mix (Forward and reverse 5 µM each) 2 µL 
cDNA       4 µL 
DEPC water      5 µL 
 
2.2.3.14 Statistical analysis 
Statistical analysis dependen on the experiment performed. Since, in most experiments, 
the number of biological and technical replicates did not exceed 20, the Student’s t-test 
(which assumes normal distribution of samples) could not be used. Thus, un-parametric 
tests (does not assume normal distribution, distribution is unknown) were used. For 
paired samples (normalized to each other) the Wilcoxon paired test was used. For 
unpaired samples (most of the experiments performed), the Mann Whitney U-test was 
used. Data was presented as mean +/- standard deviation (S.D.). P ≦ 0.05 was 
considered statistically significant. The exact value of significance are represent for 
each experiment. 
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Chapter 3. Results 
3.1 Pancreatic ductal adenocarcinoma can originate from either 
acinar or duct cells. Acinar and duct-derived PDAC have 
different progression models. 
3.1.1 Introduction to the aim 
Pancreatic ductal adenocarcinoma (PDAC) constitutes the most common type of 
pancreatic neoplasias and carries an alarmingly low prognosis (Ryan et al., 2014). Due 
to the non-specific nature of its symptoms, PDAC is detected at late stages of tumour 
development when the presence of metastases and the tumour burden reduce the 
possibility of resection (Ryan et al., 2014). Therefore, improvement of current 
therapeutic strategies relies on a better understanding of both the molecular and cellular 
biology of the initial tumourigenic events, when disease is still manageable.  
Knowledge gained from clinical observations, and genetically engineered mouse 
(GEM) models, have greatly contributed to the proposal of a step-wise progression 
model, where sequential genetic alterations correlate with morphologic abnormalities 
(Hruban et al., 2000a). However, there is still much to be discovered regarding 
molecular players and cellular origins. 
FBW7, the substrate recognition component of an SCF-type E3 ubiquitin ligase, has 
been described as a potent tumour suppressor in several organs (Welcker and Clurman, 
2008). Its importance in the gastrointestinal tract was highlighted by Rocio Sancho, a 
postdoctoral fellow in our group, who described Fbw7 as a haploinsufficient tumour 
suppressor that regulates intestinal tumourigenesis (Sancho et al., 2010). Additional 
work unveiled the potential role of Fbw7 in pancreatic tumourigenesis as its deletion in 
the mouse embryonic pancreas induced pancreatic hyperplasia (Sancho et al., 2014). 
While Fbw7 mutations had been identified in some human pancreatic tumours (Calhoun 
et al., 2003), no in depth studies had been conducted on the role of this protein in PDAC 
development and progression. Therefore, the obvious need for further assessment led 
Rocio Sancho to address the tumour suppressive role of Fbw7 in the pancreas using 
genetically engineered mouse models. 
Chapter 3 Results 
 
 116 
The most commonly used GEM to study PDAC biology has been developed by Dr 
David Tuveson’s laboratory, which promotes the induction of an activating mutation 
(G12D) in the endogenous PDAC driver gene - KRas (KRasLSL-G12D/wt ). In the model 
described by Hingorani and co-workers, the KRasLSL-G12D/wt mutation was induced in 
pancreatic progenitor cells, by means of a Pdx1-Cre (see 1.5.1, page 68), leading to the 
recapitulation of the human disease. The KRasLSL-G12D/wt; Pdx1-Cre animals initially 
developed low-grade murine pancreatic intraepithelial neoplastic lesions (mPanIN1-2), 
which later progressed to high-grade mPanIN3 lesions and PDAC (Hingorani et al., 
2003). 
By crossing Fbw7F/F mice (where exon 5 is flanked by loxP sites, allowing its removal 
after Cre expression and consequent formation of a truncated and non functional protein 
(Jandke et al., 2011)), with the previously described KRasLSL-G12D/wt; Pdx1-Cre mouse 
model, Rocio Sancho observed a drastic acceleration of PDAC development, 
confirming Fbw7 as a tumour suppressor in the embryonic pancreas. Moreover, before 
the start of my project, to study the role of Fbw7 in the adult pancreas, Rocio Sancho 
took advantage of an inducible Cre model that targets the exocrine pancreas, mainly 
ductal cells (Ck19-CreER) and could verify that, also in the adult organ, Fbw7 deletion 
with concomitant oncogenic KRasG12D activation led to PDAC onset (all mouse models 
will be explained in detail in the sections below). 
Thus, I aimed to follow up on Rocio Sancho’s observations and assess and characterize 
the effect of Fbw7 deletion in KRasG12D-induced mPDAC derived from embryonic and 
adult pancreas.  
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3.1.2 Fbw7 embryonic deletion drastically accelerates KRasG12D-induced murine 
PDAC development 
To interrogate the effect of Fbw7 deletion in the KRasG12D-induced embryonic murine 
PDAC model, I obtained, from Rocio Sancho, KRasLSL-G12D/wt; Pdx1-Cre mice, 
hereinafter referred to as KPdx1-Cre, and the Fbw7F/F; KRasLSL-G12D/wt; Pdx1-Cre, 
hereinafter F7KPdx1-Cre mice. 
As mentioned above, and as it has been described (Hingorani et al., 2003), the KPdx1-
Cre mice present an activating mutation in the KRas locus, leading to the constitutive 
activation of the Ras pathway. This mutation is inactive in the absence of Cre due to the 
presence of a lox-STOP-lox (LSL) cassette before the inserted mutated sequence. Upon 
Cre expression, the loxP sites recombine and the STOP cassette is excised, allowing 
KRasG12D expression. In this model, Cre expression is driven by the Pdx1 promoter. 
Pdx1 is a transcription factor expressed during pancreatic embryonic development 
(from embryonic day 8.5) and thus, recombination of the STOP cassette occurs in 
pancreatic progenitors, being present in all pancreatic differentiated cells of the adult 
mouse (Figure 16a) 
The F7KPdx1-Cre model also induces KRasG12D expression in pancreatic progenitors. 
However, this model presents and additional genetic alteration in the Fbw7 gene. Exon 
5 on both copies of Fbw7 harbours loxP sites, flanking the region. Upon Cre expression, 
exon 5 is excised resulting in a non-functional truncated protein (Jandke et al., 2011) 
(Figure 16a). The deletion of the protein Fbw7 in the F7Pdx1-Cre model has been 
assessed before and demonstrated to be efficient (Sancho et al., 2014).  
 
Simultaneous Fbw7 deletion and constitutive oncogenic KRas activation markedly 
decreased the survival of F7KPdx1-Cre mice compared to KPdx1-Cre, with a median 
survival of approximately 30 days (Figure 16b). F7KPdx1-cre mice were euthanized 
due to weight loss and growth retardation (data not shown), with visible swelling of the 
abdomen. Autopsies and histological analysis of 4-week-old F7KPdx1-Cre mice 
revealed the presence of a hyperplastic ductal epithelium with papillary architecture, 
sometimes cribriform, resembling the KPdx1-Cre model at 20 weeks of age. A strong 
stromal expansion (desmoplasia), characteristic of pancreatic tumours, was also 
observed (Figure 16c).  
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Human PDAC, marked by accentuated expression of the duct cell marker CK19, is 
known to be deregulated in several key signalling pathways, such as the RAS and 
NOTCH pathways (Hingorani et al., 2003, Hezel, 2006). In order to address the 
molecular profile of the generated murine tumours, I performed immunohistochemical 
analysis on murine PDAC (mPDAC) from KPdx1-Cre and F7KPdx1-Cre for Notch 
downstream effector, Hes1, for phosphorylated Erk (pERK, downstream effector of 
Ras) and for CK19. Analyses revealed that mPDAC from both KPdx1-Cre and 
F7KPdx1-Cre mice expressed CK19 (Figure 16d, first row). I additionally observed 
high levels of nuclear Hes1, indicating an increase in Notch signalling, and 
phosphorylated Erk (pERK), indicative of active KRas signalling (Figure 16d, second 
and third rows) in both models when compared with wild type controls (Pdx1-Cre). 
Interestingly, the increase in Hes1 protein levels seemed to be more pronounced in 
F7KPdx1-Cre mPDAC mice when compared to KPdx1-Cre-derived PDAC (Figure 
16d). 
Results obtained with the KPdx1-Cre model confirmed previously published data 
(Hingorani et al., 2003). Additionally, these results demonstrate that mPDAC generated 
by the F7KPdx1-Cre model resembles, on a morphological and molecular level the 
mPDAC in the KPdx1-Cre model.  Therefore, Fbw7 deletion with concomitant KRas 
oncogenic activation does not change the tumour type but accelerates mPDAC 
formation of the commonly used KPdx1-Cre model. 
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Figure 16 - Fbw7 embryonic deletion drastically accelerates KRasG12D-induced mPDAC 
development 
a) Schematic representation of the KPdx1-Cre (KRasLSL-G12D/wt; Pdx1-Cre) and the 
F7KPdx1-Cre (Fbw7F/F; KRasLSL-G12D/wt; Pdx1-Cre) mouse models. Scheme shows Cre 
expression driven by the Pdx1 promoter. Fbw7 wild type gene or with loxP sites (black 
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triangles) flanking exon 5, and KRas gene with a STOP cassette, flanked by loxP sites, 
preceding the mutation (asterisk) in exon 1. b) Survival analysis. Kaplan-Meier curve, 
generated by Rocio Sancho, with 19 KPdx1-Cre mice (red) and 12 F7KPdx1-Cre mice 
(blue). Mice were euthanized upon observation of deteriorating health conditions within 
the project license limits. c) Hematoxylin (nuclear) and eosin (cytoplasmic) (H&E) stain 
of mPDAC of a 20-week-old KPdx1-Cre mouse and a 4-week-old F7KPdx1-Cre 
mouse. d) Immuno-histological analysis of Cytokeratin 19 (CK19), Hes1 and 
phosphorylated ERK (pERK) of Pdx1-Cre (wild type control) pancreas and KPdx1-Cre 
and FKPdx1-Cre derived mPDAC. 
All scale bars represent 100µm.  
  
(Figure 16, legend continued) 
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3.1.3 The F7KPdx1-Cre model encompasses an initial ductal transformation 
step, preceding classic signs of mPDAC oncogenesis 
While human PDAC clinical observations have suggested a ductal origin for this 
disease, mouse model approaches have described acinar cells to be the origin of 
mPDAC. It has been proposed that, upon oncogenic hits, acinar cells transdifferentiate 
into ductal cells (Acinar to ductal metaplasia - ADM) expressing the marker CK19, 
which progress to PanIN (low-grade to high-grade) and PDAC (Zhu et al., 2007, Shi et 
al., 2012, Guerra et al., 2007). Since the Pdx1-Cre mouse line induces Cre-dependent 
recombination in both acinar and ducal compartments, I wanted to further characterize 
our model by analysing early time points of tumour development and describe the initial 
alterations of both compartments (Figure 17). Since, during the first weeks after birth, 
the mouse pancreas sill undergoes considerable morphologic alterations (Shih et al., 
2013) (1.1.1, page 21), I included a time point analysis of the Pdx1-Cre wild type 
control mice, to better distinguish the oncogene-related morphological alterations from 
the ones derived from normal pancreatic development. Therefore, Pdx1-Cre and 
F7KPdx1-Cre mice were euthanized at postnatal days 0 (P0), 3 (P3) and 7 (P7) (Figure 
17a,b). 
Time point analysis of control mice (Pdx1-Cre) demonstrated that at P0, the pancreas 
already contained all differentiated cells, acinar cells, ductal cells and clusters of 
endocrine cells, however lobule organization was still not obvious (Figure 17a1). Ductal 
cells in newborn pancreas did not show frequent mitotic figures (not quantified) (Figure 
17a4) and expressed CK19 (Figure 17a7), while acinar cells were negative for this 
cytokeratin marker (Figure 17a10). Three days after birth (P3), lobules became evident, 
ductal cells exhibited a clear cuboidal morphology in a flat epithelium and expressed 
CK19, however, acini still presented an immature morphology with no clear CK19 
expression (Figure 17a2,5,8,11). One week (7 days) after birth the topological 
organization of the pancreas resembled that of the adult organ (Figure 17a3,6,9,12). 
It is described that the KRas oncogenic activation, in the embryonic pancreas, allows a 
normal pancreatic development and initial transformation events are only, and rarely, 
detected 2 weeks after birth (Hingorani et al., 2003). I confirmed that Fbw7 deletion 
greatly accelerates KRasG12D-initiated tumour development, as 7 days after birth CK19-
expressing PDAC is already evident, presenting multifocal ductal structures with 
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papillary architecture, pseudo-stratified epithelium, loss of cell polarity, and 
desmoplasia (Figure 17b3,6,9). 
Interestingly, Fbw7 deletion on top of KRas oncogenic activation appeared to have little 
impact on pancreatic organo- and morphogenesis, as pancreata of new-born (P0) 
F7KPdx1-Cre mice (Figure 17b1) were shown to possess a roughly similar cellular 
composition and topological architecture to that observed in Pdx1-Cre control mice 
(Figure 17a1), with the main difference being observed in the ductal compartment 
(described below). Careful analyses of different time points revealed an increase in the 
number and type of atypical ductal structures in the F7KPdx1-Cre compared with Pdx1-
Cre. At P0, ducts of F7KPdx1-Cre mice were already crowded, with obvious and 
frequent mitotic figures (Figure 17b4). At P3, ductal cells did not resemble the ones 
observed in the control. F7KPdx1-Cre ductal cells, at P3, became enlarged with 
expansion of the cytoplasm towards the duct lumen and increased nuclear size (not 
measured) (Figure 17b25). Surprisingly, similar to control mice (Figure 17a10,11) 
acinar cells  from F7KPdx1-Cre mice, at P0 and P3, did not show any obvious CK19 
expression (Figure 17b10,11) suggesting that transformation of the ducts preceded 
acinar to ductal metaplasia (ADM). 
Chapter 3 Results 
 
 123 
 
Figure 17 - The F7KPdx1-cre model encompasses an initial ductal transformation step 
that precedes ADM 
Time-course analysis of normal pancreatic and PDAC development in the Pdx1-Cre and 
F7KPdx1-Cre mouse models. Animals were culled at postnatal day (P) 0, 3 and 7. 
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a 1-11 show the respective wild type controls (Pdx1-Cre) for b 1-11 (F7KPdx1-Cre). 
a) Time point histological analysis of pancreas of the Pdx1-Cre mouse model at P0, P3 
and P7. 1-3) H&E low magnification of pancreas of 1 - P0, 2 - P3 and 3 - P7. 4-6) H&E 
high magnification of pancreas of 4 - P0, 5 - P3 and 6 - P7. High magnification of 
nuclei in P0 demonstrates absence of mitotic figures in ductal cells. 7-9) Ck19 
immunohistochemical analysis of ductal cells of 7 - P0, 8 - P3 and 9 - P7. 10-12) CK19 
immunohistochemical analysis of acinar cells of 10 - P0, 11 - P3 and 12 - P7. 
b) Time point histological analysis of pancreas of the F7KPdx1-Cre mouse model at P0, 
P3 and P7. 1-3) H&E low magnification of pancreas of 1 - P0, 2 - P3 and 3 - P7. 4-6) 
H&E high magnification of pancreas of 4 - P0, 5 - P3 and 6 - P7. High magnification of 
nuclei in P0 demonstrates presence of mitotic figures in ductal cells. White arrows show 
mitotic figure. Black arrow shows loss of polarity (nuclear orientation) 7-9) Ck19 
immunohistochemical analysis of ductal cells of 7 - P0, 8 - P3 and 9 - P7. 10-11) Ck19 
immunohistochemical analysis of acinar cells of 10 - P0 and 11 - P3.  
For each time point two litters, each comprising of more than 3 Pdx1-Cre animals and at 
least two F7KPdx1-Cre, were used for histological analysis. 
Scale bars in a1-3 and b1-3 represent 100 µm.  Scale bars in a4-12 and b4-11 represent 
50 µm.  
  
(Figure 17, legend continued) 
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ADM is described as the initial step towards tumour formation from mutated acinar 
cells. However, ADM is also observed in wild type acinar cells, in response to 
inflammatory cues, with no progression to PDAC (Liou et al., 2013). Hence, ADM can 
be both a pre-neoplastic entity and a response to injury. Thus, it is still not clear if ADM 
is a compulsory lesion for PDAC formation. For this reason, I wondered if the observed 
ductal transformation also preceded the classical pre-neoplastic mPDAC lesions, 
mPanINs, described to be the progeny of the PDAC-initiating ADM. It has been 
described that mPanINs are classified from low (PanIN1) to high-grade (PanIN3) 
according to their cellular dysplasia and marker signature (see 1.4.4, page 59) (Hruban 
et al., 2000a, Hruban et al., 2001). Human PanINs are mucinous structures and have 
been shown to be identified by alcian blue (AB) or periodic acid-schiff (PAS) stain, 
which detect polysaccharides present in mucins (see 2.2.3.6, page 109) (Yonezawa et al., 
2008). 
I performed AB/PAS stain in P0, P3, P7 (one week) and P14 (2 weeks) pancreatic 
samples from F7KPdx1-Cre mice to detect when mPanINs first appear in the F7KPdx1-
Cre model (Figure 18a). 
As a positive control for the AB/PAS stain, I used pancreatic samples from a 20-week-
old KPdx1-Cre mice. These mice are known to develop rare low-grade mPanINs as 
early as 2 weeks after birth (Hingorani et al., 2003). Thus, 20-weeks after birth, several 
mPanINs were expected. mPanIN quantification was performed by counting the number 
of AB/PAS positive lesions per mm2 of pancreatic tissue (Figure 18b).  
At P0 and P3, no lesions histologically similar to mPanINs were observed (Figure 18a  
P0, P3). Moreover, AB/PAS stains failed to identify AB/PAS positive structures at 
these early time points (Figure 18b, P0, P3). AB/PAS positive structures were only 
detected in the F7KPdx1-Cre mouse 7 days after birth (P7) and increased in number one 
week later (P14) (Figure 18a,b P7, P14). 
These results suggest that the F7KPdx1-Cre model follows a similar mPDAC 
progression as described for the KPdx1-Cre mice and that evident ductal atypia 
precedes early grade mPanINs. 
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Figure 18 - The F7KPdx1-Cre model encompasses an initial ductal transformation step 
that precedes mPanIN 
Time-course analysis of AB/PAS positive lesions development in the F7KPdx1-Cre 
model. 
a) AB/PAS stain of F7KPdx1-Cre pancreas at P0, P3, P7 and P14. KPdx1-Cre mice 
pancreas was also collected 20 weeks after birth to be used as a positive control for the 
AB/PAS stain of mPanIN lesions. b) Number of AB/PAS positive lesions per mm2 of 
pancreatic tissue. For quantification, 2 mice per time point were used and 3 levels of 
tissue were stained for quantification (n mice = 2). Bar chart shows the mean values. 
Error bars indicate standard deviation (SD). Statistical significance was tested with the 
Mann-Whitney test. P values are indicated 
All scale bars represent 100 µm. 
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3.1.4 Fbw7 embryonic deletion mainly affects duct cells 
It has been reported that ductal cells demonstrate the highest levels of Fbw7 expression 
amongst all pancreatic compartments (Sancho et al., 2014). Given the previous 
observation that ductal cells seem to undergo oncogenic transformation before acinar 
cells show signs of disturbance (ADM and PanIN) in the F7KPdx1-Cre model, I 
hypothesized that the ductal cellular compartment might respond more significantly to 
Fbw7 deletion when compared to acinar cells. The effect of Fbw7 deletion was assessed 
by the change in number of proliferative cells.  
Proliferation was assessed by counting the number of cells positive for the mitotic 
marker phosphorylated histone 3 (pH3). I performed immunofluorescence stain on 
pancreas from Fbw7F/F; Pdx1-Cre (F7Pdx1-Cre) and Pdx1-Cre control mice for pH3 
(Figure 19a) and observed a statistically significant increase in the percentage of pH3-
positive cells in the ducts upon embryonic Fbw7 deletion (F7Pdx1-Cre mice), compared 
with ducts from Pdx1-Cre control mice. No change in the number of pH3-positve cells 
was observed for the acinar compartment after Fbw7 deletion (Figure 19b). These 
results indicate that, in terms of proliferation, Fbw7 deletion mainly affects the ductal 
compartment. 
 
I next tested if the concomitant expression of the activated KRasG12D would also 
preferentially affect one compartment over the other, in the absence of Fbw7. To avoid 
detecting increased proliferation due to secondary effects of tumourigenesis, such as 
inflammation, I focused on early stages of tumour development (P0). I performed pH3 
immunofluorescence stains on pancreas of P0 F7KPdx1-Cre mice and compared them 
with P0 Pdx1-Cre mice (Figure 19c). While no increase in proliferation was detected in 
acinar cells, the ductal compartment of F7KPdx1-Cre mice showed a marked increase 
in the number of pH3 positive cells compared with ducts of a Pdx1-Cre P0 pancreas 
(Figure 19d). These observations support the idea that Fbw7 deletion, with or without 
KRas oncogenic activation, mainly affects ductal cells. Contrasting with commonly 
accepted proposals of the non-involvement of ductal cells in tumour development (Ray 
et al., 2011, Kopp et al., 2012), these results highlight a possible contribution of the 
ductal compartment to PDAC. 
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Figure 19 - Fbw7 embryonic deletion mainly affects duct cells 
a) Immunofluorescence staining of Ck19 and pH3 in age-matched pancreas of Pdx1-
Cre control and F7Pdx1-Cre mice. 8 and 15 weeks old mice were used. For each age, 
the control Pdx1-Cre and F7Pdx1-Cre were siblings collected at the same time b) 
Percentage of pH3 cells in acinar or ductal compartments of age-matched Pdx1-Cre and 
F7Pdx1-Cre mice (calculated as number of pH3 cellsduct or acinar/total cellsduct or acinar)*100) 
c) Immunofluorescence staining of Ck19 and pH3 in pancreas of P0 Pdx1-Cre control 
and F7KPdx1-Cre mice. d) Percentage of pH3 cells in acinar or ductal compartments of 
P0 Pdx1-Cre and F7KPdx1-Cre mice (calculated as number of pH3 cellsduct or acinar/total 
cellsduct or acinar)*100). 
The number of pH3-positive cells was counted per genotype, per cellular compartment 
(acinar vs duct). pH3-positive cells are indicated in white for ducts and yellow for 
acinar cells. Each dot represents one pancreatic region used for quantification. For the 
quantification, 2 mice per time point were used and 3 levels of tissue were stained (n 
mice=2). Graph shows mean values +/- SD. Statistical significance was tested with the 
Mann-Whitney test. P values are indicated.  
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3.1.5 Fbw7 loss in KRasG12D-expressing adult ductal cells induces mPDAC 
without low-grade mPanIN (1-2) formation 
To better assess the role of ductal cells in PDAC development, I generated mice where 
Fbw7 protein deletion and simultaneous KRasG12D activation could be induced, mainly, 
in ductal cells by means of a Ck19-CreER inducible mouse line (Fbw7F/F; KRasLSL-
G12D/wt; Ck19-CreER, hereinafter referred to as F7KCk19-CreER). For full 
characterization of the F7KCk19-CreER mouse model, such as lineage tracing analysis 
and recombination efficiency see 4.1.2, page 162. 
Similar to the models explained above, upon Cre expression, and its subsequent 
translocation to the nucleus following tamoxifen treatment, the exon 5 of Fbw7 is 
excised, deleting the protein, and the KRasG12D mutation is expressed. However, this 
model differs from the previous F7KPdx1-Cre in two key aspects: (1) the Ck19, and not 
the Pdx1, promoter drives Cre expression, which is active in ductal cells, allowing 
ductal cell targeting, (2) this models harbours a mutant version of Cre that only 
translocates to the nucleus in the presence of metabolized tamoxifen. Therefore, the 
silencing of Fbw7 and expression of the oncogenic KRas can be induced by tamoxifen 
treatment. Since PDAC mainly affects adults, Cre-mediated recombination was 
stimulated in adult animals by treating 8-week-old mice with intraperitoneal (IP) 
tamoxifen injections (Figure 20a). 
One month following tamoxifen treatment, mice became symptomatic and were 
euthanized due to swollen abdomen and rapid breathing (the rapid breathing will be 
explained in 3.1.6). Post mortem analysis revealed the presence of pancreatic tumours, 
which were immediately fixed, embedded in paraffin and tissue sections were obtained 
for histological analysis. Histologically, F7KCk19-CreER generated tumours resembled 
mPDAC, exhibiting dysplastic ductal structures with papillary architecture and 
accentuated desmoplasia (Figure 20b H&E), as previously observed by Rocio Sancho. 
Similarly to the human disease, I also observed strong Ck19 protein levels together with 
high Hes1 and pERK protein levels (Figure 20b). These results support the role of 
ductal cells in PDAC development and add ductal cells to the group of currently known 
PDAC cells of origin. 
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PDAC can originate from different types of precursor lesions such as IPMN, MCN, 
ITPN and PanIN (see 1.4, page 54) (Distler et al., 2014, Yonezawa et al., 2008, Hruban 
et al., 2007). GEM models have been used to better understand the causative events for 
the different lesions. It is hypothesized that different pre-neoplastic lesions might be 
determined by the cell of origin, or, alternatively, by the genetic alteration induced (von 
Figura et al., 2014, Bardeesy et al., 2006b, Hingorani et al., 2003, Guerra et al., 2007). 
It is currently accepted that murine PanIN lesion are derived from acinar cells which, 
upon oncogenic hits and pancreatitis, undergo ADM and progress toward PDAC 
(Tuveson et al., 2006, Grippo and Sandgren, 2012, Guerra et al., 2007). Since the 
F7KCk19-CreER model mainly targets ductal cells, with some, acinar cells targeting 
being reported (Ray et al., 2011), I decided to, first confirm that transformation was 
occurring in ductal cells and, secondly, to closely analyse how PDAC is formed in this 
context. 
To investigate tumour progression, I tamoxifen-treated 8-week-old F7KCk19-CreER 
mice and collected the pancreas at different time points (0, 14, 21 and 28 days post 
tamoxifen treatment). To control for, and detect, morphological alterations soon after 
tamoxifen treatment (Day 0), I also collected the pancreas of wild type non-tamoxifen 
treated 8-week-old mice. 
To most accurately identify the sequence of morphological alterations, I looked for 
morphological deviations from wild type pancreas. Given the fact that tamoxifen-
induced, Cre-dependent, recombination is not a synchronous event, i.e. some cells 
receive the metabolized tamoxifen before others, transformation is not expected to be 
synchronous. Therefore, I searched for lesions that were frequent at initial stages and 
persisted at later time points with simultaneous appearance of structures with higher 
cellular atypia. Thus, as performed for the human disease, a linear progression was 
identified, where ductal cells progressively acquire higher levels of dysplasia (Figure 
20c). 
At day 0, no alteration was detected in the pancreas when compared with pancreata of 
8-week-old wild type mice, except a possible crowding of the ducts. Two weeks after 
tamoxifen treatment, while the acinar compartment remained morphologically 
unchanged, ducts became obviously crowded and a ductal cell expansion towards the 
lumen was discernible, similar to that detected in the F7KPdx1-Cre model at P3 (Figure 
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17b2 and 5). This result confirmed a duct-specific transformation from the Ck19-
CreER-dependent cell targeting. Three weeks (Day 21) after tamoxifen treatment, I 
detected an increase in ductal dysplasia in F7KCk19-CreER mice. Ducts became 
papillary and shedding of clusters toward the lumen was observed. At this time point, 
ductal structures closely resembled carcinoma in situ (also known as mPanIN3), which 
is characterized by papillary or cribriform epithelium, occasional fragmentation of 
epithelial clusters and low or negative for AB/PAS (low-grade PanIN markers) (Cooper 
et al., 2013, Hruban et al., 2007). Onset of focal mPDAC was detected one month after 
tamoxifen treatment with loss of duct cell polarity in the papillary structures and 
pronounced desmoplasia (Figure 20c H&E, CK19 day 28). 
During mPDAC development, I did not detect lesions morphologically similar to 
mPanIN1 or mPanIN2 (low-grade). Interestingly, consistent with the previous finding, 
in all of the tested time points before tumour onset, I did not observe AB/PAS positive 
structures, the commonly used marker for low-grade mPanINs (Figure 20c AB/PAS).  
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Figure 20 - Fbw7 loss in KRasG12D-expressing ductal cells induces mPDAC without low-
grade mPanIN formation 
a) Schematic representation of the F7KCk19-CreER mouse (Fbw7F/F; KRasLSL-G12D/wt, 
Ck19-CreER and experimental approach). Black triangles indicate loxP sites and 
asterisk indicates the exon with the G12D mutation. 8-week-old mice were 
intraperitoneally injected with tamoxifen (100 mg/kg of body weight) once a day for 
two days. Pancreatic tissue was collected for analysis at day 0, 14, 21 and 28 after last 
tamoxifen dose. b) Histological analysis of F7KCk19-CreER-derived mPDAC. One 
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month after tamoxifen treatment, H&E (upper left), CK19 (upper right), Hes1 (lower 
left) and pERK (lower right) stain. c) Immunohistological analysis of wild type (WT) 8-
week-old pancreas and time-course analysis of mPDAC development in the F7KCk19-
CreER model. Animals were culled at P0, P14, P21 and P28 after last tamoxifen 
injection. The figure displays low magnification H&E stain (first row) of different time 
points. Regions of interest are marked. Second row shows AB/PAS for the respective 
regions of interest. Third row shows CK19 immunological staining for the respective 
regions of interest. Black dashed line illustrates the ductal cell expansion. Black 
arrowheads indicate loss of cell polarity. 
For histological analysis, more than 6 animals per time point were used. Four levels of 
tissue were obtained for H&E and immunostaining to thoroughly assess the 
morphological changes.   
All scale bars represent 100 µm.  
(Figure 20, legend continued) 
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3.1.6 Uncoupling cell of origin from genetic alteration effect during PDAC 
oncogenesis 
Results obtained so far suggest that either duct cell-derived murine PDAC does not 
evolve from low-grade mPanINs, or that Fbw7 deletion promotes mPDAC in a low-
grade mPanIN independent manner. 
While the observation of low-grade mPanINs in the F7KPdx1-Cre model (Figure 18a) 
argues against the latter, the observed AB/PAS positive lesions were in fact rare in 
F7KPdx1-Cre mice when compared to the number detected in the KPdx1-Cre model 
(Figure 18b). Therefore, I aimed to more elegantly dissociate the effect of cell of origin 
versus genetic alteration on tumour development. 
The experimental approach is schematically summarized in Figure 21. To understand if 
loss of Fbw7 protein was the cause of early mPanIN absence, I interrogated Fbw7 loss 
effect with simultaneous KRasG12D genetic activation in the acinar compartment (by 
using a tamoxifen inducible, acinar cell specific, Cre line, Elastase1-CreER or Ela1-
CreER). If the absence of mPanIN1 and mPanIN2 in the F7KCk19-CreER was due to 
ductal cell targeting, then the acinar cell-derived PDAC progression from F7KEla1-
CreER should allow the easy detection of low-grade mPanINs (Figure 21a). I obtained 
additional confirmation by using the duct cell specific induction of alternative genetic 
alterations that have been shown to accelerate PDAC development through mPanIN1-
mPanIN2-mPanIN3 progression in the developing pancreas. It has been described that 
p53 or PTEN deletion, on top of KRas oncogenic activation, in the embryonic pancreas 
accelerates mPDAC oncogenesis with initial development of mPanIN1 (Hill et al., 2010, 
Guerra et al., 2007). Thus, I decided to induce the same genetic alterations using the 
duct-specific Cre mouse model (Ck19-CreER). The detection of low-grade mPanIN 
lesions formed from duct-targeted cells would suggest that the absence of low-grade 
mPanIN in the F7KCk19-CreER was a genotype specific event. On the other hand, if no 
mPanIN1 and 2 lesions would be observed, it would indicate that their absence in the 
F7KCk19-CreER was a cell of origin specific phenotype (Figure 21b). 
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Figure 21 - Uncoupling cell of origin from genetic alteration effect during PDAC 
oncogenesis 
Experimental approach undertaken to uncouple the effect of cell of origin from genetic 
alteration in PDAC initiation and progression. The mouse Cre lines used identify the 
pancreatic compartment that they target in the figure. Ela1-CreER induces tamoxifen-
dependent recombination in acinar cells while Ck19-CreER targets duct cells. a) Fbw7 
deletion will be induced in KRasG12D-expressing acinar cells (F7KEla1-CreER). If 
tumour formation occurs without low-grade mPanIN formation, it indicates that Fbw7 
deletion is the decisive factor for the lack of formation of these pre-neoplastic lesions. 
Therefore, the absence of mPanIN1 and mPanIN2 in the F7KCk19-CreER model was a 
genetic specific event. However, if low-grade mPanINs are detected, then Fbw7 
deletion has no role in pre-neoplastic lesion determination. b) p53 or PTEN deletion 
(two genetic alterations described to induce mPDAC via mPanIN1-mPanIN2-mPanIN3 
progression) will be induced in KRasG12D-expressing duct cells (p53KCk19-CreER or 
PTEN-KCk19-CreER). PDAC formation in the absence of low-grade mPanIN suggests 
that ductal cells, regardless of the oncogenic hit, do not evolve into PanIN1 and PanIN2 
during PDAC development, i.e. cell specific phenotype. However, if low-grade mPanIN 
lesions are detected, we can conclude that ductal cells, like acinar cells, can generate 
low-grade PanINs and their absence in the F7KCk19-CreER model was an Fbw7 
deletion-specific phenotype.  
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In order to test this hypothesis, I generated a panel of mouse models where the same 
genetic alteration was induced in the embryonic pancreas (Pdx1-Cre), or in adult acinar 
(Ela1-CreER) or adult ductal (Ck19-CreER) compartments (Table 10) 
Analyses started by assessing if and how mPDAC is formed in PTEN-KCk19-CreER 
mice. PTEN, an antagonist of the PI3K/PDK1/AKT pathway (a pathway involved in 
PDAC formation (Eser et al., 2013)), has been shown to be a potent tumour suppressor 
in the developing pancreas (Stanger et al., 2005, Hill et al., 2010). To test its role during 
adult pancreatic tumourigenesis, from duct cells, I deleted the tumour suppressor PTEN 
in KRasG12D, CK19-expressing cells. CK19 is a cytokeratin expressed in pancreatic 
ducts. However, other murine tissues are known to express it, such as epithelial cells in 
the oral cavity, lung, liver, kidney, stomach and intestine (Ray et al., 2011). PTEN is 
also a potent tumour suppressor in the lung, which has been shown to cooperate with 
oncogenic KRas during lung tumourigenesis (Iwanaga et al., 2008, Cui et al., 2014). 
Therefore, it is not surprising that intraperitoneal injections of tamoxifen in PTEN-
KCk19-CreER mice led to the rapid development of lung hyperplasia and respiratory 
distress. Unfortunately, mice had to be euthanized only two weeks after tamoxifen-
induced recombination with only minor alteration to the pancreas (data not shown). As 
a side observation, F7KCk19-CreER also developed lung tumours. However, the 
pancreatic tumours appeared before mice had to be culled from respiratory distress.  
To avoid whole body dissemination of tamoxifen, and consequent recombination 
outside the pancreas, I decided to inject 4-hydroxytamoxifen (the active metabolite of 
tamoxifen) intrapancreatically by non-invasive ultrasound-guided injection. A drawback 
of this approach is the trail of injectable substance that is dragged with the needle upon 
removal after injection. As a consequence, and due to PTEN’s role as tumour 
suppressor in the skin (Ming and He, 2009), mice promptly developed papillomas on 
the injection site (data not shown), impeding long term analysis of pancreatic 
tumourigenesis. Hence, I decided to stop the assessment of PTEN deletion and focus on 
the remaining models. 
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Full genotype Abbreviation Activation Target cell 
Usage 
in study 
P53F/F; KRasLSL-G12D/wt; 
Ck19-CreER 
p53KCk19-
CreER 
Adult 8 weeks 
(conditional) Duct Used 
Fbw7F/F; KRasLSL-G12D/wt; 
CK19-CreER 
F7KCk19-
CreER 
Adult 8 weeks 
(conditional) 
Duct Used 
PTENF/F; KRasLSL-G12D/wt; 
CK19-CreER 
PTEN-KCk19-
CreER 
Adult 8 weeks 
(conditional) 
Duct Used 
P53F/F; KRasLSL-G12D/wt; 
Ela1-CreER 
p53KEla1-
CreER 
Adult 8 weeks 
(conditional) 
Acinar 
Not 
used 
Fbw7F/F; KRasLSL-G12D/wt; 
Ela1-CreER F7KEla1-CreER 
Adult 8 weeks 
(conditional) 
Acinar Used 
PTENF/F; KRasLSL-G12D/wt; 
Ela1-CreER 
PTEN-KEla1-
CreER 
Adult 8 weeks 
(conditional) 
Acinar 
Not 
used 
P53F/F; KRasLSL-G12D/wt; 
Pdx1-Cre p53KPdx1-Cre 
Embryonic 
(E8.5) 
Whole 
pancreas 
Used 
Fbw7F/F; KRasLSL-G12D/wt; 
Pdx1-Cre F7KPdx1-Cre 
Embryonic 
(E8.5) 
Whole 
pancreas 
Used 
 
Table 10 - Mouse models generated for the study 
p53, Fbw7 or PTEN homozygous deletion was induced together with KRasG12D 
oncogenic activation in different pancreatic cell types, at different stages of 
development. The mouse line Pdx1-Cre was used to induce recombination in the 
developing pancreas by Pdx1-driven Cre expression at E8.5. Ck19-CreER was used to 
induce recombination in adult (8-week-old) duct cells by Ck19-driven CreER 
expression. Ela1-CreER was used to induce recombination in adult (8-week-old) acinar 
cells by means of Elastase1-driven CreER expression. CreER-dependent genetic 
recombination was induced by tamoxifen treatment.  
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3.1.7 Fbw7 loss in KRasG12D-expressing adult acinar cells leads to low-grade 
mPanIN formation 
Acinar cells have been shown to generate PDAC upon oncogenic hits. These fully 
committed exocrine cells regain plasticity in the oncogenic context and 
transdifferentiate into ductal cells by a process named acinar to ductal metaplasia 
(ADM). ADM can further progress to PDAC with the intermediate development of 
PanIN1, 2 and 3 lesions (Guerra et al., 2007, Tuveson et al., 2006, Grippo and Sandgren, 
2012, Habbe et al., 2008). Formation of mPanIN lesions, from acinar cells upon 
oncogenic transformation, appears to be a robust phenotype, as different genetic 
alterations, such as the simultaneous deletion of p16INK4A/P19ARF in KRasG12D-
expressing adult acinar cells, with induced pancreatitis, also leads to mPDAC 
development with initial mPanIN1 formation, as observed for KRasG12D genetic 
alteration alone (Guerra et al., 2011).  
In order to assess if, and how, Fbw7 deletion, with KRasG12D oncogenic activation, 
leads to PDAC from acinar cells, I generated Fbw7F/F; KRasLSL-G12D/wt; Ela1-CreER 
mice, hereinafter F7KEla1-CreER, where Fbw7 deletion and KRasG12D simultaneous 
activation occurs in acinar cells and is dependent on tamoxifen treatment (Figure 22a). 
Adult acinar cells are extremely resistant to multiple oncogenic hits. While it is 
described that, induction of oncogenic genetic alterations in embryonic or young acinar 
cells (up to 6-week-old mice) leads to tumour formation, the same does not happen if 
recombination is induced in the adult compartment (8-week-old mice) without 
additional injuri, even when potent tumour suppressors are deleted in a KRasG12D-
expressing background (Guerra et al., 2011, Habbe et al., 2008). In line with published 
data, I observed no pancreatic phenotype in F7KEla1-CreER mice 3 months after 
tamoxifen treatment in 8-week-old mice  (data not shown). Since pancreatitis is a 
known promoter of PDAC, and it has been shown to accelerate KRasG12D-dependent 
PDAC, a combinatory caerulein treatment, to induce acute pancreatitis, was used to 
promote mPDAC formation in the adult animal as described before (Carrière et al., 
2009, Carrière et al., 2011). 
Caerulein is a cholecystokinin analogue that promotes the premature activation and 
uncontrolled release of acinar-produced digestive enzymes. This release induces 
extensive acinar cell death and promotes the generation of an inflammatory 
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environment stimulating remaining acinar cells to transdifferentiate into ductal cells 
(ADM). If the treatment is performed in a wild type scenario, regeneration of the organ 
occurs within 7 days, metaplastic ductal lesions regress and the pancreas adopts a 
normal morphology. However, in the presence of oncogenic KRasG12D, metaplastic 
structures persist and tumourigenesis is promoted (Morris et al., 2010). 
As shown in Figure 22a, I induced genetic recombination by intraperitoneal tamoxifen 
injection over a 5-day period (one injection per day – 100 mg/kg of body weight/day). 
One week after recombination, mice were subjected to an acute pancreatitis protocol by 
caerulein intrapancreatic injections (6 IP injections per day, given at hourly intervals, 
over 2 days (50 µg/kg of body weight/injection) (see 2.2.1.5, page 96)). In order to 
compare the results obtained with those observed for the F7KCk19-CreER model, I 
collected the pancreas from F7KEla1-CreER tamoxifen- and caerulein-treated mice 1 
month after pancreatitis (same time point as before) (Figure 22a). Surprisingly, while 
F7KCk19-CreER mice already presented mPDAC at this particular time point in the 
absence of caerulein (Figure 20b), the F7KEla1-CreER mice only showed low-grade 
atypia with extensive ADM and stromal expansion, even after caerulein treatment 
(Figure 22b, low magnification H&E). Interestingly, I observed ductal dysplastic 
lesions with flat epithelium, expanded cytoplasm toward the lumen and nuclei located 
basally exhibiting low-grade atypia (Figure 22b high magnification H&E), 
characteristic of mPanIN1. Supporting their ductal appearance and low-grade PanIN 
biology, these structures were highly positive for Ck19 and presented supranuclear 
mucin production identified by AB/PAS stain (Figure 22b). 
The number of AB/PAS positive lesions was quantified for F7KEla1-CreER and 
F7KCk19-CreER pancreas, one month after tamoxifen induced, Cre-dependent, 
recombination. Quantification was performed counting the number of positive lesions 
per transformed area. Transformed area was used, instead of total area, for 
normalization purposes, given the difference in extent of pancreatic transformation in 
both models. Comparison of AB/PAS positive lesions in both models, demonstrated 
that Fbw7 deletion with simultaneous KRasG12D expression, in acinar cells, leads to 
extensive appearance of mPanIN1, AB/PAS positive lesions (Figure 22c,d). 
The results demonstrate that deletion of Fbw7 in KRasG12D-expressing adult acinar or 
ductal cells has different effects. While ductal cell-targeting led to mPDAC oncogenesis 
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without the development of low-grade mucinous mPanINs, acinar cell-targeting 
promoted the formation of mPanIN1 lesions. This suggests that Fbw7 deletion has no 
role in determination of the pre-neoplastic lesion and mode of progression, proposing 
the cell of origin to be an important factor in this decision. Nonetheless, I could not 
observe PDAC in the F7KEla1-CreER model, and thus, while longer time points are 
still to be analysed, further confirmation of the observed phenotype was necessary. 
 
Figure 22 - Fbw7 loss in KRasG12D-expressing adult acinar cells leads to low-grade PanIN 
formation 
a) Schematic representation of the F7KEla1-CreER mice (Fbw7F/F; KRasLSL-G12D/wt, 
Ela1-CreER) and experimental approach. Black triangles indicate loxP sites and 
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asterisk indicates the exon with the G12D mutation. 8-week-old mice were 
intraperitoneally injected with tamoxifen for a 5-day period (one injection per day – 100 
mg/kg of body weight/day). One week after tamoxifen treatment, mice were subjected 
to an acute caerulein protocol with 6 IP injections per day, given at hourly intervals, 
over 2 days (50 µg/kg of body weight/injection). Mice were culled 1 month after the last 
tamoxifen injection and the pancreas was removed and used for histological analysis. 
Eight mice were used and 4 levels of tissue of each pancreas were analysed. b) 
Histological analysis of F7KEla1-CreER pancreas one month after tamoxifen treatment. 
From left to right: H&E low magnification (region of interest illustrated by black 
square); H&E, AB/PAS and Ck19 stain of region of interest. c) H&E and AB/PAS 
representative images of acinar (F7KEla1-CreER) and duct (F7KCk19-CreER) Fbw7 
deleted, oncogenic KRasG12D pancreas, one month after tamoxifen treatment. Black 
arrows show AB/PAS positive lesions. d) Number of AB/PAS positive lesions per 
transformed area (mm2) in F7KEla1-CreER and F7KCK19-CreER mice, one month 
after tamoxifen treatment. For quantification, 2 mice were used and 3 levels of tissue 
were stained (n mice=2). Bar chart shows the mean values plus SD. Statistical 
significance was tested with the Mann-Whitney test. P values are indicated. 
All scale bars represent 100 µm.  
(Figure 22, legend continued) 
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3.1.8 p53 loss in KRasG12D-expressing adult ductal cells mimics the F7KCK19-
CreER phenotype 
Since F7KEla1-CreER mice did not form murine PDAC, up to one month following 
recombination, it was difficult to uncouple the genetic alteration from the cell of origin 
in determination of tumour progression. Hence, I decided to confirm if other genetic 
profiles would also lead to duct-derived PDAC development without low-grade 
mPanIN formation.  
P53 is commonly deleted or mutated in PDAC patient samples (Rozenblum et al., 1997). 
The role of p53 in pancreatic tumourigenesis has been extensively demonstrated by its 
simultaneous deletion with KRas oncogenic activation in the developing pancreas. 
While the loss of p53 alone has no effect in the pancreas, it drastically accelerates 
KRasG12D-driven PDAC oncogenesis via mPanIN1-2 and 3 formation (Bardeesy et al., 
2006a, Hingorani et al., 2005). The role of p53 in adult mPDAC tumourigenesis was 
also assessed where the concomitant expression of KRasG12V and pancreatitis greatly 
accelerated acinar cell-derived PDAC development. However, no comment was made 
regarding the mode of progression (Guerra et al., 2011).  If it is in fact true that tumours 
derived from duct cells do not evolve from low-grade PanIN lesions, I hypothesized that 
p53 deletion in KRasG12D-expressing adult duct cells should reproduce the F7KCk19-
CreER phenotype. 
To address this question, I treated 8-week-old p53F/F; KRasLSL-G12D/wt; Ck19-CreER 
mice, hereinafter p53KCk19-CreER, with tamoxifen (intraperitoneal injection) to 
induce duct specific recombination (Figure 23a). These mice exhibited swollen 
abdomen and respiratory distress (due to recombination in the lungs, as well as in the 
pancreas) close to one month after tamoxifen injections, at which time they were 
euthanized. Post mortem analysis revealed extensive pancreatic damage with the 
presence of a solid mass replacing the pancreatic organ and expansion of this mass to 
the intestine. Histological evaluation at endpoint demonstrated the presence of mPDAC 
represented by multiple foci of ductal transformation, loss of basement membrane from 
the epithelial structures and extensive desmoplasia (Figure 23b). It has been described 
that mPanIN lesions, although precursors to mPDAC, are also observed at the end stage 
of murine tumour development, as progression is not synchronous (Collins et al., 2012b, 
Hingorani et al., 2005). My analysis of late stage mPDAC did not identify low-grade 
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mPanIN lesions providing the first indication that duct derived PDAC does not 
encompass mPanIN1 or 2 generation. To confirm that low-grade mPanINs were not 
missed during tumour development, I collected the pancreas of p53KCk19-CreER mice 
at day 0, 21, 28 and 35 after tamoxifen treatment and assessed the morphological 
alterations. Pancreata of, 8-week-old, wild type mice were also collected to serve as a 
control for morphological changes (Figure 23c).  
Similar to the approach taken for the F7KCk19-CreER, I searched for lesions with low-
grade dysplasia at initial time points that increase in frequency over time, with 
concomitant appearance of higher-grade dysplasia at later time points. Initial 
morphological deviations from wild type and control time point (Day 0) ducts were 
detected 21 days post recombination, I could observe the crowding of the ductal 
epithelium with cellular enlargement of some ductal regions towards the lumen. Unlike 
mPanIN lesions, which also exhibit cytoplasmic expansion, the nuclei of these 
morphologic alterations were not organized basally. Instead, they expanded with the 
cytoplasm and occupied different positions within the cells (Figure 23c Day 21, H&E). 
28 days post recombination, while most pancreatic regions remained unaltered, with 
only the ductal expansion being detected, I could observe the initial appearance of 
papillary structures. However, I still could not detect any evidence of columnar 
epithelium characteristic of low-grade mPanINs (Figure 23c Day 28, H&E). Consistent 
with the failure to identify lesions morphologically similar to previously described 
mPanIN1 and mPanIN2, I could not detect any AB/PAS positivity at any of the time 
points (Figure 23c AB/PAS panel), indicating that, also in the p53KCk19-CreER model, 
duct-derived mPDAC is not preceded by mPanIN formation. 
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Figure 23 - P53 loss in KRasG12D-expressing adult ductal cells mimics the F7KCk19-CreER 
phenotype 
a) Schematic representation of the p53KCk19-CreER mouse (p53F/F; KRasLSL-G12D/wt, 
CK19-CreER) and experimental approach. Black triangles indicate loxP sites and 
asterisk indicates the exon with the G12D mutation 8-week-old mice were 
intraperitoneally injected with tamoxifen (100 mg/kg of body weight) once a day for 
two days. Pancreatic tissue was collected for analysis at day 0, 21, 28 and 35 after last 
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tamoxifen dose. b) H&E of p53KCk19-CreER-derived mPDAC, 35 days after 
tamoxifen treatment. c) Immunohistological analysis of wild type (WT) 8-week-old 
pancreas and time-course analysis of mPDAC development in the p53KCk19-CreER 
model. Animals were culled at P0, P21, P28 and P35 after last tamoxifen injection. The 
figure displays low magnification H&E stains (first row) of different time points. 
Regions of interest are marked. Second row shows AB/PAS stain for the respective 
regions of interest. Third row shows CK19 immunological staining for the respective 
regions of interest. Pancreas of four p53KCk19-CreER mice were used for the 
histological analysis of the time points day0, 21 and 28. Three mice were used for time 
point day 35. Black squares in the H&E identify regions of interest magnified in 
AB/PAS and CK19 panels. Black dashed line illustrates the ductal expansion.  
All scale bars represent 100 µm. 
  
(Figure 23, legend continued) 
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Interestingly, simultaneous with mPDAC formation, I detected pancreatic regions 
containing a different type of tumour. Histologically, the additionally found tumours 
exhibited a mesenchymal differentiation, composed of a homogeneous mass of spindle 
shaped cells (Figure 24a and b H&E). 
To better understand the biology and origin of these tumours, I performed 
immunohistological analysis for the ductal epithelial marker Ck19 and the 
mesenchymal marker smooth muscle alpha-actin (SMA). These tumours were SMA 
positive and Ck19 negative, corroborating a mesenchymal differentiation (Figure 24b). 
With the help provided by our on-site consultant histopathologist, Professor Gordon 
Stamp, the origin of these tumours was identified as being external to the pancreas and 
possibly derived from the mesenteric tissue surrounding the organ. 
In fact, by analysing R26-LSL-YFP; Ck19-CreER mice, where the expression of the 
yellow fluorescent protein is under the control of the Rosa26 promoter and preceded by 
a loxP flanked STOP cassette (Figure 24c), I have observed that the Ck19-CreER 
mouse line, upon tamoxifen treatment, promotes recombination in the pancreatic 
mesothelium as well, demonstrated by the YFP immunological staining (Figure 24d), 
confirming the previously published detection of Ck19-expressing cells in this tissue 
(Terada, 2011). 
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Figure 24 - p53KCk19-CreER mice also develop mesenteric tumours 
a) Schematic representation of the p53KCk19-CreER mouse (p53F/F; KRasLSL-G12D/wt, 
Ck19-CreER) and experimental approach. Black triangles indicate loxP sites and 
asterisk indicates the exon with the G12D mutation. 8-week-old mice were 
intraperitoneally injected with tamoxifen (100 mg/kg of body weight) once a day for 
two days. Pancreatic tissue was collected for analysis 35 days after last tamoxifen dose. 
b) Immunohistological analysis of mesenteric tumours detected in the p53KCk19-
CreER model. Upper image: H&E of a p53KCk19-CreER mouse pancreas, 5 weeks 
after tamoxifen-induced recombination. White dashed lines surround the mesenteric 
tumours and black square marks region of interest. Lower panels: magnifications of 
region of interest. From left to right: H&E, immunohistochemical stain for Smooth 
muscle alpha-actin (SMA) and Ck19. c) Schematic representation of the YCk19-CreER 
(R26-LSL-YFP, Ck19-CreER) to lineage trace recombined cells with the Ck19-Cre 
model. YFP can be recognised by the GFP antibody, hence its description as green 
cells. d) Immunohistochemical stain for the lineage tracer YFP in pancreatic samples 
from an YCk19-Cre mouse, 14 days after tamoxifen-induced recombination. High 
magnification demonstrates recombination in the pancreatic mesothelium. 
All scale bars represent 100 µm except when indicated otherwise in the figure. 
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3.1.9 PDAC oncogenesis promotes low-grade mPanIN formation in wild type 
adjacent tissues 
In this study, I have detected a different route of PDAC progression from those 
described so far. While it is commonly accepted that PDAC progresses from low-grade 
PanIN (Hruban et al., 2000a), PanINs are also observed in the context of other 
pancreatic diseases, such as acinar cell carcinomas, mucinous cystic neoplasms, 
pancreatic endocrine tumours, serous cystadenomas, solid pseudopapillary tumours and 
ampullary tumours. Therefore, it is still debatable if these ductal structures solely 
constitute  PDAC pre-neoplastic lesions (Recavarren et al., 2011, Stelow et al., 2006a). 
While studying tumour progression in the F7KCk19-CreER, I did not identify low-
grade mPanINs (1-2) before tumour onset (Figure 20c). However, when carefully 
analysing the end-stage sample, rare mucinous structures were identified by AB/PAS 
stain (Figure 22d). Moreover, lineage-tracing analysis (Rosa26-LSL-YFP) of the 
F7KEla1-CreER (F7KYEla1-CreER - Figure 25a) revealed the presence of rare, yet 
identifiable, AB/PAS positive low-grade mucinous mPanINs that were negative for 
YFP, suggesting the absence of genetic modification by Cre-mediated recombination, 
(Figure 25b). 
 
Figure 25 - Occurrence of lineage tracing negative mPanINs in the F7KYEla1-CreER 
model 
a) Schematic representation of the F7KYEla1-CreER (Fbw7F/F; KRasLSL-G12D/wt, 
Rosa26-LSL-YFP; Ela1-CreER) model. Black triangles indicate loxP sites and asterisk 
indicates the exon with the G12D mutation. YFP can be recognised by the GFP 
antibody, hence its description as green cells. b) Eight 8-week-old mice were 
intraperitoneally injected with tamoxifen for a 5-day period (one injection per day - 
100mg/kg of body weight/day). One week after tamoxifen treatment, mice were 
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subjected to an acute pancreatitis protocol with 6 caerulein IP injections per day, given 
at hourly intervals, over 2 days (50 µg/kg of body weight/injection). Mice were culled 1 
month after last caerulein injection and the pancreas was removed and used for 
histological analysis.  Upper panel demonstrates low magnification of YFP stain. YFP 
negative mPanIN highlighted by dashed black square. Lower panels present 
magnification of region of interest. From left to right: YFP, AB/PAS and H&E. 
AB/PAS positive, GFP negative lesions were observed in at least 2 of the 8 mice used. 
All scale bars represent 100 µm. 
  
(Figure 25, legend continued) 
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Given the conspicuous presence of mPanIN in non-PDAC scenarios, their increased 
incidence with age, the low risk of progression to PDAC (Hruban et al., 2001) and my 
observation of their unlabelled occurrence upon mPDAC onset, I hypothesized that low-
grade PanIN could represent a reactive response from acinar cells to damage. This 
would imply that wild type tissues could generate low-grade mPanINs as bystander 
entities, in the absence of KRasG12D mutations, in response to PDAC formation in 
adjacent areas. Thus, I attempted to induce bystander mPanINs in unlabelled wilt type 
pancreas in a homograft model with YFP-labelled tumour cells. 
To readily, and abundantly, obtain mPDAC tumour cells, I took advantage of the 
p53F/F; KRasLSL-G12D/wt; R26-LSL-YFP; Pdx1-Cre mouse model, hereinafter 
p53KYPdx1-Cre. In this model, p53 homozygous deletion is induced simultaneously 
with KRasG12D oncogenic activation in embryonic pancreatic progenitors. Additionally, 
the Cre-dependent recombined cells express the lineage tracer YFP, allowing easy 
detection of tumour cells. It has been described that p53KYPdx1-Cre mice develop 
murine PDAC (Bardeesy et al., 2006a), therefore, I obtained primary mPDAC tumour 
cells by enzymatic dissociation of p53KYPdx1-Cre derived tumours and expanded them 
in vitro. 
It has been recently shown that murine PDAC tumour cells can be grown in vitro as 
organoids, retaining their molecular signature and recapitulating PDAC development 
upon homograft transplantation (Boj et al., 2014). Therefore, after enzymatic 
dissociation, I plated the isolated cells in matrigel with organoid media (see 2.2.2.6, 
page 102). After two passages in culture it was possible to observe that all organoids 
were YFP lineage-traced. Nonetheless, to avoid the presence of rare genetically 
unrecombined cells in the culture (YFP-negative cells) that could compromise the 
interpretation of the results, I FAC sorted the isolated tumour cells for YFP (similar 
excitation and emission wavelength as GFP) (Figure 26a). This YFP pure PDAC 
tumour cell culture was then dissociated into single cells and used for orthotopic 
transplantations into the pancreas 10-week-old immunodeficient Nu/Nu mice. Nu/Nu 
mice were subjected to surgery for opening of the peritoneum and YFP-labelled tumour 
cells, mixed in matrigel, were injected into the tail of the pancreas (see 2.2.1.7, page 97). 
The pancreas of these mice was removed 14 and 21 days after surgery  (Figure 26a). 14 
days post surgery, histological analysis (H&E) and immunohistochemical analysis 
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allowed the detection of a focal Ck19 positive, YFP-labelled mPDAC (Figure 26b). 
According to published reports (Boj et al., 2014), the orthotopic transplantation of 
isolated PDAC cells from p53KYPdx1-Cre tumour-derived organoids recapitulated 
PDAC development, whereby AB/PAS-positive mPanINs are formed as well as 
AB/PAS-negative PDAC. As expected, and demonstrating the ability of the tumour 
cells to recapitulate early stages of tumour development, I observed YFP-labelled low 
and high-grade mPanINs positive for AB/PAS, as well as AB/PAS-negative advanced 
YFP-mPDAC (Figure 26b1). Surprisingly, as early as 14 days after orthotopic 
transplantation, I could observe, within the host tissue, regions of ADM with the initial 
development of small ductal mucinous structures. These duct-like lesions were Ck19-
positive with expanded cytoplasm. Their mucinous nature was identified by AB/PAS 
positivity and, importantly, they were YFP-negative, specifying their wild type 
background (Figure 26b2). Longer time points confirmed the hypothesis. 21 days 
following orthotopic transplantation, I could detect, near the YFP-positive tumour, 
YFP-negative flat ductal structures containing columnar epithelium typical of mPanIN1. 
These structures were immunohistochemically positive for early mPanIN markers, such 
as AB/PAS and Muc5AC, while labelled tumour cells were negative for both markers 
(Figure 26c). The fate of these mucinous ductal structures was not followed. 
Nevertheless, the results suggest that low-grade PanINs can be formed as a response to 
tumour formation in a wild type scenario and not necessarily only as a pre-neoplasm.  
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Figure 26 - PDAC oncogenesis promotes low-grade mPanIN formation in adjacent wild 
type tissues 
a) Schematic representation of the experimental approach to induce bystander mPanIN 
formation. p53KYPdx1-Cre mice were euthanized at 5 weeks. Tumour cells were 
isolated and expanded in vitro as organoids. YFP fluorescence activated cell sorting was 
performed to exclude any YFP-negative cells. 500x103 cells were mixed with 50 µl of 
growth factor reduced matrigel and orthotopically transplanted into the pancreas of 
Nu/Nu mice. b) Histological analysis of orthotopic tumours 14 days post 
transplantation. Four mice were injected with PDAC tumour cells. First row with low 
magnification H&E and YFP and CK19. Black dashed line representing the extent of 
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damage caused by PDAC formation. Black squares highlight regions of interest. 1 and 2 
- YFP-tumour regions and mucinous YFP-negative region, respectively. 1 – AB/PAS, 
YFP and Ck19 staining of tumour-derived mPDAC (left) and mPanIN lesion (right) 
separated by white dashed line. 2 - AB/PAS, YFP and Ck19 staining of bystander lesion 
with mucinous structure. Black arrowheads show mucinous cells. c) Histological 
analysis of orthotopic tumours 21 days post transplantation. Four mice were injected 
with PDAC tumour cells. H&E, YFP, AB/PAS and Muc5AC staining were performed. 
Pictures on the right are magnifications of region of interest on the left. Black dashed 
line delineates YFP-PDAC. All scale bars represent 100 µm, except if stated otherwise 
in the figure. 
  
(Figure 26, legend continued) 
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3.2 Discussion: The impact of the compartment of origin on PDAC 
development and the role of Fbw7 in pancreatic tumourigenesis 
 
3.2.1 Fbw7 as a tumour suppressor in PDAC  
As for most diseases, PDAC has a strong genetic component, which can be exploited 
for improvement of current therapies. The understanding of the molecular key players 
during PDAC oncogenesis is, therefore, of great importance and extensively 
investigated (Schneider et al., 2008, Hezel, 2006). 
FBW7 mutations have been identified in human pancreatic tumours (Calhoun et al., 
2003). However, no in depth studies had been performed before the start of this thesis. 
Rocio Sancho had identified Fbw7 as a strong tumour suppressor in mPDAC 
development, where the homozygous deletion of Fbw7 in the embryonic pancreas, with 
concomitant KRasG12D activation (the main PDAC driver mutation), led to strong 
acceleration of mPDAC initiation and progression compared to KPdx1-Cre mice. I 
could confirm that F7KPdx1-Cre mice developed murine PDAC with close 
recapitulation of the human disease on a molecular and morphological level. 
Results obtained during the assessment of the role of Fbw7 in PDAC biology deviated 
the scientific interrogation. The mechanism by which Fbw7 accelerates mPDAC 
tumourigenesis and how Fbw7 is regulated in this context are still open questions (In 
depth discussion in Chapter 5, page 202).  
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3.2.2 A new mPanIN-independent mPDAC progression model for duct-derived 
tumours 
Great effort has been employed towards a better understanding of PDAC biology and 
progression. The knowledge gained on the lesions that precede PDAC offers 
incomparable opportunities to detect and tackle PDAC at its earliest stages of 
development. Data obtained from the clinic, together with molecular studies and 
dynamic mouse model approaches, have allowed the identification of pre-neoplastic 
lesions that, in a step-wise manner, evolve to PDAC (Hruban et al., 2007).  
The most common lesions found in PDAC patients are PanIN lesions and, based on 
mouse model findings, are now thought to originate from acinar cells through an 
intermediate process known as acinar to ductal metaplasia (Guerra et al., 2007, Zhu et 
al., 2007, Grippo et al., 2003, Tuveson et al., 2006).  
Interestingly, results obtained in this thesis have highlighted the possibility of a 
different mode of progression. I have observed that F7KPdx1-Cre mice develop murine 
PDAC with morphological alterations to the ductal compartment preceding both ADM 
and mPanIN lesions. Moreover, Fbw7 loss had a higher proliferative impact in the 
ductal compartment. Analysis of F7Pdx1-Cre mice revealed an increase in 
phosphorylated histone 3 (pH3) in the ductal compartment compared with acinar cells. 
It is possible that acinar and ductal cells have different recombination efficiencies in the 
Pdx1-Cre model, which could compromise the interpretation of the results. While 
confirmation of equal recombination should be performed, there is no evidence in the 
literature that suggests a difference.  
Additionally, the concomitant expression of oncogenic KRasG12D did not change the 
outcome, as analysis of pH3 in pancreas of P0 F7KPdx1-Cre mice revealed an increase 
in proliferation in ductal cells, while no change was detected in acinar cells at early 
stages. This suggests that the acceleration of PDAC in the developing pancreas might be 
partially due to the contribution of the ductal compartment to tumourigenesis. 
In fact, I confirmed that Fbw7 homozygous deletion with simultaneous oncogenic 
KRasG12D activation in adult ductal cells was sufficient to develop murine PDAC, re-
adding ductal cells to the group of potential PDAC cells of origin. 
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PDAC has been proposed to arise from IPMN, MCN, ITPN or PanIN lesions (Hamilton 
and Aaltonen, 2000). Interestingly, based on histology and mucinous staining, I did not 
find any of the previously described mucinous pre-neoplastic lesions during duct-
derived mPDAC development. Fbw7-deleted, KRasG12D-expressing, duct-derived 
tumours developed through an increased acquisition of cellular dysplasia and nuclear 
atypia. I observed initial crowding of the ducts, possibly due to an increase in 
proliferation (not assessed in the Ck19-CreER model), with focal cytoplasmic and 
nuclear expansion towards the lumen. The increase in dysplasia over time led to a 
papillary architecture of the epithelium, which culminated in structures resembling 
murine carcinoma in situ (mPanIN3) and mPDAC.  
It is still not clear if determination of the type of pre-neoplastic lesion is dependent on 
the cell of origin or the genetic alteration induced (von Figura et al., 2014, Hingorani et 
al., 2003, Guerra et al., 2007, Bardeesy et al., 2006b). I observed that the same 
tumourigenic genetic alteration in different pancreatic compartments of origin promoted 
different phenotypes. While acinar cells, in the F7KEla1-CreER mouse model, 
developed mucinous positive low-grade mPanIN lesions, as expected for acinar-derived 
transformation, ductal cells from F7KCk19-CreER mice (same oncogenic background) 
failed to do so, evolving to PDAC in the absence of described mucinous pre-neoplastic 
lesions. Confirming my results was the observation that different genetic alterations, 
such as p53 homozygous deletion with KRasG12D oncogenic activation, led to a similar 
phenotype when induced in the ductal network (Figure 27). Therefore, results strongly 
suggest that the mode of PDAC progression is highly dependent on the cellular 
compartment of origin and not so much the oncogenic hit driving tumourigenesis (In 
depth discussion in Chapter 5, page 205) 
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Figure 27 - Uncoupling cell of origin from genetic activation on PDAC development and 
progression 
Schematic representation of the results obtained with F7KCk19-CreER, p53KCk19-
CreER and F7KEla1-CreER mice.  
I have observed that, the homozygous deletion of either Fbw7 or p53 in KRasG12D-
expressing duct cells forms mPDAC without the intermediate formation of low-grade 
mPanIN lesions, while the deletion of Fbw7 in KRasG12D-expressing acinar cells leads 
to the development of mPanIN1 lesions. 
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While extremely encouraging, these results still leave some questions unanswered due 
to technical issues. While Fbw7 deletion in KRasG12D-expressing ductal cells led to 
mPDAC, the same was not observed for acinar cells following the same time after 
induction. Hence, it is still not clear if F7KEla1-CreER mice can develop mPDAC, 
which raises the question, if Fbw7 loss was capable of inducing KRasG12D-driven 
mPDAC in acinar cells, would they progress via mPanIN? In order to address this 
question, F7KEla1-CreER mice should be analysed at longer time points after 
tamoxifen treatment. Simultaneously, it has been shown that chronic pancreatitis is 
more efficient in inducing acinar cell-derived mPDAC than the acute treatments (Guerra 
et al., 2007). Thus, the caerulein protocol should be changed and the acute treatment, 
after tamoxifen, should be substituted for a prolonged exposure to caerulein. 
 
Mouse models are powerful tools to study biology in the context of a whole organism. 
However, biological systems are not straightforward and some caveats arose during this 
study. It is known that CK19 is expressed in several epithelial tissues, besides 
pancreatic ductal cells, such as the oral cavity, lung, liver, kidney, stomach and intestine 
(Ray et al., 2011). Its expression has also been reported in the mesothelium (Terada, 
2011). Therefore, regarding the p53KCk19-CreER model, I cannot exclude the effect of 
the mesenteric tumour in promoting a hostile environment that suppresses mPanIN 
formation.   
Moreover, during the course of my studies, I, and other member of our research group, 
have realized that Ck19-CreER also promotes some limited recombination in acinar 
cells, as reported previously (Means et al., 2008). The reason for this acinar cell 
recombination is not immediately clear. Immunohistochemical analysis of the Ck19 
protein shows no Ck19 protein in the acinar compartment. Given their plasticity and 
ability to quickly convert into ductal cells (Strobel et al., 2007, Means et al., 2005), it is 
possible that some acinar cells regulate the Ck19 gene and, thus, harbour a constant low 
activation of the locus or a high protein degradation.  
As we know from the literature, adult acinar cells do not undergo any tumourigenic 
transformation up to one year after tumour induction, even in the context of p53 
homozygous deletion with KRasG12V oncogenic activation, without chronic caerulein 
treatment (Guerra et al., 2011). Moreover, my time course analysed allowed me to 
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observe time-dependent transformation in the ducts without acinar cell transformation 
before mPDAC onset. Therefore, it is improbable that the acinar cell targeting of the 
Ck19-CreER affects my observations. Nonetheless, the ductal targeting should be 
repeated, both for the Fbw7 and for p53 loss with a different CreER mouse line that is 
more specific to ductal cells. We have recently obtained the Hnf1β-CreER mouse, 
kindly provided by Dr Jorge Ferrer (Solar et al., 2009). Hnf1β is a transcription factor 
expressed in ductal cells during embryonic development and adulthood. While this 
protein is also present in other tissues, such as liver, intestine and kidney (Serfas and 
Tyner, 1993, Coffinier et al., 2002), it has been reported, by means of lineage tracing 
(Rosa26-LacZ) (Solar et al., 2009), and preliminary results from our group confirm, that 
in the pancreas, tamoxifen treatment of Hnf1β-CreER mice does not induce Cre-
dependent recombination in acinar cells. Moreover, no mesenteric recombination was 
detected. Thus, the substitution of the Ck19-CreER for the Hnf1β-CreER model can 
provide solid data supporting the cell of origin effect in determining PDAC pre-
neoplastic lesions. 
 
3.2.3 Origin of low-grade mPanIN lesions 
Low grade PanINs are described as the earliest, and most common, PDAC pre-
neoplastic lesions (Hruban et al., 2007). In my efforts to understand PDAC progression 
from different cell types, I observed that the ductal-derived mPDAC from the 
F7KCk19-CreER model does not develop mPanIN1 before tumour onset. However, to 
my surprise, end-stage murine tumours revealed the presence of rare low-grade, 
AB/PAS-positive mPanINs embedded in the stroma, in close proximity to mPDAC. 
This finding was considered at the time to be a possible side effect of the acinar cell 
targeting with the Ck19-CreER line. This hypothesis was then challenged when I 
observed the presence of rare, non-lineage traced, low-grade mPanINs in the 
F7KYEla1-CreER. 
These low-grade mucinous PanINs, present in the context of duct-derived tumour or as 
a non-labelled lesion in acinar cell specific tumour models following caerulein 
treatment, both appeared in pancreatic scenarios of extensive injury. Therefore, I 
hypothesized that low-grade PanINs, such as PanIN1, could be generated in hostile 
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environments, in a KRas wild type background. I observed that orthotopic 
transplantation of cultured YFP lineage-traced tumour cells from p53KYPdx1-Cre mice 
into immunodeficient Nu/Nu mice led to the development of YFP-negative PanIN1 
lesions in close proximity with the tumour. These low grade PanINs presented a 
columnar epithelium and were positive for markers of early grade PanIN, such as 
AB/PAS and Muc5AC. While the true wild type nature of these lesions has to be 
assessed by possible laser capture microdissection of the bystander mPanINs followed 
by genotyping PCR, these results suggest that KRas wild type cells are able to give rise 
to PanIN1, which might have a great impact in both PDAC diagnosis and prognostic 
value of these structures following surgical pancreatectomy in PDAC patients (In depth 
discussion in Chapter 5, page 205). 
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Chapter 4. Results 
4.1 CD9 marks a tumour-initiating population in multiple mouse 
models of PDAC 
4.1.1 Introduction to the aim 
It has been proposed, and demonstrated, for numerous neoplasias, such as for brain 
(Singh et al., 2004), breast (Al-Hajj et al., 2003), colon (Ricci-Vitiani et al., 2006) and 
small intestinal cancers (Barker et al., 2008), that the capacity to initiate tumour 
formation (tumourigenicity) relies on a subset of specialized cells, commonly referred 
to as cancer stem cells (CSCs) or tumour-initiating cells (TICs). These cells are 
particularly important for tumour biology given their unique ability to self-renew and 
give rise to differentiated progeny, initiating and maintaining tumour growth (Nguyen et 
al., 2012). Hence, great efforts have been employed towards the better understanding of 
tumour hierarchy.  
The existence of PDAC TICs has been a controversial subject. Studies conducted so far 
have failed to provide an accurate identification of the PDAC cells with a higher 
tumourigenic capacity, mainly due to lack of distinction between tumour cells versus 
stroma (Li et al., 2007, Hermann et al., 2007, Oshima et al., 2007, Immervoll et al., 
2011) (for in depth explanation see Chapter 5, page 216). 
As mentioned above, Fbw7 deletion (Fbw7F/F, where loxP sites flank exon 5), with 
concomitant KRasG12D activation (KRasLSL-G12D/wt), in adult ductal cells (F7KCk19-
CreER), led to the development of murine PDAC following tamoxifen treatment 
(Chapter 3, Figure 20). This provided me with a model to study the tumour-initiating 
capacity of adult epithelial cells. 
With the present study I aimed to identify and characterize a PDAC tumour-initiating 
population by studying early stages of adult duct-derived murine PDAC. 
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4.1.2 Duct cells have different susceptibilities to tumour formation 
Most investigations on PDAC TICs use human xenografts as source of tumour material 
(Hermann et al., 2007, Li et al., 2007). However, the use of fully developed tumours as 
a starting point hampers the distinction between pre-existent susceptible cells or de novo 
acquisition of self-renewal potential of TICs from progenitors or more differentiated 
cells. Therefore, I focused on the use of mouse models where tumour initiation could be 
thoroughly analysed. As mentioned above, in our research group I had access to a 
mPDAC inducible tumour model where Fbw7 loss with simultaneous KRasG12D 
oncogenic activation in adult duct cells led to murine PDAC development. To follow 
tumour cells throughout tumour development, I crossed in the lineage tracer R26-LSL-
YFP (explained in 3.1.9). The resulting mice from the mentioned cross will be referred 
hereinafter as F7KYCk19-CreER (Fbw7F/F; KRasLSL-G12D/wt; R26-LSL-YFP; CK19-
CreER) (Figure 28a). 
Given the structural and protein sequence similarity, as well as absorption and emission 
spectra resemblance, between the green fluorescence protein (GFP) and, its mutant 
derivative, yellow fluorescence protein (YFP), YFP can be detected using the GFP 
antibody and the same fluorescent lasers and detection filters used for GFP in flow 
cytometry analysis. Thus, in this chapter cells expressing the YFP will be referred to as 
GFP-expressing cells. 
As demonstrated in Figure 28a, 8-week-old adult mice were intraperitoneally injected 
with tamoxifen at a dose of one injection per day, for two days (100mg/kg of body 
weight). Following 4 weeks after tamoxifen treatment, mice were euthanized due to 
weight loss (data not shown) and presence of a prominent swollen abdomen. Post 
mortem analyses revealed the presence of GFP-positive mPDAC (Figure 28b).  
In order to understand if all ductal cells have the same potential for tumour initiation, I 
decided to analyse early time points after tamoxifen-induced recombination, in search 
of recombined cells (GFP-expressing cells) with different responses to the oncogenic 
hits. As a result of my previous characterization of duct-derived murine PDAC of 
F7KCk19-CreER mice (Figure 20c from Chapter 3), I focused on 2 weeks after 
tamoxifen treatment as the time point of choice, as it was the earliest stage transformed 
cells could be identified by histological analysis. By performing GFP 
immunohistological studies on pancreas of F7KYCk19-CreER mice, two weeks after 
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tamoxifen treatment, I observed that some GFP-expressing recombined cells had 
acquired a different morphology (Figure 28c1) while others remained unaltered (Figure 
28c2). Based on my previous characterization of the F7KCk19-CreER derived PDAC 
(Figure 20 from Chapter 3), the morphological difference found in these cells resembled 
the initial stages of tumour formation from duct cells. Therefore, I considered these 
cells to be transformed.  
Interestingly, this observation was not only restricted to early time points, but also 4 
weeks after recombination. Pancreas of adult F7KYCk19-CreER mice, 4 weeks after 
tamoxifen treatment, exhibited 2 fundamentally different responses: focal PDAC lesions 
composed of GFP-expressing transformed cells (Figure 28c3), and ducts harbouring 
GFP-positive cells with no evident tumourigenic response (Figure 28c4), suggesting a 
ductal heterogeneity regarding tumour susceptibility. 
To ensure that all cells that recombined the Rosa26 locus (GFP-expressing) had also 
recombined, and excised, the Fbw7 floxed exon 5 and the STOP (LSL) cassette before 
the KRasG12D mutant sequence, I sorted live (DAPI-negative) GFP-positive 
(recombined) and negative (non recombined) cells from F7KYCk19-CreER mice, 2 
weeks after tamoxifen treatment (Figure 28d), extracted DNA from these two 
populations and performed a genotyping PCR (Figure 28e). A 3-primer set was used to 
test recombination of the Fbw7 locus that recognizes the floxed (388 bp) and the 
recombined (744 bp) sequences in the same reaction. I observed that the GFP-
expressing population had completely lost the floxed-specific band (388 bp) indicative 
of complete recombination. Similarly, a 3-primer set was used to assess the 
recombination in the KRas locus. The selected primers amplify the LSL cassette (500 
bp), the wild type band (622 bp) and the recombined sequence (650 bp). Results 
demonstrated a complete recombination of the LSL cassette in the GFP-positive 
population based on the complete loss of the LSL-specific band (500 bp) and 
appearance of the recombined mutant G12D band (650 bp). As expected, the 
genotyping PCR on the GFP-negative cells demonstrated the presence of the floxed 
band for the Fbw7 locus (388 bp) and LSL cassette (500 bp). A faint band for the Fbw7 
recombination (744 bp) was detected in the GFP-negative population, which 
demonstrates that the Fbw7 locus recombines more efficiently than the Rosa26 locus. 
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Nonetheless, this does not interfere with the observation of differential susceptibility of 
ductal cells. 
 
Figure 28 - Duct cells have different susceptibilities to tumour formation 
a) Schematic representation of the F7KYCk19-CreER mouse (Fbw7F/F; KRasLSL-G12D/wt; 
R26-LSL-YFP; Ck19-CreER) and experimental approach. Black triangles indicate loxP 
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sites and asterisk indicates the exon with the G12D mutation. 8-week-old mice were 
intraperitoneally injected with tamoxifen (100 mg/kg of body weight) once a day for 
two days. Pancreatic tissue was collected for analysis at day 14 (2 weeks) and 28 (4 
weeks) after last tamoxifen dose. b) Histological analysis of F7KYCk19-CreER-derived 
mPDAC generated 4 weeks after last tamoxifen (tam.) dose. H&E (above) and GFP 
immunostain (below; to detect the YFP tracer in consecutive sections). c) GFP 
immunological stain of pancreatic sections of F7KYCk19-CreER mice 2 and 4 weeks 
after tamoxifen treatment. Transformed ducts (c1 and c3) and non-responsive ducts (c2 
and c4) and 2 and 4 weeks after last tamoxifen dose, respectively, are magnified on the 
right. Black arrows point to examples of transformed cells. The difference in 
transformation was observed in all the mice analysed (n=6 mice for each time point) d) 
Flow cytometry plot of the sorting performed on the isolated pancreatic cells of 
F7KYCk19-CreER mice, 2 weeks after tamoxifen injection. DAPI was used to assess 
viability (DAPI-negative, live cells). Sorted populations are indicated in black (GFP-
negative) and green (GFP-positive). e) DNA agarose gel for the assessment of Cre 
dependent recombination on GFP positive and negative populations by PCR. Expected 
bands and respective fragment sizes (in base pairs) are indicated. 
Scale bars in b and c (low magnification) represent 100 µm while high magnifications 
in c represent 50 µm. 
  
(Figure 28, legend continued) 
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4.1.3 CD44 expression marks early stages of tumour development allowing 
distinction between transformed and non-transformed cells 
It is believed that not all tumour cells are capable of tumour initiation. Instead, a subset 
of cells with stem cell-like properties is able to initiate and maintain tumour 
development (TICs). Different surface proteins have been described as identifiers of 
PDAC TICs, such as cluster of differentiation 133 (CD133), also known as prominin-1, 
and CD44 (Hermann et al., 2007, Li et al., 2007). However, the significance of their 
expression is still not clear (Immervoll et al., 2011). 
In order to assess if these proteins could also identify TICs in our model, I performed 
immunological stains on F7KYCk19-CreER mouse pancreas, at early stages of tumour 
initiation (2 weeks after tamoxifen treatment). Confirming previous published data 
(Oshima et al., 2007, Immervoll et al., 2011), CD133 was present in the apical surface 
of every ductal cell, excluding it as a good marker for a subpopulation of tumour 
initiating cells (Figure 29a). On the other hand, there was a correlation between cell 
surface expression of CD44 and oncogenic transformation. As described above (see 
3.1.5, page 129), ductal cell transformation is initially detected by change in cellular 
morphology (cell enlargement) with no obvious change in the nucleus:cytoplasm ratio. 
Following CD44 immunological stain, I observed that morphologically different cells 
(transformed) expressed CD44, while flat cuboidal cells in the same duct did not 
(Figure 29a), suggesting that CD44 is marking cells with tumour initiation capacity, 
supporting previous findings (Li et al., 2007). 
I decided to further assess CD44 expression in pancreatic cancer. In order to validate 
CD44 as a TIC marker, I performed CD44 antibody stains in pancreatic sections of 
control mice (Ck19-CreER) and of different stages of PDAC development from 
F7KYCk19-CreER mice (Figure 29b). I observed that duct cells from Ck19-CreER 
mice did not express CD44, even after tamoxifen treatment. As mentioned above, in 
contrast, 2 weeks after tamoxifen treatment in F7KYCk19-CreER mice, duct cells 
changed their morphology, expanded towards the lumen of the duct and initiated CD44 
expression, while morphologically unaltered cells remained negative for CD44. 4 weeks 
after tamoxifen treatment the entire tumour was composed of CD44-expressing cells 
(Figure 29b). Given the global expression of CD44 in the developed tumour, instead of 
its presence in a selected sub-population, the value of CD44 expression shifted from 
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TIC marker to general tumour cell marker, as it had also been demonstrated before for 
human and murine PDAC (Hill et al., 2010). These results highlighted a possibility for 
distinction of transformed and non-transformed cells at a molecular level by the use of 
CD44 levels.  
The results in Figure 28e suggested that recombination in GFP-expression cells was 
complete. However, it was possible that some incomplete recombination in non-
transformed, GFP-positive, cells could be masked by a larger population of transformed 
GFP-positive cells. To control for this possibility, I repeated the genotyping PCR with a 
more stringent approach. As CD44 expression could discriminate a transformed from a 
non-transformed population, I obtained, by fluorescent activated cell sorting (FACS), 
GFP-recombined cells, positive for CD44 (targeted and transformed) and GFP-
recombined, CD44-negative cells (targeted and non-transformed) and repeated the 
genotyping PCR. 
F7KYCk19-CreER mice were intraperitoneally injected with tamoxifen and the 
pancreas was collected at early stages of tumour development (2 weeks after tamoxifen). 
The pancreatic tissue was digested and stained for CD44. To control for CD44-specific 
staining, I included a control where only the secondary antibody for CD44 stain was 
used. As observed in Figure 29c, secondary antibody alone gave no significant signal. 
Consistent with the existence of a more susceptible population within the ducts, I 
observed that, soon after recombination, only 0.13% of live pancreatic cells (9.5% of 
live GFP recombined cells) underwent oncogenic transformation and exhibited CD44 
protein on the cell surface. DNA was extracted from GFP+CD44+ (recombined and 
transformed) and GFP+CD44- (recombined and non-transformed) cells, and a 
genotyping PCR was performed for the Fbw7 and KRas loci (Figure 29d). Both 
GFP+CD44+ and GFP+CD44- cell DNA lacked the flox specific sequence (388 bp) for 
the Fbw7 locus and exhibited the recombined specific sequence (744 bp). Similarly, 
both populations lost the LSL cassette on the KRas locus, indicated by the absence of 
the LSL specific band (500 bp), and exhibited the G12D recombined sequence (650 bp). 
These results confirmed that absence of transformation of some recombined duct cells 
was not due to inefficient recombination of one of the genetic alterations induced, and 
that CD44 expression could be used at, early stages of tumour development, to 
distinguish cells with different susceptibilities to tumour formation. 
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Figure 29 - CD44 expression marks early stages of tumour development allowing 
distinction between transformed and non-transformed cells 
a) Immunological stain of CD44 and CD133 in semi consecutive section of pancreatic 
samples of 3 F7KCk19-CreER mice (n=3), 2 weeks after tamoxifen treatment. Non-
transformed regions are digitally magnified. Black arrows show apical expression of 
CD133 in non-transformed cells. b) CD44 immunological stain in pancreas of 2 CK19-
CreER control mice two weeks after tamoxifen treatment and 3 F7KCk19-CreER mice 
two and four weeks after tamoxifen treatment. Magnifications of regions of interest are 
marked. NT- non-transformed; T- transformed. c) Flow cytometry analysis of pancreas 
of F7KYCK19-CreER mice 2 weeks after tamoxifen injection. DAPI was used to assess 
viability; cells were gated for DAPI negativity. Plot shows entire live pancreatic 
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population assessed for CD44 (647 nm excitation - Y axis) and GFP (488 nm excitation 
- X axis) fluorescent signal. Secondary fluorescent antibody alone was used to gate the 
CD44 positve and negative populations. Sorted populations are indicated in green 
(GFP+CD44-) and red (GFP+CD44+) d) DNA agarose gel for the assessment of Cre 
dependent recombination in GFP+CD44+ (red) and GFP+CD44- (green) populations by 
PCR. Expected bands and respective fragment sizes (in base pairs) are indicated. The 
genotyping assessment was performed for 2 F7KYCK19-CreER mice. 
All scale bars represent 50 µm. 
  
(Figure 29, legend continued) 
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4.1.4 Gene expression analysis and validation to identify novel PDAC TIC 
markers 
The observation that not all duct cells harbouring the same oncogenic hits get 
transformed, together with the detection of CD44 expression in early transformed cells, 
provided a valuable strategy to distinguish between adult duct cells susceptible to 
transformation (TICs) and cells not capable of tumour initiation with the same genetic 
background, excluding any additional mutation that could lead to higher 
tumourigenicity. Therefore, to identify PDAC TIC markers, I performed a microarray to 
assess genome-wide differential gene expression between GFP+CD44+ (transformed - 
T) and GFP+CD44- (non transformed - NT) cells at early stages of tumour development 
(Figure 30a). 
Ten F7KYCk19-CreER mice were treated with tamoxifen for 2 days (one IP injection 
per day of 100 mg/kg of body weight), pancreata were collected 2 weeks after last 
tamoxifen injection and pooled for further processing. Following enzymatic cellular 
dissociation and CD44 antibody stain, live cells (DAPI negative) were sorted according 
to their GFP and CD44 expression (GFP+CD44+ vs GFP+CD44-). Due to the harsh 
enzymatic treatment, and possibly the additional deleterious effect of acinar-derived 
enzymes, the viability after cellular dissociation was extremely compromised. Less than 
25x103 cells were obtained for each population providing less than 0.5µg of RNA. 
Given the low amount of RNA, an amplification step took place and GeneChip ® 
Mouse Gene 1.0 ST Array from affymetrix was performed. Results were analysed by 
Richard Mitter from the Bioinformatics and BioStatistics core facility at The Francis 
Crick Institute – Lincoln’s Inn Fields Laboratories, who normalized the raw values and 
calculated the fold change in gene expression between both populations (relative to 
GFP+CD44-). Significance was not calculated due to the lack of replicates. 
Differences in gene expression were extremely subtle, as expected for initial steps of 
tumour formation (Figure 30c). I observed that amongst the 30 most upregulated genes 
were several well established, and previously described, PDAC markers. Cathepsin E 
(CTSE) (Cruz-Monserrate et al., 2012); Matrix metalloproteinase-7 (Mmp7) (Park et al., 
2012), Anterior Gradient 2 (Agr2) (Riener et al., 2009),  Trefoil Factor 2 (TFF2) 
(Buchholz et al., 2005) and Mucin 1 (Muc1) (Rachagani et al., 2012) were 3.36, 3.44, 
3.32, 3.20 and 2.25 fold, respectively, upregulated in the transformed population 
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(GFP+CD44+) (Figure 30b). Moreover, CD44 was 3.8-fold upregulated in GFP+CD44+ 
cells reinforcing the validity of the array (Figure 30c).  
Specific criteria were followed for the selection of genes of interest: (1) overexpressed 
in the GFP+CD44+ cell fraction (downregulated genes were discarded from the 
analysis); (2) coding for proteins with an extracellular domain (to allow further and easy 
identification/isolation and possible therapeutic approaches); and (3) overexpressed at 
least 1.5 fold above the GFP+CD44- fraction (given the already low expression of global 
PDAC markers the cut off was established low to allow inclusion of very rare 
populations). A second selection step was employed to narrow down the number of 
genes of interest. For this next step, a bibliographic search on the relevance of the gene 
in cancer and tumour initiation biology was carried out. In parallel, the protein 
expression profile was virtually analysed using The Human Protein Atlas (Uhlen et al., 
2015). Only proteins detected by antibody stain in scattered ductal cells in the normal 
pancreatic tissue and present either in all or in a subpopulation of PDAC cells were 
selected. A handful of genes was classified as potential TIC markers and, in this thesis, I 
describe my characterisation of the most promising candidate. 
I focused on CD9, also known as Motility related protein 1 (MRP1), as a potential gene 
of interest as it met all criteria required. It was 1.5 fold upregulated in the GFP+CD44+ 
population (Figure 30c); it is a tetraspanin protein and consequently it consists of four 
transmembrane helices, one small intracellular loop and a large extracellular loop 
(extracellular domain); it has been shown to be involved in several types of cancer, such 
as gastric, lung and breast tumours (Hemler, 2014); it has been suggested as a stem cell 
marker in certain human malignancies, mainly haematopoietic (Nishida et al., 2009) and, 
according to The Human Protein Atlas, it is expressed in a subset of duct cells in normal 
human pancreatic tissue and, depending on the sample, in all or a subpopulation of 
human pancreatic cancer cells. 
Microarray validation was performed by quantitative RT-PCR (Q-PCR) (Figure 30d). 
F7KYCk19-CreER mice were treated as described in Figure 28a and GFP+CD44+ (T) 
and GFP+CD44- (NT) cells were sorted 2 weeks after the last tamoxifen intraperitoneal 
injection. As expected, expression of Fbw7 exon 5 (loxP flanked exon) was 
undetectable in both transformed (T) and non-transformed populations (NT) when 
compared to the remaining pancreatic tissue (WT) indicative of efficient deletion of the 
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gene. Ck19 expression levels were not changed. CD44 and epithelial cell adhesion 
molecule (EpCAM), both upregulated in the microarray by 3.8 and 2.25-fold, 
respectively, exhibited an approximately 4-fold upregulation by Q-PCR. Finally, CD9 
expression demonstrated a statistically significant increase in the transformed cellular 
fraction, being 2.5-fold upregulated. 
Therefore, CD9 was followed for further characterization as a PDAC TIC marker.  
 
Figure 30 - Gene expression analysis and validation to identify novel PDAC TIC markers 
a) Schematic representation of the experimental rationale and approach. Ten 
F7KYCk19-CreER mice were injected with tamoxifen for 2 days (one intraperitoneal 
injection per day 100 mg/kg of body weight). Recombined cells initiate GFP 
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expression. 2 week after tamoxifen injection some recombined cells (GFP+) undergo 
oncogenic transformation and upregulate CD44 expression (GFP+CD44+ - transformed 
T) while other recombined cells do not respond to the oncogenic hit (GFP+CD44- - 
Non-transformed NT). T and NT were sorted and RNA used for gene expression array. 
b) List of known human PDAC markers that were also upregulated in the present 
microarray amongst the 30 top upregulated hits. Respective fold changes in gene 
expression of T compared to NT are represented. c) Gene expression profiles of T and 
NT cells. Normalized expression values (arbitrary units – a.u.) for each identified gene 
were plotted; each dot represents one gene. CD9, CD44 and EpCam are indicated with 
respective fold change calculated. d) Validation of selected hits by quantitative PCR. 
Fbw7 floxed exon 5, CK19, CD44, EpCam and CD9 expression levels were measured 
in freshly sorted GFP+CD44+ (T) and GFP+CD44- (NT) cells. WT – non-recombined 
pancreatic cells (GFP-). Q-PCRs were performed in biological triplicates (3 independent 
sorts). In each experiment, a pool of 2 mice was used. Gene expression values were 
normalized to a loading control (tubulin) and fold changes were calculated relative to 
NT or WT in the case of Fbw7. Bar chart shows the mean values plus SD. Significance 
was calculated with the Mann-Whitney test. * Shows p= or <0.05. n.s =  not significant 
  
(Figure 30, legend continued) 
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4.1.5 CD9 expression marks a subpopulation of transformed cells in the 
F7KYCk19-CreER mouse model of PDAC 
As indicated by the microarray and Q-PCR validation, the CD9 gene was shown to be 
overexpressed in the transformed population at early stages of tumour development. 
Nonetheless, there was a possibility of global presence of this protein in all tumour cells. 
To investigate CD9 protein expression, I performed flow cytometry analysis on live 
PDAC tumour cells from F7KYCk19-CreER mice (Figure 31a). Mice were injected 
with tamoxifen as described in Figure 28a and the pancreas collected 4 weeks after the 
last tamoxifen injection. As demonstrated in Figure 31a, the analysis was performed on 
live (DAPI-negative) recombined (GFP-positive) cells. For this particular staining, I 
used a CD44 antibody conjugated to the fluorophore allophycocyanin (CD44-APC; 
emission peak at 660 nm) and an unconjugated antibody was used for CD9. Therefore, I 
included a control for the specificity of the secondary antibody used for the CD9 
staining (antibody isotype controls were also performed – see Figure 33, discussed 
below). It was observed that 90% of the GFP+ live cells were expressing CD44, 
consistent with the advanced stage of tumour development. Compatible with the 
definition of a TIC marker, CD9 protein was not observed in all tumour cells. CD9 was 
only detected in approximately 15% of the GFP+ population and was restricted to 
CD44-expressing cells (Figure 31a). Replicates were performed to allow quantification 
of the percentage of GFP+ cells expressing CD44 only, CD9 only and both CD44 and 
CD9 (Figure 31b). It was observed that the CD44+CD9+ population was consistently, 
and significantly, smaller than the CD44+ (tumour cell) population, reinforcing the 
potential value as a TIC marker. 
To confirm the results obtained by flow cytometry, I performed immunofluorescence 
stains for CD9 and E-Cadherin (an epithelial cell marker that distinguishes tumour cells 
from stroma) in tumours of F7KYCk19-CreER mice, 4 weeks after tamoxifen treatment 
(Figure 31c). I observed that, while the majority of the tumour cells were negative for 
CD9 (Figure 31c1), a small subset of E-cadherin-expressing tumour cells exhibited 
membrane CD9 stain and were organized in clusters (Figure 31c2). The dotted pattern 
of expression of CD9 was not surprising, as it has been described that the tetraspanin 
CD9 protein can cluster laterally in the cell membrane forming tetraspanin-enriched 
microdomains (TEMs) (Hemler, 2014).  
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Figure 31 - CD9 expression marks a subpopulation of transformed cells in the F7KYCk19-
CreER mouse model of PDAC 
a) Flow cytometry analysis of pancreas of F7KYCk19-CreER mice 4 weeks after 
tamoxifen injection. DAPI was used to assess viability. Plot on the left shows cells 
gated for DAPI negativity and GFP positivity to only assess live, recombined cells. 
Analysis was only performed in this DAPI-GFP+ population. Plots on the right show 
CD44 (647 nm excitation - Y axis) and CD9 (555 nm excitation - X axis). CD9 
secondary fluorescent antibody alone control (555nm emission) was used to set up 
gates. Sample - all antibodies used. Percentages (of DAPI-GFP+ population) are 
highlighted within the respective gates. b) Percentage of CD44 only, CD9 only and 
CD44, CD9 double positive cells within DAPI-GFP+ cells. Significance calculated using 
unpaired t test. Bar chart shows the mean values plus SD. Flow cytometry analysis was 
performed in triplicates (n=3 mice). c) Immunofluorescence analysis of CD9 and E-
Cadherin on pancreatic tumours of F7KYCk19-CreER mice, 4 weeks after tamoxifen 
injection. DAPI used for DNA stain (nuclear). Regions of interest are highlighted: 1 - 
magnification of CD9-negative cells. 2 - magnification of CD9-expressing cells. Scale 
bars in low magnification image represent 50 µm and 10 µm in high magnification. 
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4.1.6 CD9 expression marks a subpopulation of transformed cells in the 
p53KYPdx1-Cre mouse model of PDAC 
The value of tumour initiation cell markers, and their applicability in human disease, 
relies on their robustness to identify a subset of cells with tumour initiation capacity in a 
wide range of genetic backgrounds. Therefore, to rule out a dependency of the existence 
of the CD9 population on Fbw7 deletion, I also assessed the presence of CD9-positive 
tumour cells in the well-established p53KYPdx1-Cre (p53F/F; KRasLSL-G12D/wt, R26-LSL-
YFP, Pdx1-Cre) mouse model of PDAC (Bardeesy et al., 2006a). In this model, the 
Pdx1 transcription factor’s promoter, active in pancreatic progenitors, drives Cre 
expression inducing p53 deletion and KRasG12D oncogenic activation, during pancreatic 
development. At 5 to 8 weeks of age, mice had to be euthanized  (Figure 32a) due to the 
presence of a swollen abdomen and weight loss (data not shown). 
Autopsies revealed a solid and enlarged cell mass in the abdominal cavity in the 
pancreatic region. Regarding histological presentation, haematoxylin and eosin analysis 
demonstrated the presence of a strong stromal expansion (desmoplasia) and expanded 
neoplastic ductal structures, both commonly found in PDAC (Figure 32b H&E). 
Tumour cells were shown to be GFP-positive by immunological analysis, indicating 
that transformed cells could be traced by R26-LSL-YFP (Figure 32b GFP). As 
described previously (Bardeesy et al., 2006a), some regions exhibited cells with a 
spindle-like morphology embedded in the stroma, thus this tumour was classified as 
poorly-differentiated PDAC (Figure 32b). 
To assess the presence of CD9-expressing cells in the p53KYPdx1-Cre-derived tumours, 
I collected the pancreatic tumours of 5-week-old mice, stained for CD9 and performed 
flow cytometry (Figure 32c). A fluorescent secondary antibody control was included to 
validate the specificity of the CD9 stain in this new sample. Only live (DAPI-negative) 
GFP+ cells were used for the analysis. I observed that, also in this model, there is a 
CD9-positive subpopulation of PDAC tumour cells, composing approximately 5% of 
the GFP+ cells.  
The results obtained confirmed heterogeneity within the tumour population (at least at 
the molecular level of CD9 expression). 
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Figure 32 - CD9 expression marks a subpopulation of transformed cells in the 
p53KYPdx1-Cre mouse model of PDAC 
a) Schematic representation of the p53KYPdx1-Cre mouse (p53F/F; KRasLSL-G12D/wt; 
R26-LSL-YFP; Pdx1-Cre) and experimental approach. Black triangles represent loxP 
sites and asterisk represents KRasG12D mutation. Mice developed pancreatic tumours 5 
weeks after birth. b) H&E and GFP immunological stain of PDAC tumours from 5-
week-old p53KYPdx1-Cre mice. Regions of interest are highlighted and magnified. 
Black arrows show spindle-shaped tumour cells. Scale bars in low magnification 
represent 500 µm and in high magnification represent 100 µm. c) Flow cytometry 
analysis of pancreas of 5-week-old p53KYPdx1-Cre mice. DAPI was used to assess 
viability. Plot on the left shows cells gated for DAPI negativity and GFP positivity, to 
only assess live, recombined cells. Analysis was only performed in this DAPI-GFP+ 
population. Plots on the right show GFP (488 nm excitation - Y axis) and CD9 (555 nm 
excitation - X axis). CD9 secondary fluorescent antibody alone control (555 nm 
excitation) was used to set up gates. Sample - all antibodies used. Percentages (of DAPI-
GFP+ population) are highlighted within the respective gates. 
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It has been described that CD44 expression in tumour-initiating cells goes from low 
(non-TICs) to high (TICs) expression rather than absent to positive, i.e, there is not a 
distinctive observable population expressing CD44 (Li et al., 2007). The same has been 
demonstrated for other tumour initiating markers, such as CD133 and CD24, and not 
only for pancreatic samples (Hermann et al., 2007, Li et al., 2007, Al-Hajj et al., 2003). 
Since the flow cytometry results obtained with both the CD44 conjugated antibody and 
the CD9 unconjugated antibody were shifts of the fluorescence intensity, rather than the 
appearance of a distinct positive population, I decided to validate our antibodies by 
performing additional analysis with the respective isotype controls. Validation of the 
CD9 antibody was performed with cultured cells from the p53KYPdx1-Cre-derived 
tumours (Figure 33a). Cells were expanded as organoids (see Chapter 2, page 102), 
dissociated by trypsin and stained with the fluorescent secondary antibody alone, with 
the CD9 primary antibody plus secondary, or with rat IgG2a isotype primary antibody 
plus secondary. While “unstained”, “secondary antibody alone” and “rat IgG2a isotype 
primary antibody plus secondary” samples showed no positive signal, the combination 
CD9 primary antibody plus secondary promoted a shift in the population to give a 
CD9Low/Intermediate and a CD9High populations (these populations will hereinafter be 
referred to as CD9Low and CD9High). 
A similar specificity was observed for the CD44 conjugated antibody. Fully developed 
tumours from F7KYCk19-CreER mice were dissociated and stained for CD44 (Figure 
33b). Only live recombined cells (DAPI-GFP+) were included for the analysis. As seen 
for the CD9 antibody, the rat APC-isotype IgG2b showed no staining while the APC-
conjugated CD44 antibody marked most of the GFP tumour cells, as expected. 
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Figure 33 - Assessing CD44-APC and unconjugated CD9 antibody specificity 
a) Flow cytometry analysis of CD9 unconjugated antibody specificity using cultured 
cells from p53KYPdx1-Cre-derived PDAC organoids. Only live cells were included in 
the analysis (DAPI negative –marked red in the plot on the left). Flow cytometry plots 
on the right show fluorescence intensity following 555 nm excitation, on the x axis, as a 
readout of CD9 signal for: unstained, secondary antibody alone, rat IgG2a plus 
secondary antibody and rat CD9 plus secondary antibody. b) Flow cytometry analysis 
of CD44 APC-conjugated antibody specificity using primary tumour cells from 4 weeks 
F7KYCk19-CreER-derived PDAC. Only live recombined cells were included in the 
analysis (DAPI-GFP+ – marked red in plot on the left). Flow cytometry plots on the 
right show fluorescence intensity following 647 nm excitation, in the x axis, as a 
readout of CD44 signal for: rat IgG22b-APC and rat CD44-APC. 
Percentages of positive cells from previous gate are indicated. 
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4.1.7 CD9 surface expression identifies a subpopulation with higher in vitro 
organoid-forming capacity in primary and cultured tumour cells of 
different mouse models of PDAC 
TICs, initially referred to as “cancer stem cells”, have been described as a population 
with stem cell-like properties, such as the ability to self-renew and to give rise to 
differentiated progeny (Clarke et al., 2006). These stem cell-like features have been 
extensively studied in vitro. Numerous research groups have demonstrated that TICs of 
different tumour types and tissues, unlike non-tumourigenic cells, can initiate and 
propagate cell cultures, in non-adherent conditions as spheres or as organoids in 3D 
matrices (Pastrana et al., 2011). 
Sphere-forming assays have also been established for pancreatic cancer TICs, where 
tumour cells expressing TIC markers are isolated from the remaining population and 
their ability to propagate the culture in non-adherent conditions is compared to their 
marker-negative counterpart (Gaviraghi et al., 2010, Hermann et al., 2007, Lonardo et 
al., 2011). However, it is known that not all pancreatic tumour cell lines are able to form 
spheres, even though they are able to give rise to tumours upon transplantation into 
recipient mice (in vivo self-renewal property) (Gaviraghi et al., 2010). Therefore, I 
assessed the ability of freshly isolated tumour cells from F7KYCk19-CreER and 
p53KYPdx1-Cre-derived PDAC to grow as floating spheres in serum-deprived medium, 
as previously described (Gaviraghi et al., 2010, Hermann et al., 2007). Unfortunately, 
the F7KYCk19-CreER tumour cells failed to grow in these conditions (data not shown), 
which led me to use 3D matrices. 
It has been recently shown that pancreatic tumour cells derived from murine PDAC can 
be maintained and expanded as organoids in a matrigel matrix (Boj et al., 2014). It has 
also been shown that these conditions favour the growth of cells with stem cell-like 
phenotypes that are able to give rise to differentiated pancreatic progeny, while the 
remaining cells fail to grow (Huch et al., 2013). Therefore, I decided to use this 3D 
culture system to assess differences in organoid-initiation potential (see Chapter 2, page 
105) of CD9High versus CD9Low freshly isolated tumour cells from both F7KYCk19-
CreER and p53KYPdx1-Cre-derived murine PDAC (Figure 34a). 
F7KYCk19-CreER mice were intraperitoneally injected with tamoxifen for 2 days (one 
injection per day 100 mg/kg of body weight). Four weeks after injection, tumours were 
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removed, isolated DAPI-GFP+ cells were FAC sorted according to their CD9 expression 
and 1000 cells per well were plated in matrigel in 24-well plates. The experiment was 
repeated four times (four independent cell sortings, biological quadruplicates) and, at 
least technical duplicates were performed per experiment for significance assessment (n 
mice = 4). I observed that CD9High cells were significantly more capable of forming 
organoids (p<0.001) when compared with their negative counterparts, being able to 
generate an average of 0.0025 organoids per plated cell (0.25%) (Figure 34b,c). 
To verify if the organoid-initiating capacity was conserved throughout different 
oncogenic genotypes, a similar assessment was performed for tumour cells from the 
p53KYPdx1-Cre-derived PDAC. Five weeks after birth, PDAC tumours from 
p53KYPdx1-Cre mice were collected, the cells dissociated and 1000 GFP+ cells, sorted 
according to their CD9 expression, were plated per well in matrigel in 24-well plates. 
The experiment was performed in biological duplicates for significance assessment (n 
mice = 2). A significant difference was observed (p=0.05) when comparing both 
populations. While approximately 10% of the GFP+CD9High cells were capable of 
organoid formation, only 1% of GFP+CD9Low cells formed organoids (Figure 34d,e). 
Moreover, it was visually evident that the GFP+CD9High-derived organoids were bigger 
in size (no measurement was performed) (Figure 34c,e). 
Thus, the in vitro results provided the first functional evidence of a higher tumourigenic 
capacity of CD9High tumour cells. 
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Figure 34 - CD9High murine PDAC primary tumour cells have a higher organoid forming 
capacity 
a) Schematic representation of the experimental approach. Murine PDAC from 
F7KYCk19-CreER or p53KYPdx1-Cre mice were isolated and tumour cells (GFP+) 
were sorted according to their CD9 expression. GFP+CD9High and GFP+CD9Low cells 
were plated in matrigel and the organoid formation capacity was compared between the 
populations. b) Number of organoids per plated cell (1000 cells plated) formed by the 
sorted F7KYCk19-CreER tumour cells. (n=4 mice) c) Representative bright field 
images of generated organoids from the F7KYCk19-CreER GFP+CD9High (above) or 
GFP+CD9Low (below) sorted cells, 10 days after plating. d) Number of organoids per 
plated cell (1000 cells plated) formed by the sorted p53KYPdx1-Cre tumour cells. (n=2 
mice) e) Representative bright field images of generated organoids from the 
p53KYPdx1-Cre GFP+CD9High (above) or GFP+CD9Low (below) sorted cells, 10 days 
after plating. 
All scale bars show 250 µm. 
Dot blots show mean +/- SD. Significance was calculated with the Mann Whitney test. 
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Given the low percentage of tumour cells which were CD9High in both PDAC mouse 
models (10% for F7KYCk19-CreER and 5% for p53KYPdx1-Cre – Figure 31a,b and 
Figure 32c) it became apparent that the number of cells extracted per murine tumour 
constituted a challenge for in vivo studies, i.e., the number of cells obtained was not 
enough for homograft tumour analysis. Consequently, PDAC tumour cells had to be 
expanded before any in vivo approach could take place. 
For tumour cell in vitro expansion, I decided to use the 3D organoid system since cells 
from these cultures can recapitulate the human disease upon orthotopic transplantation 
(Boj et al., 2014). To ensure that culturing these freshly obtained tumour cells would 
not change the phenotypic difference between the CD9High and the CD9Low tumour cells, 
p53KYPdx1-Cre bulk tumour cells were expanded in vitro as organoids for several 
passages, sorted as single cells according to their CD9 expression and assessed for their 
ability to generate further organoids (Figure 35a). 
I dissociated murine PDAC from p53KYPdx1-Cre mice and plated the unsorted 
population in matrigel with organoid media (see Chapter 2, page 102). Six passages 
later, the cultured cells were dissociated with trypsin, stained for CD9 and plated in 
organoid-forming conditions according to their CD9 expression, as above. While in the 
previous assessment cells were plated by hand, for this experiment, to avoid human 
error during cell counting and plating, I FAC sorted 100 GFP+CD9High or 100 
GFP+CD9Low cells directly into pre-cooled, matrigel-coated wells of 96-well plates (100 
cells per well). Experiments were performed in duplicate (two independent sorts, 
biological duplicates) with, at least, technical triplicates (n mice = 2). A secondary 
antibody control was used to assess the specificity of the stain in these new conditions, 
which was shown not to have a signal (Figure 35b). 
As observed for the primary tumour cells, GFP+CD9High organoid-derived tumour cells 
formed 10 times more organoids than GFP+CD9Low cells with a significance of P=0.006. 
While the CD9High population showed 12% efficiency in organoid formation, only 2.5% 
of the CD9Low cells formed organoids (Figure 35c). The organoids formed by the 
CD9High sorted population were not only greater in number but also statistically 
significantly bigger in size (p<0.0001) (Figure 35d).  
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These results demonstrated that the organoid forming capacity of the CD9High tumour 
cells was a robust phenotype over several passages and allowed me to proceed to in vivo 
analysis. 
 
Figure 35 - CD9High murine PDAC organoid-derived tumour cells retain a higher organoid 
forming capacity 
a) Schematic representation of the experimental approach. Murine PDAC from 
p53KYPdx1-Cre mice were isolated and tumour cells grown for several passages as 
organoids. Organoids were dissociated and sorted according to their CD9 expression. 
GFP+CD9High and GFP+CD9Low cells were plated in matrigel and the organoid 
formation capacity was compared between the populations. b) Representative flow 
cytometry plot of a sort performed on the P53KYPdx1-Cre-derived tumour organoids. 
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Only live cells (DAPI-negative) were analysed (upper plot). Lower plots show 
secondary antibody alone control (left) and the CD9 stain (right). Positive CD9 gate was 
established based on the unstained population; negative CD9 gate was designed to 
reduce the chance of including cells with intermediate CD9 expression. c) Number of 
organoids per plated cell (100 cells plated) formed by the sorted p53KYPdx1-Cre-
derived PDAC tumour organoids. (n=2 mice, 4 experimental replicates). d) Organoid 
size. Pixel area (arbitrary units - a.u.) was measured using ImageJ to quantify organoid 
size. Every organoid formed in c was measured and their respective sizes were plotted 
in the dot plot (nCD9Highorganoids = 96; nCD9Loworganoids = 23). 
Dot plots show mean +/- SD. Significance was calculated with the Mann Whitney test. 
  
(Figure 35, legend continued) 
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4.1.8 CD9 surface expression identifies a murine PDAC tumour population with 
higher in vivo tumourigenic potential 
While in vitro observations of higher organoid-forming potential from CD9High cells 
suggest a tumour-initiating property, by definition, tumour-initiating cells have to be 
capable of tumour formation and maintenance in xenograft or homograft models, 
reproducing the primary disease (Clarke et al., 2006). 
Therefore, the classification of tumour-initiating cells is highly dependent on the greater 
ability of the putative TIC population to form tumours, when compared to the negative 
population in recipient mice. To assess, in vivo, the cancer stem cell-like potential, I 
generated and expanded p53KYPdx1-Cre PDAC tumour-derived organoids, sorted the 
expanded tumour cells according to their CD9 expression (GFP+CD9High versus 
GFP+CD9Low) and subcutaneously injected the sorted population into the flanks of 
immunodeficient NuNu mice (the same mouse was subcutaneously injected with both 
populations, one in each opposite flank, for comparable analysis) (Figure 36a). 
Represented results are the combination of two independent experiments. 
The tumorigenic capacity was measured by: (1) the ability of selected populations to 
form tumourigenic nodules (a nodule was considered a mass equal to 4mm3), at a 
particular time (time X), following serial dilution and (2) their capacity to maintain 
tumour development by comparing tumour sizes at endpoint. I injected 200x103, 20x103, 
2x103 or 0.2x103 GFP+CD9High and GFP+CD9Low tumour cells in the flanks of NuNu 
mice. I had observed before that p53KYPdx1-Cre organoid-derived PDAC cells have a 
pronounced tumour formation capacity even as a bulk population, since orthotopic 
transplantation of 500x103 cells generated palpable sized tumours two weeks after 
surgery (Figure 26b, Chapter 3, page 148). Therefore, measurements of initial nodules 
started one week after homograft transplantation and continued until all experimental 
animals developed tumours. 
It was seen that, in all dilutions, the CD9High cell-containing flanks developed nodules in 
all mice before all flanks with CD9Low-injected cells showed nodule formation (Figure 
36b). As expected, the biggest difference in nodule onset was observed when 2x103 and 
0.2x103 cells were injected. Upon injection of 2x103 cells, 50% of the CD9High cell-
containing flanks developed nodules at 2 weeks and all flanks were found with nodules 
at 4 weeks. However, when the same number of CD9Low cells was injected, at the third 
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week, only 50% of the mice were found with nodules, with the last nodule formation 
being registered 6 weeks after injection (Figure 36b,c). When 0.2x103 cells were 
injected, 50% of the mice developed nodules in the flank injected with CD9High cells as 
soon as 2 weeks after injection while no nodule was detected at this time point for 
CD9Low cell-containing flanks (Figure 36b,d). It is important to mention that, in 
accordance with the inability of CD9Low cells to sustain tumour development, when 200 
cells were injected, 1 out of the 4 mice demonstrated CD9Low-derived tumour regression 
and, consequently, no tumour was detected when the experiment was terminated. 
Moreover, 1 out of the remaining 3 tumours was so small at the time of removal that 
embedding and sectioning was compromised. Thus, only two tumours from the flanks 
of 0.2x103 CD9Low injected cells were left for histological analysis. 
Tumour initiation is a feature that only self-renewing cells possess given their unique 
ability to continuously give rise to tumour cells. Nevertheless, the remaining “non-
tumour-initiating cells” harbour some limited proliferative potential enabling nodule 
formation (Reya et al., 2001). Therefore, the functional assessment of TICs cannot be 
restricted to their ability to initiate nodules in recipient mice, but also to sustain the 
growth of the initiated tumour. For this reason, tumours were allowed to grow until one 
of the flanks reached 1 cm3 of tumour content or appearance of animal distress due to 
tumour load or location. Mice harbouring one 1 cm3 tumour were culled, tumours from 
both flanks were removed and their size measured. Tumour volume was calculated 
using the following formula: volume=(Height*Length*width)/2 (Tomayko and 
Reynolds, 1989). 
It was observed that while CD9High tumour cells were able to form 1cm3 tumours, 
regardless of the number of cells injected, CD9Low tumour cells failed to maintain 
tumour growth with increase in dilution (Figure 36e). I calculated the fold difference in 
tumour size between CD9High and CD9Low-developed tumours, for all dilutions 
performed, and observed that, despite the low difference in tumour onset, CD9High cells 
were 4, 3.5, 8 and 13-fold more capable of tumour growth than CD9Low cells when 
200x103, 20x103, 2x103 and 0.2x103 cells were injected, respectively (Figure 36f).  
To assess tumour maintenance, i.e., the ability to propagate and maintain tumour growth 
after tumour initiation, I calculated the final tumour volume relative to the volume of 
the initially detected nodule (=VolumeFinal/VolumeInitial). The biggest difference was 
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observed when 200 cells were inoculated. While CD9High cells demonstrated over a 
100-fold increase in tumour size compared to the initial nodule, the CD9Low cells were 
only capable of a 10-fold increase (Figure 36g). Importantly, and as mentioned above, 2 
out of 4 nodules from 200 CD9Low injected mice exhibited tumour growth 
regression/inefficient growth following nodule onset, reinforcing their limited 
proliferation capacity. 
These results corroborate the higher tumourigenic capacity suggested from my in vitro 
studies and demonstrate that CD9High PDAC tumour cells are capable of both tumour 
initiation and maintenance, while the CD9Low tumour cells fail to maintain tumour 
growth. 
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Figure 36 - CD9 surface expression identifies a murine PDAC tumour population with 
higher in vivo tumourigenic potential (TICs) 
a) Schematic representation of the experimental approach. Murine PDAC from 
p53KYPdx1-Cre mice were isolated and tumour cells grown for several passages as 
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organoids. Two independent cell lines were generated from 2 individual p53KYPdx1-
Cre mice-derived PDAC. Organoids were dissociated and sorted according to their CD9 
expression. GFP+CD9High and GFP+CD9Low cells were injected (serial dilutions) in the 
flanks of NuNu mice and tumour initiation and growth were analysed. b) Tumourigenic 
capacity of CD9High versus CD9Low tumour cells from p53KYPdx1-Cre PDAC-derived 
organoids. 200x103, 20x103, 2x103 and 0.2x103 sorted tumour cells were injected in the 
flanks of NuNu mice and the number of weeks necessary for nodule (4mm3) detection 
was registered. c) Percentage of mice injected with 2x103 sorted CD9High or Low tumour 
cells that developed tumours per week x. d) Percentage of mice injected with 0.2x103 
sorted CD9High or Low tumour cells that developed tumours per week x. e) Tumour sizes 
per flank, per dilution, in cm3. Mice were culled when one of the flanks developed a 
tumour of 1cm3. Each dot indicates a tumour (one CD9High and one CD9Low tumour per 
mouse). Dot blot indicates mean +/- SD. Volume was calculated as: 
volume=(Height*Length*width)/2. Representative image of generated tumours. Scale 
bar represents 1cm. f) Fold change of the volume between the CD9Low and CD9High-
derived tumours at each dilution. Bar chart shows mean +/- SD. g) Relative tumour 
volume (RTV) of the CD9High and CD9Low-derived tumours when 0.2x103 cells were 
subcutaneously injected. RTV = VolumeFinal/VolumeInitial. Bar chart shows mean plus 
SD. 
Significance was calculated using the Mann Whitney test for e and g, and the Wilcoson 
test was used to calculate significance in f (values were normalized to the CD9Low 
control) 
  
(Figure 36, legend continued) 
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4.1.9 CD9High PDAC TICs re-establish the cellular heterogeneity observed in the 
primary tumour 
Similar to tissue stem cells with their capacity to give rise to different cell types, 
tumour-initiating cells are known to be responsible for the cellular heterogeneity found 
in cancers, given their ability to generate differentiated progeny (Clarke et al., 2006). I 
performed histological studies in order to compare the tumours generated by the 
CD9High and CD9Low cells with their original primary tumour. For the purpose of 
simplicity, only the tumours derived from 2x103 injected cells will be described. 
Tumours formed after injection of 200x103 and 20x103 cells followed a similar pattern 
as 2x103-derived tumours. Regarding tumours formed following injection of 0.2x103 
CD9Low tumour cells, their histologic assessment is still ongoing.  
Hematoxylin and eosin analysis of tumours generated following injection of 2x103 cells 
demonstrated that, while both the primary and the CD9High-derived tumours were 
compact masses of tissue, the CD9Low-derived tumours possessed mainly cystic 
structures (Figure 37a,b,c). Ck19 and GFP immunohistochemical analysis allowed a 
better understanding of the tumour histology. Ck19 stain demonstrated that all three 
tumours presented regions of ductal differentiation by the detection of branching 
epithelial elements with ductal morphology and thus could be classified as PDAC 
(Figure 37d,e,f). However, when analysing the GFP signal (lineage tracer of injected 
tumour cells), I could detect that, while there was a good co-localization with the Ck19 
stain in the CD9Low-derived tumours, the primary and the CD9High-generated tumours 
exhibited large regions that expressed GFP but had lost Ck19 protein (Figure 37g,h,i). 
Since GFP is expressed in all tumour cells, the results suggest that some of the tumour 
cells had lost their ductal epithelial identity. Confirming the previous hypothesis, high 
magnification of GFP expression regions, that had lost Ck19 expression, demonstrated 
that most of the tumour cells in the primary and the CD9High-derived tumours presented 
a mesenchymal differentiation with cells exhibiting a spindle shape. On the other hand, 
CD9Low-derived tumours were entirely composed of cells expressing Ck19 and GFP 
with a ductal cuboidal/columnar epithelial morphology (Figure 37j,k,l,m,n,o).  
Given the difference between the generated tumours, I requested a complete pathology 
report, which was provided by our on-site consultant histopathologist, Professor Gordon 
Stamp. It has been described before that the homozygous deletion of p53 in pancreatic 
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progenitors with concomitant KRasG12D activation leads to the development of 
pancreatic ductal adenocarcinoma embedded in dense fibrous stroma or in conjunction 
with sarcomatoid or anaplastic carcinomas, characterized by the presence of spindle-
shaped cells and concomitant ductal differentiation (Bardeesy et al., 2006a). Similar to 
the primary tumour, CD9High-derived tumours presented regions with semi-polarized 
cuboidal cells, resembling a pancreatic ductal phenotype, combined with GFP-
expressing sarcomatous elements with single cell invasion. Both tumours were 
classified as carcinosarcomas. In contrast, CD9Low-derived tumours were described to 
possess similar branching tubuloglandular ductal structures but no obvious sarcomatous 
transformation, with epithelial cells clearly distinct from the desmoplastic stroma. These 
tumours were not classified as carcinosarcomas. 
The results suggest that CD9High-sorted PDAC organoid-derived tumour cells were 
capable of giving rise to the cell types found in the primary tumour reproducing the 
p53KYPdx1-Cre-derived PDAC histological heterogeneity, and that CD9Low cells retain 
their epithelial differentiation, failing to generate more mesenchymal cells. 
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Figure 37 - CD9High PDAC TICs re-establish the cellular histological heterogeneity 
observed in the primary tumour 
Representative histological analysis of the p53KYPdx1-Cre primary tumour and the 
tumours generated following injection of 2x103 p53KYPdx1-Cre PDAC organoid-
derived sorted CD9 high and low tumour cells. More than 3 p53KYPdx1-Cre primary 
tumours were analysed. Tumours from all injected mice were collected and used for 
histological analysis. a,b,c) H&E section of (a) primary, (b) CD9High and (c) CD9Low 
tumours. d,e,f) CK19 immunological staining of (d) primary, (e) CD9High and (f) 
CD9Low tumours. g,h,i) GFP immunological staining of (g) primary, (h) CD9High and (i) 
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CD9Low tumours. j,k,l) Magnified regions highlighted in g, h and i, respectively. Black 
arrows highlight ductal differentiation in primary and CD9High-derived tumours. All 
regions in CD9Low tumours possess ductal differentiation. m,n,o) Magnified regions 
highlighted in j, k and l, respectively. 
All scale bars represent 100µm, unless indicated otherwise in the figure. 
  
(Figure 37, legend continued) 
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4.1.10 Tumours derived from CD9High cells are more proliferative than the CD9Low 
generated tumours 
The assumption that the CD9Low tumour cells are non-tumour-initiating cells with 
limited proliferative potential requires the observation of reduced proliferation in 
CD9Low-generated tumours when compared with tumours generated by CD9High sorted 
cells. For this purpose, I stained the tumours generated by subcutaneous injection for 
phosphorylated histone 3 (pH3) (Figure 38a), a marker of on-going mitosis (Hans and 
Dimitrov, 2001). I could observe that CD9High tumours were significantly more 
proliferative than CD9Low-derived neoplasias (Figure 38b). As described above, 
tumours generated from CD9Low injected cells exhibited a pronounced ductal 
differentiation compared to the ones generated by CD9High injected cells. Nonetheless, I 
also observed increased proliferation in epithelial regions with ductal differentiation of 
CD9High derived tumours, excluding the status of differentiation as a cause of the 
proliferative difference (Figure 38a). 
These results corroborate a limited proliferative potential of CD9Low cells and 
incapability to maintain tumour growth, hence, their classification as non-TICs. 
 
Figure 38 - Tumours derived from CD9High cells are more proliferative than CD9Low-
generated tumours 
a) Immunological staining of CD9High and Low-derived tumours for pH3. Images show 
ductal epithelial regions of CD9Low-derived tumours and both ductal and mesenchymal 
differentiated regions of CD9High-derived tumours. Scale bars represent 100µm. b) 
Quantification of number of cells positive for pH3 per mm2. Four tumours per 
population and 3 levels per tumour were used for quantification (n mice =4). Bar chart 
shows mean plus SD. Significance was calculated using the Mann Whitney test. 
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4.2 Discussion: Identification of a specialized tumour-initiating 
population in murine PDAC 
4.2.1 Differential cancer susceptibility of ductal cells 
The pancreatic ductal compartment is commonly described as a structure composed of a 
homogeneous cellular population (ductal cells) responsible for the conduction of acinar-
derived digestive enzymes to the duodenum (Reichert and Rustgi, 2011). However, 
injuries to the organ and selective genetic manipulations have unravelled a cellular 
plasticity that might only be present in a subset of ductal cells (Sancho et al., 2014, 
Inada et al., 2008).  
Adding to this cellular heterogeneity, I observed a differential susceptibility to 
tumourigenic transformation in adult ductal cells. When the initial stages of adult 
PDAC development of F7KYCk19-CreER mice were analysed, it was observed that 
only a fraction of the lineage traced cells (recombined, GFP+) exhibited morphological 
features of transformation. Protein level analysis identified CD44, a surface protein 
previously identified in human PDAC TICs to be selectively expressed in transformed 
cells. Its presence was detected as early as 2 weeks after tamoxifen treatment, allowing 
distinction between early transformed and non-transformed cells, and persisted 
throughout tumour development proving to be a good tumour cell marker. Important to 
highlight is the fact that the GFP+CD44+ and GFP+CD44- populations harboured the 
same oncogenic hits, since genotyping PCR could not detect inefficient recombination 
for the Fbw7 and KRas loci in any of the populations assessed.  
Our research group has previously described that loss of Fbw7 protein, in adult ductal 
cells, promotes a cellular conversion of ductal cells into endocrine insulin-producing β-
cells  (Sancho et al., 2014). In that study, a simultaneous increase in proliferation was 
also observed with Fbw7 loss, which was independent from the conversion, as ductal 
cell-derived newly formed β-cells did not arise through a proliferation step. This 
suggested that, within the ductal network, some cells are more prone to proliferate than 
others (Sancho et al., 2014). Corroborating previous findings, my results support this 
proliferative heterogeneity by demonstrating that ductal cells respond differently to the 
same oncogenic hit.  These results encouraged me in the search for markers of tumour 
initiating cells for PDAC development.  
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4.2.2 CD9High PDAC cells constitute a tumour-initiating population 
The identification of tumour-initiating cells has increased the understanding of tumour 
biology and changed the way medicine approaches cancer treatments. While TIC 
identification was initially reported in haematological malignancies (Lapidot et al., 
1994), solid tumours have also been the target of tumour-initiating cell identification. 
Pancreatic cells with higher tumourigenic capacity have been reported (Hermann et al., 
2007, Lonardo et al., 2011, Li et al., 2007). However, inconsistent data has been 
obtained in different laboratories (see Chapter 5, 5.4) highlighting the need for better 
understanding of PDAC tumour-initiating biology. 
I performed a gene expression array to assess differentially expressed genes in 
transformed versus non-transformed pancreatic cells (GFP+CD44+ vs GFP+CD44-) with 
the same oncogenic hits (Fbw7 deletion and KRasG12D oncogenic activation), and 
combined it with literature and database searches (Uhlen et al., 2015). I identified CD9 
as a potential marker for a subpopulation of transformed cells. Due to technical 
difficulties, such as the number of cells of interest obtained in each pancreatic isolation, 
the execution of replicates was not possible. However, the observation that described 
pancreatic tumour markers such as CTSE, Mmp7, Agr2, TFF2 and Muc1 were included 
amongst the most upregulated genes in the transformed cell population illustrated a 
biological accuracy of the expression array. Nevertheless, validation was performed 
following repetition of the experimental outline and Q-PCR analysis of selected hits. 
 
The cancer stem cell hypothesis postulates that tumour-initiating cells are equipped with 
stem cell features; such as self-renewal capacity and ability to give rise to differentiated 
progeny, culminating in the observed cellular heterogeneity. These features are 
routinely assessed by in vitro differential sphere/organoid-forming capacity and by the 
unique aptitude to generate tumours when transplanted into recipient mice (Nguyen et 
al., 2012, Clarke et al., 2006, Jordan et al., 2006, Pastrana et al., 2011). The in vitro 
organoid-forming capacity and the in vivo tumourigenic potential, following homograft 
transplantation, of the CD9High murine PDAC population was significantly increased 
when compared with their CD9Low-expressing counterpart. 
In particular cases, such as in haematopoietic malignancies, tumour-initiating cells 
depend on the oncogenic hit received. While some genetic alterations were shown to be 
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capable of inducing TIC properties in progenitor cells, other oncogenic hits failed to do 
so (Huntly et al., 2004). Thus, my assessment included two different genetic 
backgrounds: Fbw7 or p53 homozygous deletion, both harbouring the PDAC oncogenic 
driver mutation (KRasG12D activation). I observed that, independently of the oncogenic 
hit, CD9High cells, present in murine PDAC, exhibit a significantly increased in vitro 
organoid-forming potential compared to CD9Low tumour cells. 
Interestingly, despite the higher number of CD9High cells present in the F7KYCk19-
CreER-derived murine PDAC (approximately, 15% of the tumour cell population), the 
p53KYPdx1-Cre murine PDAC-derived CD9High cells (containing approximately 5% 
CD9High cells of the tumour cell population) exhibited higher in vitro organoid-forming 
potential. Unfortunately, the organoid formation from CD9High cells of the two 
genotypes was not simultaneously assessed, introducing a great experimental variability, 
which impedes comparison. Nonetheless, replicates within each genotype were 
consistent, excluding inter-experiment variability as a causative element. The cellular 
origin of these murine PDAC should also be borne in mind. While the F7KYCk19-
CreER-derived PDAC have their origin in adult duct cells, the murine PDAC derived 
from p53KYPdx1-Cre is formed from pancreatic progenitors. It is clear that both initial 
cell types (adult ducts and pancreatic progenitors) greatly differ in their transcriptional 
programs and expression profiles, which might affect the self-renewal potential of the 
tumour-initiating cells. To accurately compare both genetic alterations, the same Cre 
driver should be used. Thus, the in vitro organoid-formation assessment should be 
repeated comparing F7KYPdx1-Cre with p53KYPdx1-Cre PDAC-derived CD9High cells 
(pancreatic progenitors) and the F7KYHnf1β-CreER with the p53KYHnf1β-CreER 
CD9High PDAC-derived cells (adult duct cells). However, the fact that the CD9-positive 
TIC population was present in PDACs originated from 2 different genetic profiles and 
cells of origin suggests that CD9 might be a general marker for PDAC TICs. 
I have also observed that the frequencies of organoid-initiating cells were extremely low 
for both murine PDAC models. Only 0.3% of the F7KYCk19-CreER PDAC-derived 
CD9High cells and approximately 10% of the p53KYPdx1-Cre PDAC-derived CD9High 
cells were capable of organoid initiation. This result can be partially explained by the 
cellular viability after FACS sorting. The tumour dissociation, the long term incubation 
of the cells in media deprived conditions before FACS (2% FBS in PBS cell 
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suspension), followed by the fluorescence activated cell sorting at high pressures, 
constitutes an extremely harsh process, which compromises cell survival. It is, thus, 
likely that not all sorted cells survive in culture and are capable of organoid formation. 
Nonetheless, the same methodology has been applied to other systems and, while 100% 
efficiency in organoid formation is never observed, a higher percentage of organoid-
forming cells is expected if the selected population constitutes a pure tumour-initiating 
cell population. It is possible that the CD9High is still a heterogeneous population. 
Therefore, it would be interesting to know if this TIC population could be further 
narrowed down. This could be addressed by single cell gene expression. Single cell 
RNA sequencing has been used to identify subpopulation within tissues based on their 
gene expression profile, reconstructing lineage hierarchies (Treutlein et al., 2014). 
Hence, the single cell gene expression analysis of the CD9High population could unveil a 
possible heterogeneity and identify additional markers that would allow the enrichment 
of the PDAC TICs. 
 
Homograft transplantation of CD9High and CD9Low PDAC tumour cells from 
p53KYPdx1-Cre-derived organoids confirmed the CD9High population as PDAC 
tumour-initiating cells. CD9High PDAC cells injected subcutaneously in a serial dilution 
approach were capable of generating tumour nodules faster than the CD9Low injected 
cells and were uniquely able to maintain tumour development demonstrating a 100-fold 
increased growth of the originating nodule when 200 cells were injected. On the other 
hand, CD9Low PDAC cells showed very limited tumour maintenance capacity with only 
a 10-fold increase in tumour growth when compared with the size of the initial nodule. 
Moreover, regression of two out of four nodules formed was observed (200 cells 
injected). 
It is common to focus only on nodule formation to identify TICs. However, tumours 
exhibit a cellular hierarchy that can be correlated with their proliferative potential. 
While tumour-initiating cells, or cancer stem cells, are described to possess unlimited 
proliferative capacity, the remaining tumour mass is known to have a limited 
proliferative potential (Reya et al., 2001). This definition suggests that, when injected, 
these non-tumour-initiating cells can expand the population to a certain extent being 
able to form nodules that do not grow extensively. In accordance with the previous 
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statement, despite their ability to form nodules, at low cell numbers the CD9Low tumour 
cells were not capable of maintaining the growth of the tumour as efficiently as the 
CD9High cells and exhibited significantly reduced proliferation, as assessed by the 
presence of phosphorylated histone 3. 
The complete absence of nodule formation by CD9Low cells might be observed if a less 
aggressive/highly proliferative genotype is used for homograft transplantation assays. It 
is known that the homozygous deletion of p53 in the embryonic pancreas with 
simultaneous KRasG12D oncogenic activation leads to anaplastic PDAC with visible 
EMT and undifferentiated cellular populations (Bardeesy et al., 2006a). Therefore, 
organoids from a less aggressive genetic background known to give rise to well-
differentiated PDAC with later onset, such as the p53F/WT; KRasLSL-G12D/Wt; Pdx1-Cre 
(Rhim et al., 2012), should be generated and the experiment repeated. 
 
As mentioned above, TICs are known to reproduce the originating disease. I observed 
that CD9High-derived tumours reproduced the p53KYPdx1-Cre-derived carcinosarcoma 
with local ductal differentiation. Conversely, CD9Low-derived tumours failed to 
reproduce the PDAC heterogeneity of the originating tumour giving rise to a well-
differentiated PDAC with no sarcomatous elements. As opposed to the approach taken 
for in vitro studies, for in vivo assessment of tumour initiating potential, only cells 
derived from p53KYPdx1-Cre tumours were used. For this reason, it is still not clear if 
this in vivo tumourigenic potential is dependent on the oncogenic hit. Hence, a similar 
approach with a comparable Cre model and a different induced genetic alteration (such 
as F7KYPdx1-Cre) should be performed. 
 
The results obtained so far strongly suggest that CD9 expression and surface 
localization marks a population within pancreatic tumours that is responsible for tumour 
initiation, maintenance and cellular heterogeneity. The implications and potential utility 
of such marker will be discussed further in Chapter 5. 
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Chapter 5. Discussion 
5.1 Introduction to the aim 
Pancreatic ductal adenocarcinoma (PDAC), comprising 85% of all pancreatic cancers, 
is a neoplastic disease of the pancreas with an extremely poor prognosis (less than 4% 
5-year survival) (Hariharan et al., 2008, Hezel, 2006). Given the non-specific nature of 
symptoms, PDAC is usually detected at advanced stages, where tumour grade/stage and 
presence of metastases compromise the benefits of surgical resection. Current PDAC 
chemotherapy strategies rely on the unspecific targeting of proliferative cells by the use 
of nucleoside analogues, such as Gemcitabine (Burris et al., 1997). However, not all 
patients benefit from this approach. So, there is a urgent need for improvement in drug 
development and cell-specific therapeutic targeting (Bittoni et al., 2014). Therefore, 
extensive efforts have been made to fully understand the molecular and cellular biology 
of the disease. 
 
At the molecular level, it is well known that PDAC tumour initiation is driven by KRAS 
mutations, mainly occurring in exon 1 (codon 12), leading to a glycine to aspartic acid 
or valine change (G12D or G12V) (Eser et al., 2014). While KRAS mutations are 
present in over 90% of human PDAC samples, other, less represented, 
genetic/epigenetic alterations, such as inactivation of p53 (50-70%), SMAD4 (30-80%) 
and CDKN2A (35-50%), have also been reported to have crucial roles in PDAC biology 
(Waddell et al., 2015, Eser et al., 2014, Rozenblum et al., 1997, Hong et al., 2011). 
Moreover, comprehensive genetic analysis and genome-wide studies on human PDAC 
samples confirmed its complex molecular profile and highlighted the possible 
contribution of other genes to PDAC development (Waddell et al., 2015, Jones et al., 
2008), calling for more in depth studies on additional genetic players. 
 
At the cellular level, based on human and mouse data, a histological progression from 
low to high-grade cellular dysplasia has been proposed. Four types of precursor lesions 
have been described to precede PDAC: intraductal papillary mucinous neoplasia 
(IPMN); pancreatic mucinous cystic neoplasm (MCN); intraductal tubular papillary 
neoplasm (ITPN); and, the most common pre-neoplastic lesion, pancreatic 
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intraepithelial neoplasia (PanIN) (Distler et al., 2014, Cooper et al., 2013). The 
identification of pre-neoplastic lesions has made it possible to develop strategies for 
PDAC early detection (Cruz-Monserrate et al., 2012, Stefan Eser, 2011, Tanaka et al., 
2012). Furthermore, survival studies have reported that different pre-neoplastic lesions 
confer different prognosis for the developed PDAC (Cooper et al., 2013). Since mouse 
models of PDAC have demonstrated that PDAC arising from different pre-neoplastic 
lesions have no discernible features at endpoint (von Figura et al., 2014, Bardeesy et al., 
2006b), a better understanding of PDAC origin and biology might allow patient 
stratification and development of personalized medicine. 
 
During the course of my studies I focused on the role of the tumour suppressor gene 
Fbw7 in PDAC development and investigated the cellular origins of this pancreatic 
neoplasia. 
 
5.2 The role of FBW7 in PDAC tumourigenesis 
FBW7 is an F-box protein that confers substrate specificity to an SCF-type E3 ubiquitin 
ligase, responsible for protein ubiquitination and consequent proteasomal degradation of 
its targets. Due to the nature of its substrates, FBW7 has been described as a tumour 
suppressor, targeting several proteins involved in cell fate decisions and proliferation 
for degradation, such as c-Myc, cyclin E, Notch, c-Jun and Mcl-1 (Welcker and 
Clurman, 2008). Numerous studies have addressed the role of FBW7 in cancer 
development and progression (Cheng and Li, 2011, Crusio et al., 2010). However, its 
relevance in PDAC tumourigenesis is still not well established.  
In this thesis, I confirmed and followed up Rocio Sancho’s findings that Fbw7 protein 
loss with concomitant KRasG12D oncogenic activation, in the developing pancreas, 
greatly accelerates murine PDAC (mPDAC) onset, when compared to KRasG12D 
activation alone. Histologically, Fbw7F/F; KRasLSL-G12D/wt; Pdx1-Cre pancreatic tumours 
(F7KPdx1-Cre mice) resembled the mPDAC derived from the established KRasLSL-
G12D/wt; Pdx1-Cre model (KPdx1-Cre mice) (Hingorani et al., 2003). Furthermore, 
tumours from both models exhibited increased pErk (downstream target of the Ras 
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pathway) and nuclear Hes1 (readout of Notch pathway activation) immunoreactivity, as 
described for human PDAC (Hezel, 2006). 
The mPDAC obtained with the KPdx1-Cre model has been described to closely mimic 
human PDAC (Hingorani et al., 2003). Therefore, the similarity between mPDAC from 
the KPdx1-Cre and the F7KPdx1-cre mouse models indicates that Fbw7 deletion does 
not change the tumour type of a KRasG12D-driven pancreatic tumour, but it accelerates 
PDAC onset and recapitulates the human disease, adding Fbw7 to the list of mPDAC 
tumour suppressors. 
Interestingly, I also observed that Cre-dependent Fbw7 deletion in the embryonic 
pancreas, with or without KRasG12D, mainly increased proliferation of the ducts, having 
no effect on acinar cell proliferation, and that ductal dysplasia occurred without any 
obvious alteration to remaining organ. This finding highlighted the importance of Fbw7 
in ductal cell biology and shifted the focus of my research to explore this new finding. 
Thus, the mechanism by which Fbw7 deletion accelerates PDAC in the F7KPdx1-Cre 
model is still an open question.  
 
FBW7 mutations have been identified in KRAS wild type human pancreatic cancer 
samples (Calhoun et al., 2003). However, while no mutations have been reported in 
KRAS mutant PDAC, downregulation of FBW7 has been observed by 
immunohistochemistry of some KRAS mutant patient samples and in mouse models of 
PDAC harbouring mutant KRas (Ji et al., 2015). In that study, the mechanism by which 
FBW7 is downregulated was attributed to ERK kinase-dependent FBW7 degradation. 
The authors demonstrated that overexpression of ERK1 in human PDAC cell lines led 
to phosphorylation of FBW7 at threonine 205 and protein ubiquitination, with 
detectable reduction in FBW7 levels. Expression of a phospho-deficient mutant version 
of FBW7 led to stabilization of the protein and reduction in tumourigenic potential, 
following subcutaneous injection of PDAC transfected cell lines (Ji et al., 2015), 
corroborating the role of FBW7 in PDAC biology. While the regulation of the protein 
has begun to be addressed, the tumour suppressive mechanism of FBW7 in PDAC 
biology is still poorly understood. 
The Notch pathway has been suggested to be involved in PDAC tumourigenesis, as 
members of the pathway, such as HES1 and NOTCH1, are upregulated in human 
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PDAC. Moreover, mouse model studies have identified this pathway as capable of 
increasing PDAC oncogenesis by promoting the development of pancreatic pre-
neoplastic lesions (Miyamoto et al., 2003, De La O et al., 2008). Interestingly, in the 
F7KPdx1-Cre-derived PDAC, I observed an increase in Hes1, compared with wild type 
pancreatic. Additionally, this increase in protein levels seemed to be more pronounced 
when compared to KPdx1-Cre-derived PDAC. It is, thus, possible that Fbw7 deletion 
accentuates the activation of the Notch pathway, promoting PDAC tumourigenesis. 
Nonetheless, in order to validate the hypothesis, Notch, or its downstream targets, 
should be knocked out in an Fbw7 deleted background.  
Additionally, it is possible that other FBW7 targets are involved in PDAC 
tumourigenesis. It has been observed that cyclin E is overexpressed in PDAC samples 
and that high levels of this protein is a good indicator of poor prognosis (Skalicky et al., 
2006). It has been shown that oncogenic Ras can promote cyclin E protein stability, and 
its consequent cellular increase, at least partially, by inhibiting FBW7-dependent cyclin 
E degradation (Minella et al., 2005). Furthermore, c-Myc has also been implicated in 
PDAC development, as its expression under the acinar-specific Elastase1 promoter, 
during pancreatic development, is sufficient to induce ductal adenocarcinoma (Sandgren 
et al., 1991). While it is necessary to address which of Fbw7’s targets are deregulated in 
the F7KPdx1-Cre-derived PDAC, given the suggested involvement of most of the 
targets in human PDAC oncogenesis, it is likely there is not one unique mechanism to 
PDAC development in the absence of FBW7, but a complex cooperation of various 
pathways. 
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5.3 Origins of PDAC: The importance of the pancreatic cellular 
compartment of origin. 
5.3.1 Adult ductal cells give rise to PDAC without the formation of mucinous 
pre-neoplastic lesions 
PDAC has been proposed to originate from different types of precursor lesions such as 
IPMN, MCN, ITPN and PanIN1 to 3 (Distler et al., 2014, Yonezawa et al., 2008, 
Feldmann et al., 2007). It is hypothesized that different pre-neoplastic lesions might be 
determined by the cell of origin, or, alternatively, by the genetic alteration induced (von 
Figura et al., 2014, Bardeesy et al., 2006b, Hingorani et al., 2003, Guerra et al., 2007, 
Izeradjene et al., 2007). 
Histological analysis of human samples has demonstrated that, while MCNs have no 
direct connection to the ductal network, IPMNs, ITPN and PanINs do. This observation, 
coupled with the ductal morphology of the pre-neoplastic lesions, led to the assumption 
that most of the PDAC precursors, and by association PDAC, had their origin in the 
ductal network. However, mouse model studies have allowed a better understanding of 
the pancreatic compartment of origin for PDAC. 
Initial GEM studies targeted the PDAC driver mutation (KRasG12D) to the developing 
pancreas, showing that KRasG12D initiates mPDAC development and KRasG12D-driven 
mPDAC evolves from mPanIN1-2 lesions (low-grade), which progress to mPanIN3 
(high-grade, carcinoma in situ) and PDAC (Hingorani et al., 2003). Additional work 
suggested that the type of pre-neoplastic lesion formed is dependent on the oncogenic 
hit, as the concomitant loss of Smad4 protein with the KRasG12D mutation, in the 
embryonic pancreas, led to the development of murine IPMN instead of mPanINs 
(Bardeesy et al., 2006b). However, later studies have also induced the loss of Smad4 
with KRasG12D expression in pancreatic progenitor and showed that it leads to the 
formation of MCN instead of PanIN and IPMNs (Izeradjene et al., 2007). Interestingly, 
different Cre mouse lines were used to target the genetic alteration to pancreatic 
progenitors. While Bardeesy and co-workers used Pdx1-Cre (expressed from E8.5), 
Izeradjene and co-workers used Ptf1a-Cre (Expressed from E9.5). Thus, while the 
molecular cell signalling at these two days might differ, it also raises the possibility of 
different cells being targeted by the Cre mouse line. 
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The development of inducible mouse models, able to target the genetic alteration to 
specific exocrine compartments in the adult pancreas (acinar vs duct), has greatly 
contributed to a better assessment of the compartment of origin of PDAC (Kopp et al., 
2012, von Figura et al., 2014, Guerra et al., 2007, Ray et al., 2011, Friedlander et al., 
2009). Using acinar-specific inducible models (Ela-tTA/tetO-Cre, Ptf1a-CreER and 
CPA1-CreER) it was demonstrated that, while acinar cells of young mice can initiate 
mPDAC development via mPanIN1-2-3 lesion formation, adult acinar cells (8-week-old 
mice) are very refractory to PDAC initiation. Nevertheless, the combination of 
oncogenic hit (KRasG12D) and pancreatitis (caerulein-induced, acinar cell-specific 
damage) enabled all grades of mPanIN formation and mPDAC onset (Kopp et al., 2012, 
Guerra et al., 2007, Friedlander et al., 2009). 
Conversely, the assessment of the ability of the ductal network to form PDAC had only 
been superficially performed at the start of this project. The Sox9-CreER and the Ck19-
CreER mouse models (duct-specific) were used to target the PDAC driver KRasG12D 
mutation to the ductal network. In both studies, ductal cells were shown to be refractory 
to tumourigenesis, as no significant transformation was observed, besides the formation 
of some rare low-grade mPanIN lesions (Kopp et al., 2012, Ray et al., 2011). From the 
results obtained with the oncogenic targeting of both exocrine compartments, before the 
start of my thesis, it was accepted that acinar cells were the origin of PDAC and they 
would evolve via PanIN lesions. 
However, a few caveats with the approaches taken at the time to assess ductal cell-
derived tumourigenesis were detected. Firstly, while the Sox9-CreER and the Ck19-
CreER mouse models mainly induce Cre-dependent recombination in ductal cells, 
results from our group, and from published reports, indicate that both models also 
induce some acinar cell recombination (Means et al., 2008, Kopp et al., 2012). 
Therefore, the possibility that the mPanIN lesions observed were due to acinar cell 
targeting remained. Secondly, while, acinar cell injury (by caerulein treatment) had to 
be performed to induce adult acinar cell-derived mPDAC, ductal cell injury was not 
tested. Lastly, the additional deletion of tumour suppressors in acinar cells such as p16 
and p19 or p53, reinforced the ability of this pancreatic compartment to induce PDAC 
(Guerra et al., 2011). However, before the start of my studies, this had not been done for 
the ductal compartment. 
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In this thesis, I reported that the loss of Fbw7 protein with concomitant activation of 
mutant KRasG12D expression in the adult ductal compartment (Fbw7F/F; KRasLSL-G12D/wt; 
Ck19-CreER – F7KCk19-CreER mice) led to mPDAC development, which was not 
preceded by low-grade mPanIN lesions. Other mucinous pre-neoplastic lesions, such as 
IPMN or MCN were also not detected. Additionally, loss of p53 protein with 
simultaneous KRasG12D expression in adult ductal cells (p53F/F; KRasLSL-G12D/wt; Ck19-
CreER – p53KCk19-CreER mice) was also able to induce mPDAC with no low-grade 
mPanIN lesion development. This is particularly important, as it has been shown that 
p53 deletion with concomitant KRasG12D expression leads to the formation of mPanINs 
in the developing pancreas (Aguirre, 2003). While results obtained in this thesis with 
the F7KCk19-CreER and p53KCk19-CreER mouse models need confirmation from 
more specific models, as discussed in Chapter 3, page 155, the data so far suggests that 
ductal cells can generate PDAC in the absence of previously described mucinous 
lesions. 
To confirm that the absence of mucinous precursor lesions in the F7KCk19-CreER 
model was dependent on the cell of origin, I induced acinar cell-specific loss of the 
Fbw7 protein with concomitant KRasG12D activation in adult acinar cells (Fbw7F/F; 
KRasLSL-G12D/wt; Ela1-CreER – F7KEla1-CreER mice) before acinar cell injury. I 
observed the presence of AB/PAS-positive mucinous low-grade mPanIN lesions, 
indicating that the loss of Fbw7 does not prevent their formation. These results suggest 
that the cell of origin has a great impact in determining the presence of mucinous pre-
neoplastic lesion. Hence, while acinar cells formed PanINs, ductal cells did not form 
mucinous precursor lesions with these genetic alterations. Nevertheless, it can be argued 
that ducts were able to give rise to PDAC in this study while acinar cells, with the 
genetic alteration, were not. Thus, it is not yet clear whether in our model the Fbw7 
deletion with KRasG12D activation in acinar cells would lead to PDAC preceded by 
PanIN lesions. Longer time points after tamoxifen-induced recombination are necessary 
to address the issue. 
In summary, contrasting with previous findings, results in this thesis demonstrate that 
ductal cells should also be considered cells of origin of PDAC (Figure 39). 
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During the course of my studies, work performed by Matthias Hebrok’s research group 
suggested that, while ductal cells are capable of PDAC formation, ductal cell oncogenic 
targeting leads to PDAC preceeded by IPMN lesions (IPMN-PDAC) (von Figura et al., 
2014, Roy et al., 2015). In the work published in 2014, von Figura and co-workers 
studied the effect of Brg1 deletion (a component of the SWI-SNF chromatin 
remodelling complex) in the developing pancreas with concomitant KRasG12D activation. 
They observed that loss of Brg1 protein rapidly accelerated KRasG12D-driven murine 
PDAC, which was preceded by AB/PAS-positive IPMN lesions (IPMN-PDAC). All the 
characterization of the murine IPMN lesions was performed in the pancreatic 
embryonic Cre driver model - Pdx1-Cre (Brg1F/F; KRasLSL-G12D/wt; Pdx1-Cre). Nine 
weeks after birth, mice developed cystic lesions expressing mucin (detected by 
AB/PAS), which resembled human pancreatobiliary IPMNs with pronounced tree-
resembling papillae. The suggestion of a ductal origin was indicated by the direct 
connection of these structures to the ductal network. However, acinar cells also have a 
direct connection to the ductal network. Since the Pdx1-Cre model induces Cre-
dependent recombination in pancreatic progenitors, work performed with this model did 
not provide sufficient evidence to establish a ductal origin. In order to assess if ductal 
cells give rise to IPMN-PDAC, the authors generated Brg1F/F; KRasLSL-G12D/wt; Hnf1β-
CreER mice. Hnf1β is a transcription factor and, in the pancreas, is specifically 
expressed in ductal cells. Therefore, in this model, upon tamoxifen treatment, Brg1 
expression is lost specifically in ductal cells, together with oncogenic KRas activation. 
Firstly, Brg1F/F; KRasLSL-G12D/wt; Hnf1β-CreER mice failed to generate mPDAC, 
impeding the assessment of whether ductal cell-derived PDAC progresses via IPMN. 
Secondly, only one out of 5 mice developed enlarged ductal structures that the authors 
refer to as mucinous reminiscent of the IPMN lesion (von Figura et al., 2014). 
Interestingly, the mucinous nature of this lesion was not assessed by any mucin or 
AB/PAS staining. Moreover, according to the images in the published work, these 
structures did not present a papillary structure, nor the extended papillae characteristic 
of IPMN. Images show an enlargement of the ductal cells morphologically similar to 
the ones obtained in early stages of my time point assessment of duct-derived PDAC. 
Therefore, while the proposal of Brg1 as a tumour suppressor in embryonic pancreas is 
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convincing, the suggestion that its deletion in a KRasG12D background induces duct-
derived IPMN-PDAC is not supported by their data. 
Nevertheless, Brg1 loss of expression has been shown to be common in IPMN lesions 
in human samples (Dal Molin et al., 2012). Therefore, while results presented in this 
thesis suggest that the cell of origin is the main determinant in the presence or absence 
of mucinous pre-neoplastic lesions, they do not exclude the possibility that genetic 
alterations can have a strong effect. It would be interesting to assess whether Brg1 loss 
in adult ductal cells with KRasG12D expression would, in fact, lead to PDAC, to better 
understand if, in the context of Brg1 loss, KRasG12D-driven duct cell-PDAC occurs via 
IPMN. 
 
The majority of the knowledge obtained so far on the precursor lesions of PDAC 
(IPMN, MCN, PanIN and ITPN) has been acquired from the study of human samples. 
This static analysis of fixed tissue and mutational landscapes from biopsies and tumour 
samples, fails to incorporate time course analysis and detailed investigation of initiating 
events. It is obvious from the literature that there is no consensus on the origin of these 
lesions. The integration of data obtained from GEM models is essential for the thorough 
understanding of these lesions and their roles in PDAC development. While some 
studies have reported that the cell of origin determines the pre-neoplastic lesion (von 
Figura et al., 2014, Roy et al., 2015, Kopp et al., 2012), others described the oncogenic 
hit as the determinant for the PDAC precursor (Izeradjene et al., 2007, Bardeesy et al., 
2006b). In this study I tested the same oncogenic hit in different pancreatic 
compartment components (acinar versus duct cells) and observed different 
morphological responses, suggesting that the cell receiving the hit has a great influence 
in the determination of the pre-neoplastic lesion. However, it is known that, while the 
different precursor lesions roughly harbour mutations in the main key genes (KRAS, p53, 
CDKN2A) some mutations are more common than others in particular lesions. As an 
example, it has been observed that while MCNs frequently present loss of SMAD4 
(Iacobuzio-Donahue et al., 2000b), IPMNs only rarely show low SMAD4 expression 
(Iacobuzio-Donahue et al., 2000a). Additionally, IPMNs present frequent inactivation 
of the Serine/threonine kinase 11 (STK11) gene, also known as liver kinase B1 (LKB1) 
(Sato et al., 2001); however, no alterations have been reported for MCNs, ITPNs or 
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PanINs. Therefore, it is possible, that additional mutations might define the route of 
PDAC development. Hence, it is important to test additional genetic alterations in 
acinar and ductal cells-derived PDAC.  
 
Moreover, the ductal network is a heterogeneous entity. While cells in large-calibre 
ducts have a columnar morphology, interlobular ducts exhibit a cuboidal epithelial 
morphology (Reichert and Rustgi, 2011). Thus, it is possible that different calibre ducts 
respond differently to oncogenic hits. Hence, the influence of the type of duct, in 
combination with additional genetic backgrounds, on the mode of PDAC induction and 
progression should be assessed. This could be performed in vivo by carefully analysing 
the oncogenic effect in ducts of different calibres or ex vivo by the use of slice cultures 
combined with in vitro recombination of ducts of different calibres (Marciniak et al., 
2013). By combining slice cultures with live imaging, the morphologic changes induced 
by oncogenic hits can be followed for individual ducts; thus enabling the identification 
of potential differences in response from ducts of different calibre.  
 
5.3.2 Clinical relevance of acinar and duct derived PDAC 
In this thesis, murine PDAC developed from either the developing pancreas or from 
adult duct cells were morphologically indistinguishable. However, as mentioned above, 
ductal targeting of oncogenic hits led to murine PDAC without the development of 
mucinous precursors. It is known that human PDAC derived from different pre-
neoplastic lesions is associated with different prognoses (Cooper et al., 2013). Moreover, 
it has been hypothesized that these tumours originating from different precursors might 
be biologically distinct (von Figura et al., 2014). Therefore, results obtained in this 
thesis raise important questions: (1) Are acinar and duct derived tumours different 
entities with regard to aggressiveness? (2) Are they characterized by different 
prognoses? (3) Are they equally represented in the human disease or is one type of 
origin more common than the other? (4) Can acinar and duct-derived tumours be 
distinguished?  
It has been reported that some human PDAC patients (9% of samples) do not exhibit 
PanINs at the time of diagnosis (Hassid et al., 2014). The absence of PanIN lesions in 
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these patients was associated with poor survival independent of tumour size, stage of 
the disease, tumour location and lymphovascular invasion (Hassid et al., 2014). The 
absence of PanINs could be explained by the high aggressiveness of the tumours, and 
thus quick progression of the pre-neoplastic lesions. Alternatively, It could be explained 
by the fact that some human PDAC might arise in a PanIN-independent manner. Given 
that the absence of PanINs was correlated to a worse prognosis independent of stage of 
the tumour, it is more luckily that some PDAC arise independently of these lesions. 
This has great implications based on the findings reported in this thesis. If in fact ductal 
cell-derived PDAC does not evolve via PanINs, PDAC arising from ductal cells might 
be rarer than acinar-derived PDAC but they might be biologically distinct, exhibiting a 
more aggressive phenotype. Another important point is that, I observed that low-grade 
PanIN lesions can be generated as a consequence of tumour formation (bystander 
PanINs) and not necessarily as a precursor lesion. Thus, some duct-derived tumours 
might not be identified as such due to detection of bystander PanINs at the time of 
diagnosis.  
 
Evidence regarding the different aggressiveness of acinar and duct-derived pancreatic 
tumours remains inconclusive. Fbw7 protein loss, in an oncogenic KRasG12D 
background, led to mPDAC from ductal cells, but it failed to induce tumour formation 
in acinar cells at comparable time points with additional injury. Moreover, p53 deletion 
in ductal cells led to more rapid mPDAC development, compared to the onset described 
in the literature for acinar cells with the same genetic alteration (Guerra et al., 2011). 
While the present results suggest that ductal cells exhibit a more profound 
transformation before observation of acinar-cell-derived PDAC, it is not clear if duct-
derived tumours are more aggressive than acinar cell-derived ones. Genetic alterations 
in different cells might have different phenotypes, which are cell-dependent. Thus, 
Fbw7 deletion might have no tumourigenic effect in acinar cells, impairing the cell 
dependence assessment. Additionally, the onset of PDAC development reported in this 
thesis for ductal cells cannot be compared with published data for acinar cells, as it is 
known that the strain background has a significant impact on tumour onset (J Puccini, 
2013, Demant, 2003). Moreover, the genetic Cre line used for acinar cell targeting in 
other studies relied on doxycycline rather than tamoxifen (Guerra et al., 2011); thus, the 
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treatments used to induce recombination are significantly different. To better assess 
differences in tumourigenic capacity and aggressiveness from the different pancreatic 
compartments, comparable genetic models should be generated, such as p53KEla1-
CreER (p53F/F; KRasLSL-G12D/WT; Ela1-CreER) and p53KHnf1β-CreER (p53F/F; KRasLSL-
G12D/WT; Hnf1β-CreER) mice.  
 
5.3.2.1 Acinar and duct-derived PDAC gene signatures 
The answers to the above questions will have great implications for PDAC medicine, as 
the full understanding of PDAC origins might allow patient stratification and 
development of different therapies based on the origin of the tumours (Figure 39). 
Therefore, a distinction between acinar and duct-derived tumours, such as gene 
signature, is necessary. In fact, it has been proposed that human PDAC can be 
molecularly sub-classified into 3 different types: classical; exocrine-like and quasi-
mesenchymal (Collisson et al., 2011). While gene signature analysis on PDAC samples 
mostly suggests a ductal origin, this study unveiled the existence of a tumour type 
(exocrine-like) that might reflect an acinar cell origin due to the high content of acinar-
specific digestive enzyme genes expressed. Interestingly, these PDAC subtypes showed 
different responses to therapy and were associated with different survival rates 
(Collisson et al., 2011). This study raises the idea that ductal and acinar cell-derived 
tumours might be identified on the basis of their molecular profile and that this could 
bring new critical information for the clinic. To assess the possible gene signature 
associated with ductal versus acinar-derived tumours, the tumours generated from adult 
duct- and acinar-specific PDAC mouse models (with the same genetic alterations) 
should be collected and compared at the gene expression level. If a differential signature 
is found, this should be compared with human samples. 
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Figure 39 – Proposed model for acinar and duct-derived PDAC  
Schematic representation of the proposed model for progression of PDAC tumours 
derived from the acinar and ductal pancreatic exocrine compartments. 
Acinar cells in the presence of a PDAC-generating oncogenic hit undergo a 
transdifferentiation process known as acinar-to-ductal metaplasia (ADM) where cells 
acquire a ductal morphology. These lesions develop increasing cellular atypia and 
progress to pancreatic intraepithelial neoplasias (PanINs). The initial low-grade PanIN 
(PanIN1A-B) is characterized by expansion of the cytoplasm with supranuclear mucin 
production and the nuclei organize basally. In PanIN2 the structure becomes papillary 
with increased nuclear abnormalities. These structures lose polarity and start budding 
into the lumen of the lesions where they form PanIN3 (or carcinoma in situ). 
Carcinoma in situ is the first recognized tumourigenic lesion and progresses to PDAC 
with observed loss of the basement membrane.  
When the oncogenic hit occurs in ducts, an increase in proliferation is observed, with 
increased cellularity of the ductal tree. Ductal cells increase in size, expanding towards 
the lumen of the duct. In this case, the nuclei do not organize basally, instead they 
increase in size with the cytoplasm. Without forming mucinous structures, the ducts 
become papillary, present pseudostratification, lose polarity, and shedding of cells 
towards the lumen is observed, resembling the carcinoma in situ neoplastic lesion. Loss 
of the basement membrane takes place and the lesions progress to PDAC.  
While morphologically and architecturally indistinguishable, PDAC derived from 
acinar cells and ductal cells might be different entities and better understanding of their 
biology might allow patient stratification. 
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5.3.3 Low-grade PanIN lesions can be formed as a consequence of tumour 
formation (bystander). 
In this thesis, I observed that low-grade PanIN lesions can be induced in wild type 
tissues in the presence of tumours. By injecting lineage-traced mPDAC tumour cells 
into the unlabelled pancreas of immunodeficient mice, I detected the formation of 
unlabelled mucinous low-grade mPanINs in close proximity to labelled mPDAC. 
Interestingly, while low-grade PanIN lesions, such as PanIN1, were described as pre-
neoplastic lesions that evolve into PDAC, reports have indicated that they can be 
detected in the context of other pancreatic neoplasias such as acinar cell carcinomas, 
mucinous cystic neoplasms, pancreatic endocrine tumours, serous cystadenomas, solid 
pseudopapillary tumours and ampullary tumours (Recavarren et al., 2011, Stelow et al., 
2006a). Additional evidence against the sole pre-neoplastic nature of these lesions is the 
fact that the majority of low-grade PanINs do not harbour mutations in the KRAS gene 
(Feldmann et al., 2007). Moreover, gene expression profiles performed in PanIN lesions 
of different grades have separated PanIN1 from the remaining PanINs. In that study it 
was suggested that PanIN1 lesions are not true pre-neoplastic lesions (Buchholz et al., 
2005). While the neoplastic nature of PanIN1 lesions was not addressed in this thesis, 
my results reinforce the fact that the diagnostic value of PanIN1 lesions should include 
the appreciation that they can arise as a result of tumour formation, as a bystander, and 
not always as precursor lesions. 
 
The mechanism behind this observation is still far from being understood. It is possible 
that the inflammatory environment signals to acinar cells, activating signalling 
pathways involved in ADM, such as Sox9 upregulation (shown to drive mucinous 
ductal structures when overexpressed in acinar cells) and cytokine-induced responses 
(Liou et al., 2013, Kopp et al., 2012). 
The fact that the observation was obtained in immunodeficient NuNu mice could lead to 
the exclusion of an inflammatory driven mechanism. NuNu mice have a homozygous 
deletion of Forkhead box protein N1 (Foxn1) leading to the lack of Thymus and 
consequently, lack of immune T-cells. However, it has been shown that ADM depends 
on macrophage-secreted cytokines (Liou et al., 2013). Hence, the absence of T-cells 
would not impair macrophage-mediated phenotypes. If the inflammatory response is the 
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driver of bystander PanIN formation, it would be by a mechanism independent of T-cell 
and macrophage interaction. The role of macrophages in this bystander PanIN 
formation could be tested chemically by intravenous treatment with gadolinium chloride 
promoting transient macrophage depletion or using inducible mouse models for cell 
targeted depletion (Gheryani et al., 2013). 
 Additionally, it is possible that tumour cells directly promote the acinar to mucinous 
ductal metaplasia conversion by vesicle-mediated signal exchange. Cancer cells have 
been shown to release exosomes, small vesicles of endocytic origin. These exosome 
carry cargo such as protein, DNA or RNA, which, are release in the microenvironment 
or transferred to neighbouring cells by internalization of the vesicle (Kahlert and Kalluri, 
2013, Zomer et al., 2015). Depending on their cargo, exosomes could mediate the 
cancer cell-dependent induction of bystander PanINs. To test the hypothesis, exosomes 
from murine PDAC could be isolated and injected into the pancreas of NuNu mice to 
generate bystander PanINs. Interestingly, all bystander PanINs observed during my 
studies were in close proximity to the tumour. This suggests that signals that induce 
bystander PanIN formation are mainly short-range. More in depth studies are necessary 
to further dissect the mechanism of PanIN bystander formation. 
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5.4 Origins of PDAC: CD9 as a marker for PDAC tumour-initiating 
cells 
5.4.1 CD9High PDAC cells constitute a tumour-initiating population 
It has become increasingly evident that tumours of most organs exhibit cellular 
heterogeneity regarding tumourigenic capacity, i.e., not all cells within a tumour are 
responsible for tumour propagation. An extensive search for and characterization of 
these tumour-propagating cells has been performed and it is now accepted that, a 
subpopulation of cells, named cancer stem cells or tumour-initiating cells (TICs), 
resides within certain tumours, that is able to propagate the tumour upon transplantation, 
to give rise to the cellular heterogeneity characteristic of the primary tumour and to 
recapitulate the primary tumour histology (Nguyen et al., 2012). 
This definition implies that for complete therapeutic remission, this specific 
subpopulation of cells should be targeted and eradicated. Moreover, numerous studies 
have addressed the clinical relevance of TICs by demonstrating that they possess a 
unique ability to evade or resist drug treatments and to generate metastases (Li et al., 
2007, Hirschmann-Jax et al., 2004, Zhou et al., 2001, Alvi et al., 2003). Therefore, it 
has been suggested that, in combination with tumour-bulk targeting strategies, more 
cell-specific therapeutic approaches are necessary for improvement of current survival 
figures (Jordan et al., 2006). 
While initially described in haematopoietic malignancies, cancer stem cells/TICs have 
been reported in solid tumours of the brain (Singh et al., 2004), breast (Al-Hajj et al., 
2003), colon (Ricci-Vitiani et al., 2006) and small intestine (Barker et al., 2008), 
providing important information on the tumour biology and its molecular dependencies. 
The importance of the identification of this tumour-initiating subpopulation has 
prompted the development of assays and tools that allow both their isolation and the 
investigation of their functional cancer stem cell-like features. Thus, efforts have been 
made to identify markers that might be differentially expressed in TICs versus non-TICs. 
Several proteins have been commonly described to be present at the surface of these 
tumour-initiating cells, such as CD133, CD24 and CD44, amongst others, with each 
type of tumour exhibiting a different marker or combination of markers. The 
identification of these surface proteins aided in the isolation of tumour-initiating cells 
Chapter 5 Discussion 
 
 217 
and their functional assessment versus the remaining tumour cells. As well as the 
identification of markers, cancer stem cell assays have been developed. Current in vitro 
investigation of tumour-initiating properties relies on the ability of cells to grow as 
spheres in non-adherent conditions or as organoids in soft matrices. However, as the 
name indicates, the gold standard in assessing tumour-initiating potential is their unique 
ability to initiate secondary tumours in recipient mice, when isolated from the bulk 
population, recapitulating the histology and cellular hierarchy of the primary source 
(Clarke et al., 2006). 
 
The identification of tumour-initiating cells in human PDAC has also been reported. In 
2007, two different groups approached the problem in different ways. Li and co-
workers took advantage of the described CD44, CD24 and ESA (epithelial-specific 
antigen) surface proteins to isolate human PDAC cells that were positive for one or 
more of these markers and tested their ability to generate tumours following xenograft 
transplantation (Li et al., 2007). On the other hand, Hermann and co-workers used 
CD133 surface protein to isolate a putative tumour-initiating population from human 
PDAC samples (Hermann et al., 2007). Both studies demonstrated that, following serial 
dilution and transplantation into immunodeficient mice, cells which were either positive 
for CD44+CD24+ESA+ or CD133+ exhibited a unique capacity to generate secondary 
PDAC, when compared with CD44-CD24-ESA- and CD133- cells, respectively. 
However, they failed to address the origin of the population negative for the markers of 
choice. According to their protocol description, human primary PDAC samples were 
enzymatically dissociated into single cells, stained for the proteins of interest (CD44, 
CD24, ESA and CD133) and injected into mice at a serial dilution. No epithelial cell 
isolation or stromal exclusion was performed. This generates a great concern of the 
possibility of inclusion of stromal cells in their negative cellular fractions. It is known 
that PDAC exhibits a pronounced stromal expansion (desmoplasia). While the extent of 
expansion varies from patient to patient, it has been reported that it can account for up 
to 90% of the tumour volume (Xie and Xie, 2015). Knowing that stromal cells are 
CD133-negative, as the authors have nicely shown by immunofluorescence (Hermann 
et al., 2007), and that pancreatic stromal cells are also ESA-negative (Miranda-Lorenzo 
et al., 2014), there is a high probability that the majority of their  CD44-CD24-ESA- and 
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CD133- cells were, in fact, stromal cells and thus it is not surprising that they are non-
tumourigenic. Moreover, follow up work from the group of Christopher Heeschen has 
highlighted that the presence of CD133 protein can vary between samples. Thus, they 
focused on the autofluorescence as a marker of cells with higher tumourigenic potential 
(Miranda-Lorenzo et al., 2014). While their results are compelling, it is well accepted 
that autofluorescence is a cell property that can result from the handling of the sample. 
In sum, before the start of this project, there were significant gaps in knowledge 
regarding PDAC tumour-initiating cells.  
 
During my studies, I used a mouse model where loss of Fbw7 protein, with concomitant 
KRasG12D expression, could be induced in adult ductal cells by tamoxifen treatment, 
leading to mPDAC development. To further characterize these duct-derived PDAC, I 
crossed in the R26-LSL-YFP tracer (F7KYCk19-CreER mice), which enabled the 
identification of recombined cells throughout different stages of tumour development. I 
observed that, soon after recombination, some lineage-traced cells exhibited 
morphological alteration, reminiscent of initial stages of tumour development, while 
others remained morphologically unaltered. This difference persisted even 4 weeks after 
tamoxifen treatment, excluding the possibility of asynchronous recombination at early 
time-points. Additional profiling for surface proteins by immunohistochemistry 
highlighted a correlation between CD44 and initial stages of tumour development. 
Furthermore, sorting of recombined cells (GFP+) positive and negative for CD44 
protein, and consequent genotyping PCR, demonstrated that the difference in the 
response to the tumourigenic hit was not due to incomplete recombination of any of the 
genetically altered alleles. Thus, I used this system to address the gene expression 
profile (by microarray) of cells with similar genetic backgrounds but different 
phenotypes (GFP+CD44+ [recombined and transformed] versus GFP+CD44- 
[recombined and non-transformed]) at early stages of tumour development. Analysis 
was performed searching for possible cell surface markers of tumour-initiating cells that 
would be upregulated by, at least, 1.5-fold in the GFP+CD44+ cellular fraction. The 
most promising candidate was the protein CD9. 
CD9, also known as motility-related protein 1 (MRP1), is a member of the tetraspanin 
protein family of transmembrane proteins. It is composed of four transmembrane 
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domains, 2 extracellular loops and a small intracellular domain (one loop, one small N-
terminus tail and one c-terminus region) and it is present at the cell membrane, in 
organelle membranes and in granules, such as exosomes. Little is known about 
tetraspanin proteins. However, evidence has been gathered demonstrating that members 
of this family can directly interact with intracellular and extracellular ligands, and 
associate laterally, forming tetraspanin-enriched microdomains (TEMs), which can 
modulate crucial cellular functions such as cell adhesion and migration, signalling and 
survival (Hemler, 2014). 
CD9 has been shown to identify cells with in vitro and in vivo tumour-initiating ability 
in human B cell acute lymphoblastic leukemia (Nishida et al., 2009). Moreover, it was 
recently described as a marker for haematopoietic stem cells, allowing a pure isolation 
of the entire population (Karlsson et al., 2013). Its role in cancer is still under debate as 
it has been described to promote, or be associated with, contrasting tumour-related 
phenotypes. CD9 was primarily described as a tumour suppressor where its high 
expression correlated with better prognosis and lower lymph node status in esophageal 
squamous cell carcinoma and gastric cancer (S Uchida, 1999, Yoko Murayama, 2015). 
Moreover, CD9 re-expression in CD9-depleted small-cell lung cancer cells reduced 
their in vitro and in vivo motility/metastatic and proliferative potential (Zheng et al., 
2005). Nevertheless, tumour-promoting features have also been associated with the 
CD9 protein. Overexpression was shown to increase in vitro cell invasion in human 
fibrosarcoma cells (Herr et al., 2013). Furthermore, the in vivo use of a CD9-blocking 
antibody reduced the establishment of bone metastasis following tail vein injection of 
highly metastatic breast cancer cells (Kishel et al., 2012). Interestingly, contradicting 
the abovementioned results, CD9 expression in gastric cancers has also been found to 
significantly correlate with lymphatic invasion, clinical stage and vessel invasion (Hori 
et al., 2004). It is difficult to speculate the reason for the conflicting data obtained so far. 
However, it is hypothesized that different functions might be due to association of CD9 
with different molecular partners, which include integrins, surface receptors and other 
tetraspanin proteins (Hemler, 2014). 
In PDAC, CD9 has not been thoroughly studied. As observed for other tumour types, 
data obtained by gene expression profiles and proteome arrays, comparing tumour and 
normal tissue, and survival analysis, has attributed conflicting roles to CD9 (Grønborg 
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et al., 2006, Sho et al., 1998, Gesierich, 2005). While initial studies have proposed low 
CD9 expression to correlate with PDAC poor prognosis (Sho et al., 1998), subsequent 
studies have described CD9 to be overexpressed in PDAC patient samples and 
pancreatic cancer cells lines compared with normal pancreatic tissue. CD9 expression 
was higher in high-grade PDAC and in PDAC-derived metastasis to the liver (Grønborg 
et al., 2006, Gesierich, 2005). 
 
In this study, I used CD9 as a surface marker to isolate tumour cells and address its 
potential in identifying a tumour-initiating population within murine PDAC. In addition, 
since variable results have been obtained with TIC markers, I addressed the value of 
CD9 across different genetic backgrounds. CD9High primary tumour cells from 
F7KYCk19-CreER and p53KYPdx1-Cre-derived PDAC exhibited higher in vitro stem 
cell potential compared to CD9Low cells, assessed by their capacity to form organoids 
when plated in, previously described, organoid-forming conditions (Huch et al., 2013). 
Interestingly, in vitro expansion of dissociated murine PDAC cells did not change the 
outcome. Sorted CD9High tumour cells, which grew in matrigel for several passages, 
continued exhibiting higher organoid-forming capacity compared to their CD9Low 
counterparts. Lastly, CD9High and CD9Low cells were sorted from murine PDAC 
organoids, grown for several passages, and injected into the flanks of immunodeficient 
NuNu mice, following serial dilution. Measurements of initial nodule formation 
indicated that CD9High cells were faster in establishing nodules. Upon termination of the 
experiment, CD9High-derived tumours recapitulated the cellular heterogeneity observed 
in the primary mPDAC, while the CD9Low tumour cells failed to do so. Moreover, 
contrasting with CD9High-derived tumours, which exhibited over a 100-fold increase in 
tumour size, CD9Low tumour cells were not capable of tumour maintenance, as injection 
of 200 cells led to the regression of the nodule initially detected. 
The results indicate that CD9 protein can identify a population within primary mPDAC, 
and cultured cells, with in vitro tumour-initiating properties and capable of in vivo 
tumour initiation, tumour maintenance and cellular heterogeneity (Figure 40). 
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Figure 40 - CD9 marks a PDAC tumour-initiating cell population 
Schematic representation of the cellular histological hierarchy in PDAC and main 
findings.  Advanced PDAC tumours exhibit a cellular heterogeneity with presence of 
both epithelial (cuboidal or columnar shaped cells) and mesenchymal-like cells (spindle 
shaped). PDAC TICs can be identified by their levels of CD9 protein at the cell surface. 
CD9High cells are able to initiate tumour formation in recipient mice (at serial dilutions 
of up to 200 cells) and maintain tumour growth. CD9High-derived tumours recapitulate 
the cellular heterogeneity of the primary source. The remaining population (CD9Low) is 
not capable of initiating and sustaining the growth transplants when 200 cells are 
injected. Injecting a higher number of cells leads to small tumours, but which do not 
recapitulate the primary counterpart. 
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5.4.2 Potential therapeutic value of CD9 
Contrasting with previously described PDAC TIC markers, the surface presence of CD9 
was able to identify a more tumourigenic population within murine PDAC across 
different genotypes and isolation protocols. Given that one of the main clinical concerns 
in using surface markers for the identification of the TIC subpopulation is their 
unreliability, CD9 seems to offer a more reliable identification of mPDAC TICs for 
therapeutic approaches. However, it is important to bear in mind that the findings 
obtained for CD9 were based on mouse tissues with genetic labelling of tumour cells. 
Thus, it is important to address whether CD9 also identifies a more tumourigenic 
population within human PDAC. Since CD9 is expressed in some immune cells, this 
assessment might require the additional use of tumour or epithelial cell specific markers, 
such as EpCam, to discriminate tumour cells from remaining microenvironment 
components. 
 
While I have demonstrated a higher tumourigenic capacity of CD9High tumour cells, in 
this study, I did not address whether eradication of the CD9-expressing population from 
an established PDAC would lead to tumour regression. Human PDAC is known for its 
strong drug resistance (Ryan et al., 2014) which is not only explained by the tumour 
molecular heterogeneity and strong desmoplasia, but also due to the presence of a drug 
resistant subpopulation of cells with tumour-initiating properties (Hermann et al., 2007). 
Therefore, the selective elimination of this population, and possible PDAC remission, 
could represent a promising therapeutic strategy with high probability of efficiency. In 
order to test the clinical value of CD9 two routes could be pursued. (1) The use of mice 
expressing conditional diphtheria toxin (DT) or diphtheria toxin receptor (DTR) under 
the control of a cell-specific promoter or knock-in in a specific locus, has allowed the 
selective eradication of specific cell populations (Saito et al., 2001). Mice with an 
inducible knock-in DTR in the CD9 locus could be crossed with the p53KYPdx1-Cre to 
address the effect of CD9High cell depletion specifically in murine PDAC at different 
stages of tumour development. (2) An alternative approach could be the use of cytotoxic 
drug-coupled antibodies  (antibody-drug conjugates – ADC) against CD9. One would 
have to initially check whether these antibodies are internalized upon binding to CD9 at 
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the cell surface. If that would be the case, then the antibody would bind to CD9-
expressing cells, would be internalized and selectively kill cells expressing CD9. 
This particular approach might be more relevant for clinical purposes, as human cells 
could be used in xenograft models and then targeted using ADC. Also, the effect of 
whole body CD9-expressing cell ablation could be addressed. Importantly, ADCs 
conjugated to toxins have been used in the clinic for the treatment of acute myeloid 
leukaemia, Hodgkin’s lymphoma and other haematopoietic malignancies (Scott et al., 
2012). Therefore, the successful regression of PDAC xenografts from human patients 
could constitute the first step for PDAC targeted therapies. 
Additionally, it would be interesting to compare the gene expression profiles of CD9High 
PDAC cells (human or murine) with CD9Low tumour cells in order to identify pathways 
that might be important for the survival and self-renewal of the CD9High cells, or to find 
druggable targets that could be explored in the clinic. 
 
The CD9High mPDAC cells studied here were shown to constitute a TIC population in 
tumours derived from both adult ducts (F7KYCk19-CreER) and developing pancreas 
(p53KYPdx1-Cre). However, it would be important to address if CD9 also identifies a 
TIC population in adult acinar cell-derived mPDAC (p53KYEla1-CreER) and human 
PDAC. In the search for the PDAC compartment of origin, acinar cells were proposed 
as the main origin of PDAC. It was described that, in the presence of an oncogenic hit 
and acinar cell injury (caerulein), acinar cells undergo a metaplastic change where they 
transdifferentiate into ducts (ADM) (Guerra et al., 2007, Kopp et al., 2012). Besides the 
morphologic similarity and the mutual presence of a small number of ductal proteins 
(including CK19 and Hnf1β), it is not clear if ADM-derived ductal cells are the same as 
true pancreatic ductal cells. Supporting a possible difference is my observation that 
tumour progression from ducts and acinar cells seems to differ in the morphology of the 
initial steps. Nonetheless, it is possible that the cells driving tumourigenesis in both 
models are comparable. Therefore, the potential of CD9 to identify a general PDAC 
TIC population should also be tested on acinar-derived mPDAC in order to gain a 
complete understanding of the origins of the disease. As mentioned before, it should 
also be addressed if human PDAC samples contain a CD9High population and if 
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xenograft transplantations also demonstrate a higher tumourigenic capacity for these 
cells to increase relevance for the human disease.  
 
 
5.4.3 Is CD9 a functional PDAC TIC marker? 
Conflicting data has been published on the value and role of CD9 in various tumour 
models. Also, for PDAC, it is not clear from the studies conducted so far if CD9 acts as 
a tumour suppressor or oncogene (Hemler, 2014). CD9 has a wide range of interacting 
partners, such as integrins (mainly α3β1) (Gesierich, 2005), growth factors (Shi et al., 
2000), membrane proteases (Yáñez-Mó et al., 2011), and other signalling proteins 
(Zhang et al., 2001, Hemler, 2014). For this reason, CD9 modulation has been shown to 
affect migration, angiogenesis, proliferation, apoptosis and drug resistance, which could 
explain the discrepant results reported. In this thesis, I did not assess whether the 
tumour-initiating capacities detected in the CD9High population were due to CD9 
expression itself or if CD9 surface detection was a consequence of additional molecular 
mechanisms. It would be interesting to either knockdown or knockout CD9 in CD9High 
cells and assess whether they retain their tumour-initiating potential. As a different 
approach, CD9Low cells could be used for overexpression of the CD9 gene. If CD9 has a 
functional role in this high-expressing population, the therapeutic value and 
applicability could be increased by the use of blocking antibodies. The use of 
monoclonal antibodies such as cetuximab (epidermal growth factor inhibitor), and 
trastuzumab (HER2/neu receptor inhibitor) has greatly improved clinical outcome for 
colorectal and breast cancer patients. By inhibiting the respective targeted receptor, the 
monoclonal antibodies have demonstrated to be extremely successful in abrogating 
tumour cell signalling, reviewed in Scott et al., 2012. 
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5.4.4 Do PDAC TICs originate from pancreatic adult progenitor cells? 
Nowadays, the concept of tumour-initiating cells, or cancer stem cells, does not 
necessarily reflect a stem cell origin of the formed tumours in question. It rather implies, 
that some cells within the tumour possess the capacity to initiate a tumour and maintain 
its growth, regardless of whether this property is derived from a transformation step of 
differentiated or progenitor/stem cells. Nevertheless, it is known that, in some, mainly 
hematopoietic, malignancies, it is in fact a tissue stem cell or an immediate progenitor 
that, upon an oncogenic hit, undergoes transformation and initiates tumour development. 
The existence of progenitor cells in the pancreas is still a controversial subject. Studies 
investigating the ability of the pancreatic organ to regenerate have suggested that 
differentiated cells undergo a transdifferentiation process to convert into other cell types 
and then proliferate, rather than an existence of a pool of progenitor cells that 
continuously gives rise to more differentiated cell types (see 1.1.2, page 26). However, 
studies from our laboratory have implied the existence of subpopulation within the 
ducts that responds differentially to genetic alterations (Sancho et al., 2014). 
I observed in the F7KYCk19-CreER model that, 4 weeks after tamoxifen treatment, not 
all recombined duct cells gave rise to tumours. Corroborating previous hypotheses, this 
suggests that the ductal network is a heterogeneous entity, since only a subset of cells 
was capable of being transformed by the genetic tools used. Given that CD9 was 
capable of distinguishing between TICs and non-TICs in murine PDAC, it would be 
interesting to assess whether the adult ductal network of wild type animals harbours a 
CD9High population and if so, whether these cells represent an adult pancreatic 
progenitor population more susceptible to tumour transformation. Preliminary data 
suggest that the ductal network does have a rare CD9High population. Thus, while 
genetic approaches could be developed to address the different tumourigenic potential 
of these cells, it would also be possible to sort CD9High and CD9Low cells from a p53F/F; 
KRasLSL-G12D/wt mouse and, following in vitro recombination of floxed alleles, assess the 
ability of the two cell populations to initiate PDAC in the flanks of immunodeficient 
NuNu mice. The meaning of the existence of a CD9High population in adult wild-type 
ductal cells is not yet clear. Nonetheless, it would be interesting to study a possible 
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progenitor nature of this population in the adult organ in more detail. Preliminary data 
could be gathered by genetically tracing CD9-expressing cells in the wild type pancreas 
and follow the fate of the labelled cells over time in both normal conditions and after 
various injuries to specific pancreatic compartments. 
 
 
5.5 Concluding remarks 
This thesis addresses the origins of pancreatic ductal adenocarcinoma by: (1) evaluating 
how the different components of the pancreatic exocrine compartment (acinar and duct 
cells) contribute to PDAC development, and (2) by identifying the cell population 
responsible for initiation and maintenance of PDAC. 
I was able to confirm that murine adult ductal cells can originate mPDAC when potent 
tumour suppressors (Fbw7 and p53) are deleted with concomitant induction of the 
PDAC driver mutation (KRasG12D). Adding to this observation, I described a different 
progression model for mPDAC development from that described for acinar cell-derived 
mPDAC (Figure 39), which could provide useful information for patient stratification in 
clinical strategies.  
Furthermore, the investigation of mPDAC TICs led me to the identification of CD9 as a 
surface marker for pancreatic tumour cells with the capacity to initiate secondary 
mPDAC upon transplantation and to recapitulate the cellular heterogeneity observed in 
primary mPDAC tumours (Figure 40). These findings offer valuable information on 
PDAC biology and might aid in the development of PDAC targeted therapies.  
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Chapter 6. Appendix 
- Figure 1 was adapted from Shih et al., 2013. No permission was required from the 
publisher Annuals Reviews for the purposes of thesis and dissertations (RightsLink). 
 
- Figure 11 was adapted from Tanaka et al., 2012. Reprinted from Pancreatology, Vol 
12/3, Masao Tanaka, Carlos Fernández-del Castillo, Volkan Adsay, Suresh Chari, 
Massimo Falconi, Jin-Young Jang, Wataru Kimura, Philippe Levy, Martha Bishop 
Pitman, C. Max Schmidt, Michio Shimizu, Christopher L. Wolfgang, Koji Yamaguchi, 
Kenji Yamao, “International consensus guidelines 2012 for the management of IPMN 
and MCN of the pancreas”, page 191, with permission from Elsevier. License number 
3702040187175. 04 September 2015 
 
- Figure 12 was adapted from Distler et al., 2014. No permission was required from 
BioMed Research International. Copyright © 2014 M. Distler et al. This is an open 
access article distributed under the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. 
 
- Figure 13 was adapted from Distler et al., 2014. No permission was required from 
BioMed Research International. Copyright © 2014 M. Distler et al. This is an open 
access article distributed under the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. 
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